PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PURILISHED LINDER THE PATENT COOPERATION TREATY (PCT)

INTERNATIONAL APPLICATION PUBLISH		1	DAK IIID IIIIDAII COOLDINIII	
(51) International Patent Classification 6:	ا ا	(1	1) International Publication Number:	WO 98/24782
C07D 401/04, 405/04, 409/14, A61K 31/505, C07D 403/04, 401/14, A61K 31/44	A2	(4	3) International Publication Date:	11 June 1998 (11.06.98)
(22) International Application Number: PCT/US: (22) International Filing Date: 4 December 1997 (6. 60/032,128 5 December 1996 (05.12.96 60/050,950 13 June 1997 (13.06.97) Not furnished 21 November 1997 (21.11.9 INC. IUS/US); Amgen Center, 1840 De Havillan Thousand Ooks, CA 91322-1789 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SPOHR, UI (US/US); 2925 Glenwood Drive #305, Beudler, CUS) MALONE, Michael J, IUS/USI; 6054H d Avenue, Boulder, CO 80030 (US) MANTLO, N (US/US); 2338 Ginny Way, Lafsyette, CO 80026 (74) Agents: ODRE, Steven, M. et al.; Amgen, Inc., Amge 1840 De Havilland Drive, Thousand Oaks, CA 913 (US).	04.12.9) U I I I I I I I I I I I I I I I I I I I	US US US US US US US US US US US US US U	(81) Designated States: AL, AM, AT, A BY, CA, CH, CN, CL, CZ, DE, GH, HU, ID, IL, IS, IP, KE, K, LR, LS, LT, LU, LV, MD, MG, NZ, PL, PT, RO, RU, SD, SE, SC, TT, UA, UG, US, UZ, VN, YU KE, LS, MW, SD, SZ, UG, ZW), BY, KG, KZ, MD, RU, TJ, TM), CH, DE, DK, ES, FI, FR, GB, PT, SE), OAPI patent (BF, B), CML, MR, NE, SN, TD, TG). Published Without international search repaper receipt of that report.	DK, EE, ES, FI, GB, GE, G, KP, KR, KZ, LC, LK, MK, MN, MW, MX, NO, S, SI, SK, SL, TJ, TM, TR, ZW, ARIPO patent (GH, Eurosian patent (AM, AZ, European patent (AT, BE, GR, IE, IT, LU, MC, NL, F, CG, CI, CM, GA, GN,
(\$4) Title: SUBSTITUTED PYRIMIDINE COMPOUND (\$7) Abstract Selected novel substituted pyrimidine compounds at IL—6 and/or IL—8 mediated diseases, and other maladies, su prodrugs and pharmaceutically acceptable salts thereof, phad other maladies or conditions involving inflammation, making such compounds as well as to intermediates useful	re effe uch as p armacer pain, o	ctiv pair utic	e for prophylaxis and treatment of disease and diabetes. The invention encompasses al compositions and methods for prophylax etes and the like. The subject invention a	novel compounds, analogs is and treatment of diseases

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
ĐE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

WO 98/24782 PCT/US97/22390

SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE

BACKGROUND OF THE INVENTION

5 This is a nonprovisional application derived from U.S. provisional application serial no. 60/032,128 filed December 5, 1996, U.S. provisional application serial no. 60/050,950 filed June 13, 1997 and U.S. nonprovisional patent application serial no. not yet assigned filed November 21, 1997 each of which are 10 incorporated herein by reference in their entirety. The present invention comprises a new class of compounds useful in treating diseases, such as TNF-a, IL-1B, IL-6 and/or IL-8 mediated diseases and other maladies, such 15 as pain and diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. This invention also relates to intermediates and processes useful in the preparation of such compounds. 20

Interleukin-1 (IL-1) and Tumor Necrosis Factor α (TNF- α) are pro-inflammatory cytokines secreted by a variety of cells, including monocytes and macrophages, in response to many inflammatory stimuli (e.g., lipopolysaccharide - LPS) or external cellular stress (e.g., osmotic shock and peroxide).

25

Elevated levels of TNF-α and/or IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid

30 arthritis; Pagets disease; osteophorosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; pancreatic β cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome

(ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia, Reiter's

syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster are also exacerbated by TNF- α .

It has been reported that $TNF-\alpha$ plays a role in

head trauma, stroke, and ischemia. For instance, in 10 animal models of head trauma (rat), TNF-0 levels increased in the contused hemisphere (Shohami et al., J. Cereb. Blood Flow Metab. 14, 615 (1994)). In a rat model of ischemia wherein the middle cerebral artery was occluded, the levels of TNF-α mRNA of TNF-α increased 15 (Feurstein et al., Neurosci. Lett. 164, 125 (1993)). Administration of TNF-α into the rat cortex has been reported to result in significant neutrophil accumulation in capillaries and adherence in small blood 2.0 vessels. TNF-α promotes the infiltration of other cytokines (IL-1B, IL-6) and also chemokines, which promote neutrophil infiltration into the infarct area (Feurstein, Stroke 25, 1481 (1994)). TNF-α has also been implicated to play a role in type II diabetes 25 (Endocrinol. 130, 43-52, 1994; and Endocrinol. 136, 1474-1481, 1995).

TNF-α appears to play a role in promoting certain viral life cycles and disease states associated with them. For instance, TNF-α secreted by monocytes induced 30 elevated levels of HIV expression in a chronically infected T cell colone (Clouse et al., J. Immunol. 142, 431 (1989)). Lahdevirta et al., (Am. J. Med. 85, 289 (1988)) discussed the role of TNF-α in the HIV associated states of cachexia and muscle degradation.

3, are also affected by IL-1.

PCT/US97/22390

3

 $TNF-\alpha$ is upstream in the cytokine cascade of inflammation. As a result, elevated levels of $TNF-\alpha$ may lead to elevated levels of other inflammatory and proinflammatory cytokines, such as IL-1, IL-6, and IL-8. 5 Elevated levels of IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; ulcerative 10 colitis; anaphylaxis; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; 15 sepsis; septic shock; and toxic shock syndrome. Viruses sensitive to TNF- α inhibition, e.g., HIV-1, HIV-2, HIV-

TNF- α and IL-1 appear to play a role in pancreatic ß cell destruction and diabetes. Pancreatic ß cells 20 produce insulin which helps mediate blood glucose homeostasis. Deterioration of pancreatic & cells often accompanies type I diabetes. Pancreatic & cell functional abnormalities may occur in patients with type II diabetes. Type II diabetes is characterized by a functional resistance to insulin. Further, type II 25 diabetes is also often accompanied by elevated levels of plasma glucagon and increased rates of hepatic glucose production. Glucagon is a regulatory hormone that attenuates liver gluconeogenesis inhibition by insulin. 30 Glucagon receptors have been found in the liver, kidney and adipose tissue. Thus glucagon antagonists are useful for attenuating plasma glucose levels (WO 97/16442, incorporated herein by reference in its entirety). By antagonizing the glucagon receptors, it 35 is thought that insulin responsiveness in the liver will

35

improve, thereby decreasing gluconeogenesis and lowering the rate of hepatic glucose production.

In rheumatoid arthritis models in animals, multiple intra-articular injections of IL-1 have led to an acute and destructive form of arthritis (Chandrasekhar et al., Clinical Immunol Immunopathol. 55, 382 (1990)). In studies using cultured rheumatoid synovial cells, IL-1 is a more potent inducer of stromelysin than is TNP- α (Firestein, Am. J. Pathol. 140, 1309 (1992)). At sites of local injection, neutrophil, lymphocyte, and monocyte emigration has been observed. The emigration is attributed to the induction of chemokines (e.g., IL-8), and the up-regulation of adhesion molecules (Dinarello, Eur. Cytokine Netw. 5, 517-531 (1994)).

15 IL-1 also appears to play a role in promoting certain viral life cycles. For example, cytokine-induced increase of HIV expression in a chronically infected macrophage line has been associated with a concomitant and selective increase in IL-1 production
20 (Folks et al., J. Immunol. 136, 40 (1986)). Beutler et al. (J. Immunol. 135, 3969 (1985)) discussed the role of IL-1 in cachexia. Baracos et al. (New Eng. J. Med. 308, 553 (1983)) discussed the role of IL-1 in muscle decemeration.

25 In rheumatoid arthritis, both IL-1 and TNF-α induce synoviocytes and chondrocytes to produce collagenase and neutral proteases, which leads to tissue destruction within the arthritis joints. In a model of arthritis (collagen-induced arthritis (CIA) in rats and mice), intra-articular administration of TNF-α either prior to

Intra-articular administration of TNF-α either prior to or after the induction of CIA led to an accelerated onset of arthritis and a more severe course of the disease (Brahn et al., Lymphokine Cytokine Res. 11, 253 (1992); and Cooper, Clin. Exp. Immunol. 898, 244 (1992)).

IL-8 has been implicated in exacerbating and/or

causing many disease states in which massive neutrophil

15

25

infiltration into sites of inflammation or injury (e.g., ischemia) is mediated by the chemotactic nature of IL-8, including, but not limited to, the following: asthma, inflammatory bowel disease, psoriasis, adult respiratory distress syndrome, cardiac and renal reperfusion injury, thrombosis and glomerulonephritis. In addition to the chemotaxis effect on neutrophils, IL-8 also has the ability to activate neutrophils. Thus, reduction in IL-8 levels may lead to diminished neutrophil infiltration.

Several approaches have been taken to block the effect of TNF- α . One approach involves using soluble receptors for TNF- α (e.g., TNFR-55 or TNFR-75), which have demonstrated efficacy in animal models of TNF- α -mediated disease states. A second approach to neutralizing TNF- α using a monoclonal antibody specific to TNF- α , cA2, has demonstrated improvement in swollen joint count in a Phase II human trial of rheumatoid arthritis (Feldmann et al., Immunological Reviews, pp. 195-223 (1995)). These approaches block the effects of TNF- α and IL-1 by either protein sequestration or receptor antagonism.

Bennett et al. (*J. Med. Chem.* 21, 623 (1978)) synthesized a number of pyrimidines of the form:

$$R_a^1 \bigvee_{N \in \mathbb{N}} R_a^3$$

where, inter alia, R_a^1 is 2-, 3-, or 4-pyridyl, R_a^2 is H, methyl, or phenyl, and R_a^3 is H, amino. They reported that none of these compounds tested against rat adjuvant-induced edema displayed a level of activity sufficient to warrant further investigation and that additional testing confirmed that the compounds represented a series of false positives in the carrageenan-induced edema model.

20

25

30

Ife et al. (Bioorg. Med. Chem. Lett. 5, 543 (1995)) reported that another pyrimidine ($R_a^1 = 2$ -methylphenyl, $R_a^2 = 2$ -pyridyl, and $R_a^2 = n$ -propyl, wherein R_a^1 , R_a^2 , and R_a^3 are as in structure i, supra) had several times lower H'/K'-ATPase inhibitory activity than related 4-(2-pyridyl)-5-phenylthiazole compounds.

WO 97/33883 describes substituted pyrimidine compounds useful in treating cytokine mediated diseases.

BRIEF DESCRIPTION OF THE INVENTION

The present invention comprises a new class of compounds useful in the prophylaxis and treatment of diseases, such as TNF- α , IL-1 β , IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds, methods for the prophylaxis and treatment of TNF- α , IL-1 β , IL-6 and/or IL-8 mediated diseases, such as inflammatory, pain and diabetes diseases, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of the compounds of the invention.

The compounds of the invention are represented by the following general structure:

wherein R1, R2, R11 and R12 are defined below.

The foregoing merely summarizes certain aspects of the invention and is not intended, nor should it be construed, as limiting the invention in any way. All patents and other publications recited herein are hereby incorporated by reference in their entirety.

15

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there is provided compounds of the formula:

$$R_{11}$$
 R_{12}
 R_{12}
 R_{13}
 R_{14}

or a pharmaceutically acceptable salt thereof, wherein

R₁ and R₂ are each independently -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and 10 heterocyclyl radicals in each -Z-Y is 0-3; preferably, 0-2; more preferably, 0-1; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R₁ and R₂ is 0-4; preferably, 0-3; more preferably, 0-2: most preferably, 0-1;

preferably, R₂ is a radical of hydrogen, C₁-C₄ alkyl,
halo, hydroxy, C₁-C₄ alkoxy, C₁-C₂ haloalkoxy of 1-3 halo
radicals, thiol, C₁-C₄ alkylthio, aminosulfonyl, C₁-C₄
alkylaminosulfonyl, di-(C₁-C₄ alkyl)aminosulfonyl,

20 amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅
alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄
alkylsulfonylamino or C₁-C₂ haloalkyl of 1-3 halo
radicals;

25 more preferably, R₂ is a radical of hydrogen, C₁-C₄
 alkyl, halo, hydroxy, C₁-C₄ alkoxy, trifluoromethoxy,
 thiol, C₁-C₄ alkylthio, amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
 alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino or
30 trifluoromethyl;

more preferably, R_2 is a radical of hydrogen, methyl, ethyl, fluoro, chloro, hydroxy, methoxy, trifluoromethoxy, amino, methylamino, dimethylamino, acetylamino or trifluoromethyl; and most preferably, R_2 is a radical of hydrogen or hydroxy;

wherein each Z is independently a

- (1) bond;
- (2) alkyl, alkenyl or alkynyl radical optionally
- substituted by (a) 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoy, alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino,
- alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, halo, alkyl or haloalkyl;
 - (3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino,
- 20 alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino,
- alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino,
 25 hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or
 haloalkyl;

preferably, each Z is independently a

- bond;
- 30 (2) C₁-C₈ alkyl, C₂-C₈ alkenyl or C₂-C₈ alkynyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or halo, and (b)
- 35 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino,

 $(C_1-C_4 \text{ alkoxy})$ carbonylamino, $C_1-C_4 \text{ alkylsulfonylamino}$, hydroxy, $C_1-C_4 \text{ alkoxy}$, $C_1-C_4 \text{ alkylthio}$, halo, $C_1-C_4 \text{ alkylor } C_1-C_4 \text{ haloalkyl of } 1-3 \text{ halo radicals}$; (3) heterocyclyl radical optionally substituted by 1-3

- 5 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or
- (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl
- 15 or C₁-C₄ haloalkyl of 1-3 halo radicals;

more preferably, each Z is independently a

- bond;
- (2) C₁-C₈ alkyl, C₂-C₈ alkenyl or C₂-C₈ alkynyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄
 - alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b)
 - 1-2 radicals of heterocyclyl, aryl or heteroaryl
- optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
- 30 (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl) amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy) carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄
- 35 haloalkyl of 1-3 halo radicals; or

(4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl) amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy) carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, 5 C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

more preferably, each Z is independently a

- (1) bond;
- 10 (2) C₁-C₈ alkyl or C₂-C₈ alkenyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy) carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy, C₁-C₄ alkoxy) carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals:
 - (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, $di-(C_1-C_4$ alkyl)amino, $(C_1-C_4$ alkoxy)carbonylamino, hydroxy, C_1-C_4 alkoxy, C_1-C_4 alkylthio or C_1-C_4 alkyl radicals; or
- 25 (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or C₁-C₅ haloalkyl of 1-3 halo radicals;

more preferably, each Z is independently a

- (1) bond;
- (2) C_1-C_4 alkyl or C_2-C_5 alkenyl radical optionally
- 35 substituted by 1-3 radicals of amino, di-(C1-C2

- alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3
- 5 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₂ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl radicals:
- 10 (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C₁-C₂ alkyl)amino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio or C₁-C₄ alkyl radicals; or
 - (4) aryl or heteroaryl radical optionally substituted by
- 15 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl radicals;
- 20 more preferably, each Z is independently a
 - (1) bond:
 - (2) C_1 - C_4 alkyl or C_2 - C_5 alkenyl radical optionally substituted by 1-3 radicals of amino, di- $(C_1$ - C_2 alkyl)amino, $(C_1$ - C_4 alkoxy)carbonylamino, hydroxy, C_1 - C_2
- 25 alkoxy, C₁-C₂ alkylthio or halo, and (b) 1-2 radicals of aryl or heteroaryl optionally substituted by 1-2 radicals of amino, di-(C₁-C₂ alkyl)amino, acetamido, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl
- 30 radicals: or
 - (3) aryl or heteroaryl radical optionally substituted by
 - 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, acetamido, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkvlthio, cvano, halo, C₁-C₄ alkyl or trifluoromethyl
- 35 radicals:

more preferably, each Z is independently a

- (1) bond: or
- (2) C1-C4 alkyl radical optionally substituted by 1-2
- 5 radicals of amino, di-(C₁-C₂ alkyl)amino, (C₁-C₄ alkoxy) carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, halo or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl
- 10 radicals; and

most preferably, each Z is independently a

- (1) bond: or
- (2) C1-C4 alkyl radical optionally substituted by 1-2
- 15 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;

each Y is independently a

- hydrogen radical;
- 20 (2) halo or nitro radical;
 - (3) -C(0)-R20 or -C(NR5)-NR5R21 radical;
 - (4) $-OR_{21}$, $-O-C(O)-R_{21}$, $-O-C(O)-NR_5R_{21}$ or $-O-C(O)-NR_{22}-S(O)_2-R_{20}$ radical;
 - (5) $-SR_{21}$, $-S(O)-R_{20}$, $-S(O)_2-R_{20}$, $-S(O)_2-NR_5R_{21}$, $-S(O)_2-NR_5R_{21}$
- 25 $NR_{22}-C(0)-R_{21}$, $-S(0)_2-NR_{22}-C(0)-OR_{20}$ or $-S(0)_2-NR_{22}-C(0)-NR_{5}R_{21}$ radical; or
 - (6) $-NR_5R_{21}$, $-NR_{22}-C(O)-R_{21}$, $-NR_{22}-C(O)-OR_{20}$, $-NR_{22}-C(O)-NR_5R_{21}$, $-NR_{22}-C(O)_2-R_{20}$ or $-NR_{22}-C(O)_2-NR_5R_{21}$ radical;
- 30

preferably, each Y is independently a

- (1) hydrogen radical;
- (2) halo radical;
- (3) -C(0)-R20 or -C(NR5)-NR5R21 radical;
- 35 (4) -OR₂₁, -O-C(0)-R₂₁ or -O-C(0)-NR₅R₂₁ radical;

- (5) $-SR_{21}$, $-S(0)-R_{20}$, $-S(0)_2-R_{20}$ or $-S(0)_2-NR_5R_{21}$ radical; or
- (6) $-NR_5R_{21}$, $-NR_{22}-C(O)-R_{21}$, $-NR_{22}-C(O)-OR_{20}$, $-NR_{22}-C(O)-NR_5R_{21}$, $-NR_{22}-C(NR_5)-NR_5R_{21}$, $-NR_{22}-S(O)_2-R_{20}$ or $-NR_{22}-C(NR_5)-NR_5R_{21}$, $-NR_{22}-S(O)_2-R_{20}$ or $-NR_{22}-C(NR_5)-NR_{22}-C(NR_5)-NR_{22}-C(NR_5)$
- 5 S(0)₂-NR₅R₂₁ radical;

more preferably, each Y is independently a

- (1) hydrogen radical;
- (2) -C(0)-R20 radical:
- 10 (3) $-OR_{21}$, $-SR_{21}$, $-S(O)-R_{20}$, $-S(O)_2-R_{20}$ or $-S(O)_2-NR_5R_{21}$ radical; or
 - (4) -NR₅R₂₁, -NR₂₂-C(O)-R₂₁, -NR₂₂-C(O)-OR₂₀, -NR₂₂-C(O)-NR₅R₂₁, -NR₂₂-S(O)₂-R₂₀ or -NR₂₂-S(O)₂-NR₅R₂₁ radical;
- 15 more preferably, each Y is independently a
 - (1) hydrogen radical;
 - (2) -C(0)-R20 radical;
 - (3) $-OR_{21}$, $-SR_{21}$, $-S(0)-R_{20}$, $-S(0)_2-R_{20}$ or $-S(0)_2-NR_5R_{21}$ radical; or
- 20 (4) $-NR_5R_{21}$, $-NR_{22}-C(0)-R_{21}$ or $-NR_{22}-S(0)_2-R_{20}$ radical;

more preferably, each Y is independently a

- (1) -C(0)-R20 radical;
- (2) $-OR_{21}$, $-SR_{21}$, $-S(O)-R_{20}$, $-S(O)_2-R_{20}$ or $-S(O)_2-NR_5R_{21}$
- 25 radical; or
 - (3) $-NR_5R_{21}$, $-NR_{22}-C(0)-R_{21}$ or $-NR_{22}-S(0)_2-R_{20}$ radical.

most preferably, each Y is independently a $-OR_{21}$, $-SR_{21}$ or $-NR_{5}R_{21}$ radical:

30

wherein each R₅ is independently

- (1) hydrogen radicals;
- (2) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino,
- 35 dialkylamino, hydroxy, alkoxy, alkylthio, -SO₃H or halo; or

- (3) aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl or cycloalkylalkyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy,
- 5 alkoxy, alkylthio, alkyl or haloalkyl;

preferably, each R5 is independently

- (1) hydrogen radicals;
- (2) C_1 - C_8 alkyl, C_2 - C_8 alkenyl or C_2 - C_8 alkynyl radicals
- optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, -SO₃H or halo; or
 - (3) aryl, heteroaryl, aryl- C_1 - C_4 -alkyl, heteroaryl- C_1 - C_4 -alkyl, heterocyclyl, heterocyclyl- C_1 - C_4 -alkyl, C_3 - C_8
- 15 cycloalkyl or C₃-C₈-cycloalkyl-C₁-C₄-alkyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

20

- more preferably, each R5 is independently
- (1) hydrogen radicals;
- (2) C_1 - C_4 alky1, C_2 - C_5 alkenyl or C_2 - C_5 alkynyl radicals optionally substituted by 1-3 radicals of amino, C_1 - C_4
- 25 alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, -SO.H or halo; or
 - (3) aryl, heteroaryl, aryl- C_1 - C_4 -alkyl, heteroaryl- C_1 - C_4 -alkyl, heterocyclyl, heterocyclyl- C_1 - C_4 -alkyl, C_3 - C_8 -cycloalkyl- C_1 - C_4 -alkyl radicals
- 30 optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
- 35 more preferably, each R5 is independently

- (1) hydrogen radicals;
- (2) C_1-C_4 alkyl or C_2-C_5 alkenyl radicals optionally substituted by 1-3 radicals of amino, $di-(C_1-C_4-alky)$ amino, hydroxy, C_1-C_4 alkoxy, C_1-C_4 alkylthio, -
- 5 SO,H or halo; or
 - (3) phenyl-C₁-C₂-alkyl, heteroaryl-C₁-C₂-alkyl, heterocyclyl-C₁-C₂-alkyl or C₃-C₆-cycloalkyl-C₁-C₂-alkyl radicals optionally substituted by 1-3 radicals of amino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylyl or C₁-C₅ alkylyl of 1-3 halo
- 10 C_4 alkylthio, C_1 - C_4 alkyl or C_1 - C_2 haloalkyl of 1-3 halo radicals;

more preferably, each R5 is independently

- (1) hydrogen radical;
- 15 (2) C_1 - C_4 alkyl radical optionally substituted by 1-3 radicals of amino, di- $(C_1$ - C_2 -alkyl)amino, hydroxy, C_1 - C_2 alkoxy, C_1 - C_2 alkylthio or halo; or
 - $\label{eq:condition} \begin{tabular}{ll} (3) & phenyl-C_1-C_2-alkyl, & heterocyclyl-C_1-C_2-alkyl & or C_3-C_6-cycloalkyl-C_1-C_2-alkyl & or C_3-C_6-cycloalkyl-C_1-C_2-cycloalkyl-C_1-C_2-cycloalkyl-C_1-C_2-cycloalkyl-C_1-C_2-cycloalkyl-C_1-C_2-cycloalkyl-C_1-C_2-cycloalkyl-C_1-C_2-cycloalkyl-C_1-C_2-cycloalkyl-C_1-C_2-$
- 20 radicals optionally substituted by 1-3 radicals of amino, di-(C₁-C₂-alkyl)amino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, methoxy, methylthio, C₁-C₄ alkyl or trifluoromethyl radicals;
- 25 more preferably, each R_5 is independently
 - (1) hydrogen radical;
 - (2) C_1 - C_4 alkyl radical optionally substituted by 1-3 halo radicals; or
 - (3) phenyl-C₁-C₂-alkyl or heteroaryl-C₁-C₂-alkyl,
- 30 radicals optionally substituted by 1-3 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, methyl or trifluoromethyl radicals;
 - more preferably, each R_5 is independently hydrogen or
 - 35 C₁-C₄ alkyl radical; and most preferably, each R₅ is a hydrogen radical;

- wherein each R20 is independently
- (1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino,
- 5 dialkylamino, alkanoylamino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, aminocarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halo or aralkoxy, aralkylthio, aralkylsulfonyl, cycloalkyl, heterocyclyl,
- aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkanoylamino, alkanoyl, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halo, alkyl or haloalkyl;
- 15 (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or (3) aryl or heteroaryl radicals optionally substituted
- 20 by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, cyano, halo, azido, alkyl or haloalkyl;
- 25 preferably, each R₂₀ is independently (1) C₁-C₈ alkyl, C₂-C₈ alkenyl or C₂-C₈ alkynyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-
- 30 N-(C₁-C₄ alkyl)amino, aminocarbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-alkylthio, aryl-C₁-C₄-alkylsulfonyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl or
- 35 heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄

- alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
 alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, C₁-C₅
 alkanoyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄
 alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo, C₁-C₄ alkyl or

 5 C₁-C₄ haloalkyl of 1-3 halo radicals:
 - (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, d_1 - $(C_1$ - C_4 alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4 alkoxy)carbonylamino, C_1 - C_4 alkylsulfonylamino, hydroxy,
- 10 C_1-C_4 alkoxy, C_1-C_4 alkylthio, C_1-C_4 alkyl or C_1-C_4 haloalkyl of 1-3 halo radicals; or
 - (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, C_1 - C_5 alkanoylamino, C_1 - C_4
- alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
- 20 more preferably, each R₂₀ is independently (1) C₁-C₈ alkyl, C₂-C₅ alkenyl or C₂-C₅ alkynyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-
- N-(C₁-C₄ alkyl)amino, aminocarbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkylsulfonyl, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-alkylsulfonyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl or
- 30 heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4

- alkylsulfinyl, C_1 - C_4 alkylsulfonyl, halo, C_1 - C_4 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals;
- (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, $C_1\text{-}C_4$ alkylamino, $\text{di-}(C_1\text{-}C_4$
- 5 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or
- (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-
- 15 3 halo radicals;

more preferably, each R20 is independently

- (1) C_1 - C_8 alkyl or C_2 - C_5 alkenyl radicals optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino,
- 20 di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-N-(C₁-C₄ alkyl)amino, aminocarbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-
- 25 alkylthio, aryl-C₁-C₄-alkylsulfonyl, C₃-C₆ cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl) amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoy) carbonylamino, C₁-C₄ alkylsulfonylamino, C₁-C₅
- 30 alkanoyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals;
 - (2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4 alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4

alkoxy) carbonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio or C_1 - C_4 alkyl; or

- (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C_1-C_4 alkylamino, $di-(C_1-C_4)$
- alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals;

10

- more preferably, each R_{20} is independently
- (1) C_1 - C_8 alkyl or C_2 - C_5 alkenyl radicals optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4 alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4
- 15 alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-N-(C₁-C₄
 alkyl)amino, aminocarbonylamino, hydroxy, C₁-C₄ alkoxy,
 C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄
 alkylsulfonyl, halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄ alkylthio, aryl-C₁-C₄-alkylsulfonyl, C₃-C₆ cycloalkyl,
- 20 heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, C₁-C₅ alkanoyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo,
- 25 C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals;
 (2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C₁-C₄ alkyl)amino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkvlthio or C₁-C₄ alkvl: or
- 30 (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, acetamido, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄
- 35 alkyl or trifluoromethyl radicals;

- more preferably, each Ron is independently
- (1) C_1 - C_8 alkyl radicals optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4
- 5 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-N-(C₁-C₄ alkyl)amino, aminocarbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo or C₃-C₆ cycloalkyl, heterocyclyl,
- aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl
- 15 radicals:
 - (2) heterocyclyl radical optionally substituted by 1-2 radicals of hydroxy, C_1-C_4 alkoxy, C_1-C_4 alkylthio or C_1-C_4 alkyl; or
 - (3) aryl or heteroaryl radicals optionally substituted
- 20 by 1-2 radicals of (C₁-C₄ alkoxy)carbonyl, amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or trifluoromethyl radicals;
- 25 more preferably, each R_{20} is independently
 - (1) C_1-C_6 alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, t-butoxycarbonylamino, N-((t-butoxy)carbonyl)-N-(methyl)amino, aminocarbonylamino, hydroxy, butoxy,
- 30 methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or
- 35 trifluoromethyl radicals;

- (2) heterocyclyl radical optionally substituted by 1-2 radicals of hydroxy or C_1 - C_4 alkyl; or
- (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy,
- 5 methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

more preferably, each R20 is independently

- (1) C_1 - C_6 alkyl radicals optionally substituted by 1-3
- 10 radicals of amino, methylamino, dimethylamino, tbutoxycarbonylamino, N-((t-butoxy)carbonyl)-N(methyl)amino, aminocarbonylamino, hydroxy, butoxy,
 methoxy, butylthio, methylthio, methylsulfinyl,
 methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl,
- 15 phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
 - cillidolomechyl ladicals;
 - (2) heterocyclyl radical; or
- 20 (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
- 25 most preferably, each R20 is independently
 - (1) C₁-C₆ alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, hydroxy or phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy,
- 30 methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
 - (2) heterocyclyl radical; or
 - (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy,
- 35 methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

each R21 is independently hydrogen radical or R20;

- each Roo is independently
- (1) hydrogen radical;
- 5 (2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl,
- alkylsulfonyl, cyano, halo, alkyl or haloalkyl; or (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio,
- 15 alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl; provided when Z is a bond and Y is -NR22-C(0)-NH2, then R22 is other then an optionally substituted aryl radical;
- 20 preferably, each R_{22} is independently
 - (1) hydrogen radical;
 - $\label{eq:condition} \begin{tabular}{ll} (2) C_1-C_4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C_1-C_4 alkylamino, C_2-C_4 alkylamino, C_1-C_4 alkylamino, C_2-C_4 alkylamino, C_2-C_4 alkylamino, C_2-C_4 alkylamino, C_2-C_4 alkylamino, C_2-C_5 alkylamino, C_2-C_6 alkylamino, C_2
- 25 di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or
- 30 (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄
- 35 alkylsulfonyl, cyano, halo, C_1-C_4 alkyl or C_1-C_4 haloalkyl of 1-3 halo radicals; provided when Z is a

bond and Y is $-NR_{22}-C(0)-NH_2$, then R_{22} is other then an optionally substituted aryl radical;

more preferably, each R22 is independently

- 5 (1) hydrogen radical; or
- (2) C₁-C₄ alkyl radical optionally substituted by a radical of phenyl or heteroaryl optionally substituted by 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-10 C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or
- C1-C2 haloalkyl of 1-3 halo radicals;

 more preferably, each R22 is independently hydrogen or

C₁-C₄ alkyl radical; and most preferably, each R₂₂ is independently hydrogen or methyl radical;

 $R_{\rm 11}$ and $R_{\rm 12}$ are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radicals of

- (1) R₃₀;
- 20 (2) halo or cyano radicals;
 - (3) $-C(0)-R_{30}$, $-C(0)-OR_{29}$, $-C(0)-NR_{31}R_{32}$ or $-C(NR_{31})-NR_{31}R_{32}$ radicals;
 - (4) $-OR_{29}$, $-O-C(O)-R_{29}$, $-O-C(O)-NR_{31}R_{32}$ or $-O-C(O)-NR_{33}-S(O)_2-R_{30}$ radicals;
- 25 (5) $-SR_{29}$, $-S(O)-R_{30}$, $-S(O)_2-R_{30}$, $-S(O)_2-NR_{31}R_{32}$, $-S(O)_2-NR_{33}-C(O)-R_{30}$, $-S(O)_2-NR_{33}-C(O)-R_{30}$ or $-S(O)_2-NR_{33}-C(O)-NR_{31}R_{32}$ radicals; or
 - (6) $-NR_{31}R_{32}$, $-NR_{33}-C$ (O) $-R_{29}$, $-NR_{33}-C$ (O) $-OR_{30}$, $-NR_{33}-C$ (O) $-NR_{31}R_{32}$, $-NR_{33}-C$ (NR₃₁) $-NR_{31}R_{32}$, $-NR_{33}-S$ (O) $2-R_{30}$ or $-NR_{33}-S$
- 30 S(O)₂-NR₃₁R₃₂ radicals;
 - provided that (1) R_{11} is other than a 4-pyridyl, 4-pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and
- 35 heterocyclyl radicals substituted on each of R₁₁ and R₁₂ is 0-1;

preferably, R_{11} and R_{12} are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of

- 5 (1) R₃₀;
 - (2) halo or cyano radicals;
 - (3) $-C(0)-R_{30}$, $-C(0)-OR_{29}$, $-C(0)-NR_{31}R_{32}$ or $-C(NR_{31})-NR_{31}R_{32}$ radicals;
 - (4) $-OR_{29}$, $-O-C(O)-R_{29}$, $-O-C(O)-NR_{31}R_{32}$ or $-O-C(O)-NR_{33}-C(O)$
- 10 S(0)2-R₃₀ radicals;
 - $\label{eq:continuous} $$(5) -SR_{29}, -S(0)-R_{30}, -S(0)_2-R_{30}, -S(0)_2-NR_{31}R_{32}, -S(0)_2-NR_{33}-C(0)-R_{30}, -S(0)_2-NR_{33}-C(0)-OR_{30} \mbox{ or } -S(0)_2-NR_{33}-C(0)-NR_{31}R_{32} \mbox{ radicals; or }$
 - (6) $-NR_{31}R_{32}$, $-NR_{33}-C$ (O) $-R_{29}$, $-NR_{33}-C$ (O) $-OR_{30}$, $-NR_{33}-C$ (O) $-OR_{30}$
- 15 NR₃₁R₃₂, -NR₃₃-C(NR₃₁)-NR₃₁R₃₂, -NR₃₃-S(O)₂-R₃₀ or -NR₃₃-S(O)₂-NR₃₁R₃₂ radicals; provided that (1) R₁₁ is other than a 4-pyridyl, 4-pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the
- 20 total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R₁₁ and R₁₂ is 0-1;

more preferably, R_{11} and R_{12} are each independently an 25 aryl or heteroaryl radical optionally substituted by 1-2 radicals of

- (1) R₃₀;
- (2) halo or cyano radicals;
- (3) $-C(O)-R_{30}$, $-C(O)-OR_{29}$, $-C(O)-NR_{31}R_{32}$ or $-C(NR_{31})$ -
- 0 NR₃₁R₃₂ radicals; or

more preferably, R_{11} is an aryl radical and R_{12} is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of

WO 98/24782 PCT/US97/22390

25

(1) R30;

(1) R30;

- (2) halo or cvano radicals:
- (3) $-C(0)-R_{30}$, $-C(0)-OR_{29}$, $-C(0)-NR_{31}R_{32}$ or $-C(NR_{31})-NR_{31}R_{32}$ radicals; or
- 5 (4) -OR₂₉, -SR₂₉, -S(0)-R₃₀, -S(0)₂-R₃₀, -S(0)₂-NR₃₁R₃₂, -NR₃₁R₃₂ or -NR₃₃-C(0)-R₂₉ radicals;

more preferably, R_{11} is an aryl radical and R_{12} is a heteroaryl radical, wherein the aryl and heteroaryl

- 10 radicals are optionally substituted by 1-2 radicals of
 - (2) halo or evano radicals; or
 - $(3) -C(0) -NR_{31}R_{32}, -OR_{29}, -SR_{29}, -S(0) -R_{30}, -S(0)_2 -R_{30}, -S(0)_3 -R_{30}, -S(0)_4 -R_{30}, -S(0)_5 -R$

 $S(0)_2-NR_{31}R_{32}$, $-NR_{31}R_{32}$ or $-NR_{33}-C(0)-R_{29}$ radicals;

15

more preferably, R_{11} is an aryl radical optionally substituted by 1-2 radicals of (1) R_{30} ; (2) halo or cyano radicals; or (3) -C(0)-NR3₁R₃₂, -OR₂₉, -SR₂₉, -S(0)-R₃₀, -S(0)₂-R₃₀, -S(0)₂-R₃₁R₃₂, -NR3₁R₃₂ or -NR3₁R₃₂

20 $C(0)-R_{29}$ radicals; more preferably, R_{11} is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl,

aminocarbonyl, methyl or trifluoromethyl radicals; more

- 25 preferably, R₁₁ is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl
- 30 radicals; and most preferably, R₁₁ is an unsubstituted phenyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfonyl, methyl or trifluoromethyl radicals;

more preferably, R₁₂ is a heteroaryl radical optionally substituted by 1-2 radicals of (1) Ran; (2) halo or cyano radicals; or (3) -C(0)-NR31R32, -OR29, -SR29, -NR31R32 or -NR33-C(0)-R29 radicals; more preferably, R12 is a heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; more preferably, R12 is a 4-pyridyl, 4quinolinyl, 4-imidazolyl or 4-pyrimidinyl radical optionally substituted by a radical of amino, 10 dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and most preferably, R12 is a 4-pyridyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl 15 radicals:

wherein each R30 is independently

- (1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of -NR31R31, -CO2R23, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo or aralkoxy, aralkylthio, aralkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of 25 amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl;
- (2) heterocyclyl radical optionally substituted by 1-3 30 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
- (3) aryl or heteroaryl radicals optionally substituted 35 by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino,

hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl;

preferably, each R30 is independently

- 5 (1) C₁-C₄ alkyl, C₂-C₄ alkenyl or C₂-C₄ alkynyl radicals optionally substituted by 1-3 radicals of -NR₃₁R₃₁, -C₀-C₂R₂₃, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, cyano, halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-alkylthio, aryl-C₁-C₄-alkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals
 - 0 alkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄
- 15 alkylsulfinyl, C₁-C₄ alkylsulfonyl, cyano, halo, C₁-C₄
 alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
 (2) heterocyclyl radical optionally substituted by 1-3
 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄
 alkyl)amino, C₁-C₅ alkanovlamino, (C₁-C₄
- 20 alkoxy)carbonylamino, C_1 - C_4 alkylsulfonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, cyano, C_1 - C_4 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals; or
 - (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, $C_1\text{-}C_4$ alkylamino, $di\text{-}(C_1\text{-}C_4$
- 25 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
- 30 more preferably, each R30 is independently
 - (1) C_1 - C_4 alkyl radical optionally substituted by 1-3 radicals of
 - (a) -NR₃₁R₃₁;
 - (b) C1-C4 alkoxy-carbonyl or phenoxycarbonyl or
- 35 phenylmethoxycarbonyl optionally substituted by 1-3

radicals of amino, alkylamino, di- $(C_1-C_4-alkyl)$ amino, C_1-C_5 alkanoylamino, $(C_1-C_4$ alkoxy) carbonylamino, C_1-C_4 alkylsulfonylamino, hydroxy, C_1-C_4 alkoxy, C_1-C_4 alkylthio, cyano, halo, C_1-C_4 alkyl or trifluoromethyl;

5

- (c) hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, or phenyl- C_1 - C_4 -alkoxy, phenyl- C_1 - C_4 -alkylthio, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4
- 10 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
 - (2) C1-C4 haloalkyl of 1-3 halo radical; or
- 15 (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl
- 20 radicals:

25

- more preferably, each $\ensuremath{\text{R}}_{30}$ is independently
- (1) C_1-C_4 alkyl radical optionally substituted by
- (a) amino, C₁-C₄ alkylamino or di-(C₁-C₄-alkyl)amino
- radicals; or
- (b) hydroxy, C_1 - C_4 alkoxy, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4 alkylamino, $(C_1$ - C_5 alkanoylamino, $(C_1$ - C_4
- 30 alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl radicals:
 - (2) C1-C2 haloalkyl of 1-3 halo radical; or
 - (3) aryl or heteroaryl radicals optionally substituted
- 35 by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4

alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4 alkoxy)carbonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, cyano, halo, C_1 - C_4 alkyl or trifluoromethyl radicals:

5

more preferably, each R30 is independently

- (1) C₁-C₄ alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, acetamido,
- 10 hydroxy, C₁-C₂ alkoxy, halo, C₁-C₄ alkyl or trifluoromethyl radicals:
 - (2) trifluoromethyl radical; or
 - (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, $di-(C_1-C_2 \text{ alkyl})$ amino,
- 15 acetamido, hydroxy, C₁-C₂ alkoxy, halo, C₁-C₄ alkyl or trifluoromethyl radicals;

more preferably, each R30 is independently

- (1) C₁-C₄ alkyl radical optionally substituted by a 20 phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
 - (2) trifluoromethyl radical; or
- 25 (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals:
- 30 most preferably, R30 is independently
 - (1) C_1-C_4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl
- 35 radicals;
 - (2) trifluoromethyl radical; or

(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

5

10

each R₂₉ is independently hydrogen radical or R₃₀; and most preferably, R₂₉ is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

each R31 is independently

- (1) hydrogen radicals:
- (2) alkyl radical optionally substituted by an
 15 cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkylamino, hydroxy, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
 (3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical
 - optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;

25

preferably, each R31 is independently

- hydrogen radicals;
- (2) C₁-C₄ alkyl radical optionally substituted by an C₃-C₈ cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or
- 35 (3) aryl, heteroaryl, heterocyclyl or C_3 - C_8 cycloalkyl radical optionally substituted by 1-3 radicals of amino,

 C_1-C_4 alkylamino, $di-(C_1-C_4$ alkyl)amino, C_1-C_5 alkanoylamino, $(C_1-C_4$ alkoxy)carbonylamino, C_1-C_4 alkylsulfonylamino, hydroxy, C_1-C_4 alkoxy, C_1-C_4 alkylthio, cyano, C_1-C_4 alkyl or C_1-C_4 haloalkyl of 1-3 halo radicals:

more preferably, each R31 is independently

- (1) hydrogen radicals; or
- (2) C1-C4 alkyl radical optionally substituted by an
- phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, d_1 - $(C_1$ - C_4 alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4 alkoxy)carbonylamino, hydroxy, C_1 - C_4 alkylthio, cyano, C_1 - C_4 alkyl or trifluoromethyl
- 15 radicals;

more preferably, each R_{31} is independently hydrogen or C_1 - C_4 alkyl radicals; and most preferably, each R_{31} is independently hydrogen, methyl or ethyl radicals;

20

each R32 is independently

- (1) hydrogen radicals:
- (2) alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical
- 25 optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or (3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical
- 30 optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;
- 35 preferably, each R32 is independently
 - (1) hydrogen radicals:

(2) C_1-C_4 alkyl radical optionally substituted by an C_3-C_8 cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C_1-C_4 alkylamino, d_1-C_5 alkanoylamino,

5 (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C₃-C₈ cycloalkyl

radical optionally substituted by 1-3 radicals of amino,

10 C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals:

15

more preferably, each R32 is independently

- hydrogen radicals;
- (2) C_1 - C_4 alkyl radical optionally substituted by an C_3 - C_6 cycloalkyl, aryl, heterocyclyl or heteroaryl radical
- 20 optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl) amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy) carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or
- 25 (3) aryl, heteroaryl, heterocyclyl or C_3-C_6 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C_1-C_4 alkylamino, $di-(C_1-C_4$ alkyl)amino, C_1-C_5 alkanoylamino, $(C_1-C_4$ alkoxy)carbonylamino, C_1-C_4 alkylsulfonylamino, hydroxy, C_1-C_4 alkoxy, C_1-C_4
- 30 alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

more preferably, each R₃₂ is independently

(1) hydrogen radicals;

- (2) C₁-C₄ alkyl radical optionally substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
- 5 alkoxy) carbonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkyl or trifluoromethyl radicals; or
 - (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
- 10 alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkyl or trifluoromethyl radicals;

more preferably, each R32 is independently

- hydrogen radicals;
- 15 (2) C₁-C₄ alkyl radical or C₁-C₂ alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals: or
- 20 (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals;

most preferably, R32 is independently

- 25 (1) hydrogen or C1-C4 alkyl radical; or
 - (2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; and

3.0

wherein each R33 is independently

- (1) hydrogen radical; or
- (2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted
- 35 by 1-3 radicals of amino, alkylamino, dialkylamino,

alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;

preferably, each R33 is independently

- (1) hydrogen radical; or
 - (2) C_1-C_4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C_1-C_4 alkylamino, C_1-C_5 alkanoylamino, (C_1-C_4)
- 10 alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

more preferably, each R₃₃ is independently hydrogen or 15 C₁-C₄ alkyl radical; and most preferably, each R₃₃ is independently hydrogen or methyl radical.

The following provisos relate to compounds of the invention, only, and not to the pharmaceutical

20 compositions or methods of use, which encompass the full breadth of compounds recited above (unless expressly stated otherwise):

- when R' and R" are the same and are a 5- or 6-member ring having from 1-3 heteroatoms
 independently selected from N, S, and O, to which
 ring a benzene ring is optionally fused, R" is
 phenyl or naphthyl optionally substituted with
 halo, C_i-C_i alkyl, C_i-C_i alkoxy, C_i-C_i alkylthiol,
 hydroxy, amino, C_i-C_i alkylamino, or dialkylamino,
 or R" is a 5- or 6-membered ring having from 1-3
 heteroatoms independently selected from N, S, and
 O, to which ring a benzene ring is optionally
 fused and optionally substituted with C_i-C_i alkyl,
 then R' is other than OH or NH_i;
- when R¹ is H, R¹¹ is phenyl and R¹² is phenyl or 4pyridyl, then R¹ is other than H, methyl, or amino;

5

- when R² is H, R¹¹ is 2-methylphenyl and R¹² is 2-pyridyl, then R¹ is other than n-propyl; and
- when R¹¹ and R¹² are each an optionally substituted phenyl radical, then R¹ is other than an optionally substituted 2-pyridyl radical.

The compounds of this invention may have in general several asymmetric centers and are typically depicted in the form of racemic mixtures. This invention is intended to encompass racemic mixtures, partially racemic mixtures and separate enantiomers and

diasteromers.

Compounds of interest include the following:

wherein R² is H and R¹¹, R¹², and R¹ are one of the combinations given in the following table:

R ¹¹	R12	R ¹
Phenvl	4-pyridyl	1-piperazinyl
4-fluorophenyl	4-pyridyl	1-piperazinyl
3-fluorophenyl	4-pyridyl	1-piperazinyl
2-fluorophenyl	4-pyridyl	1-piperazinyl
4-chlorophenyl	4-pyridyl	1-piperazinyl
3-chlorophenyl	4-pyridyl	1-piperazinyl
2-chlorophenyl	4-pyridyl	1-piperazinyl
4-tolyl	4-pyridyl	1-piperazinyl
3-tolyl	4-pyridyl	1-piperazinyl
2-tolyl	4-pyridyl	1-piperazinyl
4-trifluoro-	4-pyridyl	1-piperazinyl
methylphenyl		
3-trifluoro-	4-pyridyl	1-piperazinyl
methylphenyl	L	
2,6-	4-pyridyl	1-piperazinyl
dichlorophenyl		
2,6-dimethyl	4-pyridyl	1-piperazinyl
phenyl	1 1 2 2	1
3,4-	4-pyridyl	1-piperazinyl
dichlorophenyl 3,4-dimethyl	A merci deri	1 minoroginul
phenyl	4-pyridyl	1-piperazinyl
2,4-	4-pyridyl	1-piperazinyl
dichlorophenyl	4 DATIGAT	1 - bibergrinki
archizor Ophieny i		<u></u>

2,4-dimethyl phenyl	4-pyridyl	1-piperazinyl
Phenyl	2-amino-4- pyridyl	1-piperazinyl
4-fluorophenyl	2-amino-4- pyridyl	1-piperazinyl
3-fluorophenyl	2-amino-4- pyridyl	1-piperazinyl
2-fluorophenyl	2-amino-4- pyridyl	1-piperazinyl
4-chlorophenyl	2-amino-4- pyridyl	1-piperazinyl
3-chlorophenyl	2-amino-4- pyridyl	1-piperazinyl
2-chlorophenyl	2-amino-4- pyridyl	1-piperazinyl
4-tolyl	2-amino-4- pyridyl	1-piperazinyl
3-tolyl	2-amino-4- pyridyl	1-piperazinyl
2-toly1	2-amino-4- pyridyl	1-piperazinyl
4-trifluoro- methylphenyl	2-amino-4- pyridyl	1-piperazinyl
3-trifluoro- methylphenyl	2-amino-4- pyridyl	1-piperazinyl
2,6- dichlorophenyl	2-amino-4- pyridyl	1-piperazinyl
2,6-dimethyl phenyl	2-amino-4- pyridyl	1-piperazinyl
3,4- dichlorophenyl	2-amino-4- pyridyl	1-piperazinyl
3,4-dimethyl phenyl	2-amino-4- pyridyl	1-piperazinyl
2,4- dichlorophenyl	2-amino-4- pyridyl	1-piperazinyl
2,4-dimethyl phenyl	2-amino-4- pyridyl	1-piperazinyl
Phenyl	2-acetamido- 4-pyridyl	1-piperazinyl
4-fluorophenyl	2-acetamido- 4-pyridyl	1-piperazinyl
3-fluorophenyl	2-acetamido- 4-pyridyl	1-piperazinyl
2-fluorophenyl	2-acetamido- 4-pyridyl	1-piperazinyl
4-chlorophenyl	2-acetamido- 4-pyridyl	1-piperazinyl
3-chlorophenyl	2-acetamido- 4-pyridyl	1-piperazinyl
2-chlorophenyl	2-acetamido- 4-pyridyl	1-piperazinyl
4-tolyl	2-acetamido- 4-pyridyl	1-piperazinyl

2-acetamido- 4-pyridy 2-acetamido- 4-pyridy 3-trifluoro- 2-acetamido- 4-pyridy 3-trifluoro- 4-pyridy 4-pyridy 3-dinchropheny 4-pyridy 1-piperaziny 4-pyridy 3-4-dinchropheny 4-pyridy 1-piperaziny 1-piperazin			
2-acetamido-	3-tolyl	2-acetamido-	1-piperazinyl
4-pyridy 1-piperaziny 2-acetamido-methylpheny 4-pyridy 2-acetamido-methylpheny 4-pyridy 2-acetamido-methylpheny 2-acetamido-methylpheny 4-pyridy 2-acetamido-methylpheny 2-acetamido-dichloropheny 4-pyridy 1-piperaziny 1-pipera		4-pyridyl	
4-pyridy 1-piperaziny 2-acetamido-methylpheny 4-pyridy 2-acetamido-methylpheny 4-pyridy 2-acetamido-methylpheny 2-acetamido-methylpheny 4-pyridy 2-acetamido-methylpheny 2-acetamido-dichloropheny 4-pyridy 1-piperaziny 1-pipera	2-tolv1	2-acetamido-	1-piperazinyl
4-trifluoro-	2		- procuration
	4 + x i f 1 110 x 0		1 -111
3-trifluoro-methylphenyl			1-piperazinyi
methylphenyl			
2-6- dichlorophenyl 4-pyridyl 2-acetamido-dichlorophenyl 2-acetamido-phenyl 2-acetamido-phenyl 4-pyridyl 2-acetamido-phenyl 4-pyridyl 4-pyridyl			1-piperazinyl
dichlorophenyl 4-pyridyl 2,6-dimethyl 2-acetamido- jhenyl 4-pyridyl 3,4-dimethyl 2-acetamido- 4-pyridyl 1-piperazinyl 3,4-dimethyl 2-acetamido- jhenyl 4-pyridyl 2,4-dimethyl 2-acetamido- dichlorophenyl 4-pyridyl 2,4-dimethyl 2-acetamido- phenyl 2-acetamido- phenyl 2-acetamido- phenyl 2-acetamido- phenyl 2-acetamido- phenyl 1-piperazinyl 4-fluorophenyl 2-amino-4- pyrimidinyl 1-piperazinyl 2-fluorophenyl 2-amino-4- pyrimidinyl 1-piperazinyl 2-chlorophenyl 2-amino-4- pyrimidinyl 1-piperazinyl 2-chlorophenyl 2-amino-4- pyrimidinyl 1-piperazinyl 2-tolyl 2-amino-4- pyrimidinyl 1-piperazinyl 2-tolyl 2-amino-4- 1-piperazinyl pyr			
2-actamido-phenyl 2-acetamido-phenyl 4-pyridyl 3,4-dinethyl 2-acetamido-dichlorophenyl 4-pyridyl 1-piperazinyl 4-pyridyl 2-acetamido-phenyl 4-pyridyl 4-pyridyl 1-piperazinyl 4-pyridyl 2-acetamido-phenyl 4-pyridyl 1-piperazinyl 4-pyridyl 1-piperazinyl 4-pyridyl 1-piperazinyl 4-pyridyl 1-piperazinyl 4-pyridyl 1-piperazinyl 1-piperaz		2-acetamido-	1-piperazinyl
Dhemyl 4-pyridyl 3,4-dimethyl 2-acetamido-phemyl 4-pyridyl 1-piperazinyl 1-piper	dichlorophenyl	4-pyridyl	_
Dhemyl 4-pyridyl 3,4-dimethyl 2-acetamido-phemyl 4-pyridyl 1-piperazinyl 1-piper	2.6-dimethvl	2-acetamido-	1-piperazinyl
3.4- 2-acetamido- 1-piperazinyl 3,4-dimethyl 2-acetamido- 1-piperazinyl 2-acetamido- 1-piperazinyl 2-acetamido- 1-piperazinyl 2-acetamido- 1-piperazinyl 2,4-dimethyl 2-acetamido- 1-piperazinyl 1-piperazinyl		4-pyridyl	F=F=====2=
			1-ninerazinyl
2-actamido-phemyl 2-acetamido-phemyl 4-pyridyl 2-4-dichlorophemyl 4-pyridyl 2-acetamido-phemyl 4-pyridyl 1-piperazinyl 4-pyridyl 4-pyridyl 4-pyridyl 4-pyridyl 4-pyridyl 4-pyridyl 4-pyridyl 4-pyridyl 4-pyridyl 4-pyrimidinyl 4-fluorophemyl 2-amino-4-pyrimidinyl 1-piperazinyl 2-amino-4-pyrimidinyl 4-chlorophemyl 2-amino-4-pyrimidinyl 4-chlorophemyl 2-amino-4-pyrimidinyl 2-amino-4-pyrimidinyl 2-amino-4-pyrimidinyl 2-amino-4-pyrimidinyl 4-tolyl 2-amino-4-pyrimidinyl 2-amino-4-pipenyl 2-amino-4-pipenyl 2-amino-4-pipenyl 2-amino-4-pipenyl 2-amino-4-pipenyl 2-amino-4-pipenyl 2-amino-4-pipenyl 2-amino-4-pipenyl 2-amino-4-pipenyl 2-amino-4-pyrimidinyl 2-amino-4-pipenyl 2-amino-4-pipenyl 2-amino-4-pyrimidinyl 2-amino-4-pipenyl 2-amino-4-pyrimidinyl 2-amino-4-pipenyl 2-amino-4-pyrimidinyl 2-amino-			1 piperazinyi
phenyl			1 min annaimed
2.4- 2-acetamido- 1-piperazinyl 2.4-dimethyl 2-acetamido- 1-piperazinyl 2.4-dimethyl 2-acetamido- 1-piperazinyl 2-amino-4-			1-bibergzinki
dichlorophenyl 4-pyridyl 1-piperazinyl 2,4-dimethyl 2-acetamido- phenyl 1-piperazinyl Phenyl 2-amino-4- pyrimidinyl 1-piperazinyl 4-fluorophenyl 2-amino-4- pyrimidinyl 1-piperazinyl 3-fluorophenyl 2-amino-4- pyrimidinyl 1-piperazinyl 2-fluorophenyl 2-amino-4- pyrimidinyl 1-piperazinyl 3-chlorophenyl 2-amino-4- pyrimidinyl 1-piperazinyl 3-chlorophenyl 2-amino-4- pyrimidinyl 1-piperazinyl 4-tolyl 2-amino-4- pyrimidinyl 1-piperazinyl 3-tolyl 2-amino-4- pyrimidinyl 1-piperazinyl 4-trifluoro- methylphenyl 2-amino-4- pyrimidinyl 1-piperazinyl 3-trifluoro- methylphenyl 2-amino-4- pyrimidinyl 1-piperazinyl 2,6- dichlorophenyl 2-amino-4- pyrimidinyl 1-piperazinyl 2,6- dichlorophenyl 2-amino-4- pyrimidinyl 1-piperazinyl 3,4- dichlorophenyl 2-amino-4- pyrimidinyl 1-piperazinyl 3,4- dichlorophenyl 2-amino-4- pyrimidinyl 1-piperazinyl 3,4- 2-amino-4- phenyl 1-piperaziny			
2.4-dimethyl 2-acetamido- 1-piperazinyl 1-piperazinyl			1-piperazinyl
phenyl	dichiorophenyl		
Phenyl		2-acetamido-	1-piperazinyl
Phenyl	phenyl	4-pyridyl	
pyrimidinyl 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl phenyl 2-amino-4- 1-piperazinyl pyrimidinyl 3-amino-4- 1-piperazinyl pyrimidinyl 3-amino-4- 1-piperazinyl pyrimidinyl 3-amino-4- 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl			1-piperazinyl
4-fluorophenyl 2-amino-4- 1-piperazinyl 2-amino-4- pyrimidinyl 2-amino-4- 1-piperazinyl 1-pip			- F-F
pyrimidinyl 2-amino-4- 1-piperazinyl 1-pipe	4-fluorophenyl		1-ninoraginul
3-fluorophenyl 2-amino-4- 1-piperazinyl 2-fluorophenyl 2-amino-4- 1-piperazinyl 1-pipe	4 lidelophenyi		1-piperazinyi
pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 3-amino-4- 1-piperazinyl pyrimidinyl 3-amino-4- 1-piperazinyl pyrimidinyl 3-amino-4- 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl 1-pi	2 #1		1
2-fluorophenyl 2-amino-4- 1-piperazinyl pyrimidinyl	3-11uoropneny1		1-piperazinyi
pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-chlorophenyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-chlorophenyl 2-amino-4- 1-piperazinyl pyrimidinyl 3-trifluoro- 2-amino-4- 1-piperazinyl pyrimidinyl 2-6-chlorophenyl pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl phenyl pyrimidinyl 3-4-chlorophenyl pyrimidinyl 3-amino-4- 1-piperazinyl pyrimidinyl 3-amino-4- 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl 1-piperazi			
4-chlorophenyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-chlorophenyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-chlorophenyl 2-amino-4- 1-piperazinyl pyrimidinyl 4-tolyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 4-trifluoro- pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl 1-piperazinyl	2-fluorophenyl		1-piperazinyl
Dyrimidinyl			
3-chlorophenyl 2-amino-4- 1-piperazinyl 1-	4-chlorophenyl	2-amino-4-	1-piperazinyl
Dyrimidinyl 2-amino-4- 1-piperazinyl		pyrimidinyl	7 7
pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 3-tolyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-tolyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-tolyl 2-amino-4- 1-piperazinyl pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 3-trifluoro- pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 2,6- 2-amino-4- 1-piperazinyl pyrimidinyl 2,6- 2-amino-4- 1-piperazinyl pyrimidinyl 2,6- 2-amino-4- 1-piperazinyl phenyl pyrimidinyl 3,4- 2-amino-4- 1-piperazinyl pyrimidinyl 3,4-dimethyl pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 2,4- 2-amino-4- 1-piperazinyl pyrimidinyl 2,4- 2-amino-4- 1-piperazinyl pyrimidinyl 2,4- 2-amino-4- 1-piperazinyl 1-piperazinyl 2,4- 2-amino-4- 1-piperazinyl 1-piperaziny	3-chlorophenvl	2-amino-4-	1-piperazinvl
2-amino-4- 1-piperazinyl		pyrimidinyl	- F-F
Dyrimidinyl 2-amino-4- 1-piperazinyl 1-piperaz	2-chlorophenyl		1-niperaginul
2-amino-4- 1-piperazinyl 1-piper	z chiolophenyi		1-pipeluzinyi
Dyrimidinyl 2-amino-4- 1-piperazinyl 1-piperazinyl 2-amino-4- 1-piperazinyl	4 5 2 3 2 3		4
3-toly1	4-coryr		1-piperazinyi
Dyrimidinyl 2-amino-4- 1-piperazinyl 1-piperazi			
2-toly1	3-folat		1-piperazinyl
4-trifluoro-	2-tolyl		1-piperazinyl
methylphenyl pyrimidinyl 1-piperazinyl methylphenyl pyrimidinyl 2.6-		pyrimidinyl	
methylphenyl pyrimidinyl 1-piperazinyl methylphenyl pyrimidinyl 2.6-	4-trifluoro-		1-piperazinvl
3-trifluoro-	methylphenyl	pyrimidinyl	
methylphenyl pyrimidinyl 2,6-dimethyl pyrimidinyl 2,6-dimethyl 2-amino-4- 1-piperazinyl pyrimidinyl 3,4- 2-amino-4- dichlorophenyl pyrimidinyl 3,4-dimethyl pyrimidinyl 3,4-dimethyl pyrimidinyl 2-amino-4- 1-piperazinyl pyrimidinyl 2,4- 2-amino-4- 1-piperazinyl pyrimidinyl 2,4- 2-amino-4- 1-piperazinyl		12-amino-4-	1-ninerazinyl
2.6- 2-amino-4- 1-piperazinyl			- prpcraning
dichlorophenyl pyrimidinyl 2,6-dimethyl 2-amino-4- 1-piperazinyl phenyl 2-amino-4- 1-piperazinyl pyrimidinyl 3,4-dimethyl 2-amino-4- 1-piperazinyl phenyl pyrimidinyl 2,4- 2-amino-4- 1-piperazinyl pyrimidinyl 2,4- 2-amino-4- 1-piperazinyl 2,4- 2-amino-4- 1-piperazinyl		2-amino-4	1-ninoraginul
2.6-dimethyl 2-amino-4- 1-piperazinyl pyrimidinyl 3.4- 2-amino-4- 1-piperazinyl 1-piperazinyl			r-brbergzruhr
phenyl pyrimidinyl 1-piperazinyl	Q.C. Identification		<u> </u>
3,4- 2-amino-4- 1-piperazinyl 3,4-dimethyl 2-amino-4- 1-piperazinyl 1-piperazinyl 2,4- 2-amino-4- 1-piperazinyl 1-piperazinyl			1-piperazinyl
dichlorophenyl pyrimidinyl 1-piperazinyl phenyl pyrimidinyl 2-amino-4- 1-piperazinyl 2-amino-4- 1-piperazinyl 2-amino-4- 1-piperazinyl			
3.4-dimethyl			1-piperazinyl
phenyl pyrimidinyl 2,4- 2-amino-4- 1-piperazinyl			
phenyl pyrimidinyl	3,4-dimethyl	2-amino-4-	1-piperazinyl
2,4- 2-amino-4- 1-piperazinyl		pyrimidinyl	1
			1-piperazinyl
dismissipplicity i pyrimidinyi			- brbergarni
	Carrier Opiniony 1	1 P. J. Z. Z. Z. COLLEGE T. Y. T.	

2,4-dimethyl	2-amino-4-	1-piperazinyl
phenyl	pyrimidinyl	
Phenyl	4-pyridyl	2,6-dichlorobenzyl
4-fluorophenyl	4-pyridyl	2,6-dichlorobenzyl
3-fluorophenyl	4-pyridyl	2,6-dichlorobenzyl
2-fluorophenyl	4-pyridyl	2,6-dichlorobenzyl
4-chlorophenyl	4-pyridyl	2,6-dichlorobenzyl
3-chlorophenyl	4-pyridyl	2,6-dichlorobenzyl
2-chlorophenyl	4-pyridyl	2,6-dichlorobenzyl
4-tolyl	4-pyridyl	2,6-dichlorobenzyl
3-tolyl	4-pyridyl	2,6-dichlorobenzyl
2-tolyl	4-pyridyl	2,6-dichlorobenzyl
4-trifluoro-	4-pyridyl	2,6-dichlorobenzyl
methylphenyl		
3-trifluoro-	4-pyridyl	2,6-dichlorobenzyl
methylphenyl		
2,6-	4-pyridyl	2,6-dichlorobenzyl
dichlorophenyl		
2,6-dimethyl	4-pyridyl	2,6-dichlorobenzyl
phenyl	L	
3,4-	4-pyridyl	2,6-dichlorobenzyl
dichlorophenyl		
3,4-dimethyl	4-pyridyl	2,6-dichlorobenzyl
phenyl		
2,4-	4-pyridyl	2,6-dichlorobenzyl
dichlorophenyl	·	
2,4-dimethyl	4-pyridyl	2,6-dichlorobenzyl
phenyl Phenyl	2-amino-4-	2,6-dichlorobenzyl
PHEHYI	pyridyl	2,6-dichiorobenzyi
4-fluorophenyl	2-amino-4-	2,6-dichlorobenzyl
4 lidolophenyi	pyridyl	z,o-dichiolobenzyi
3-fluorophenyl	2-amino-4-	2,6-dichlorobenzyl
5 11uolopheny1	pyridyl	2,0 dichiologonigi
2-fluorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyridyl	2,0 4201121212121
4-chlorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyridyl	
3-chlorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyridyl	
2-chlorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyridyl	
4-tolyl	2-amino-4-	2,6-dichlorobenzyl
_	pyridyl	
3-tolyl	2-amino-4-	2,6-dichlorobenzyl
	pyridyl	
2-tolyl	2-amino-4-	2,6-dichlorobenzyl
	pyridyl	
4-trifluoro-	2-amino-4-	2,6-dichlorobenzyl
methylphenyl	pyridyl	
3-trifluoro-	2-amino-4-	2,6-dichlorobenzyl
methylphenyl	pyridyl	
2,6- dichlorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyridyl	

2,6-dimethyl phenyl	2-amino-4-	2,6-dichlorobenzyl
	pyridyl	0.6.11.11.11.11
3,4-	2-amino-4-	2,6-dichlorobenzyl
dichlorophenyl	pyridyl	0.6.11.1.
3,4-dimethyl	2-amino-4-	2,6-dichlorobenzyl
phenyl 2.4-	pyridyl	0.6.11.12
	2-amino-4-	2,6-dichlorobenzyl
dichlorophenyl	pyridyl	
2,4-dimethyl	2-amino-4-	2,6-dichlorobenzyl
phenyl	pyridyl	
Phenyl	2-acetamido-	2,6-dichlorobenzyl
4 63	4-pyridyl	0.6.11.13
4-fluorophenyl	2-acetamido-	2,6-dichlorobenzyl
	4-pyridyl	
3-fluorophenyl	2-acetamido-	2,6-dichlorobenzyl
	4-pyridyl	
2-fluorophenyl	2-acetamido-	2,6-dichlorobenzyl
	4-pyridyl	
4-chlorophenyl	2-acetamido-	2,6-dichlorobenzyl
	4-pyridyl	
3-chlorophenyl	2-acetamido-	2,6-dichlorobenzyl
	4-pyridyl	
2-chlorophenyl	2-acetamido-	2,6-dichlorobenzyl
	4-pyridyl	
4-tolyl	2-acetamido-	2,6-dichlorobenzyl
	4-pyridyl	
3-tolyl	2-acetamido-	2,6-dichlorobenzyl
	4-pyridyl	
2-tolyl	2-acetamido-	2,6-dichlorobenzyl
	4-pyridyl	
4-trifluoro-	2-acetamido-	2,6-dichlorobenzyl
methylphenyl	4-pyridyl	
3-trifluoro-	2-acetamido-	2,6-dichlorobenzyl
methylphenyl	4-pyridyl	
2,6-	2-acetamido-	2,6-dichlorobenzyl
dichlorophenyl	4-pyridyl	
2,6-dimethyl	2-acetamido-	2,6-dichlorobenzyl
phenyl	4-pyridyl	
3,4-	2-acetamido-	2,6-dichlorobenzyl
dichlorophenyl	4-pyridyl	
3,4-dimethyl	2-acetamido-	2,6-dichlorobenzyl
phenyl	4-pyridyl	-
2,4-	2-acetamido-	2,6-dichlorobenzyl
dichlorophenyl	4-pyridyl	
2,4-dimethyl	2-acetamido-	2,6-dichlorobenzyl
phenyl	4-pyridyl	
Phenyl	2-amino-4-	2,6-dichlorobenzyl
-	pyrimidinyl	
4-fluorophenyl	2-amino-4-	2.6-dichlorobenzyl
	pyrimidinyl	
3-fluorophenyl	2-amino-4-	2,6-dichlorobenzyl
J LIGGEOPHCHY!	pyrimidinyl	2,0 22222232
2-fluorophenyl	2-amino-4-	2.6-dichlorobenzyl
	pyrimidinyl	_,
	1 P. J Internal Transport	

4-chlorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyrimidinyl	
3-chlorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyrimidinyl	
2-chlorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyrimidinyl	
4-tolvl	2-amino-4-	2,6-dichlorobenzyl
	pyrimidinyl	_, = ==================================
3-tolvl	2-amino-4-	2,6-dichlorobenzyl
5 00171	pyrimidinyl	z, o diemiorobenzyi
2-tolyl	2-amino-4-	2,6-dichlorobenzyl
2 COLYT	pyrimidinyl	z, o-dichiolobenzyi
4-trifluoro-	2-amino-4-	2,6-dichlorobenzyl
		2,6-dichiorobenzyi
methylphenyl	pyrimidinyl	2 2 11 11
3-trifluoro-	2-amino-4-	2,6-dichlorobenzyl
methylphenyl	pyrimidinyl	
2,6-	2-amino-4-	2,6-dichlorobenzyl
dichlorophenyl	pyrimidinyl	
2,6-dimethyl	2-amino-4-	2,6-dichlorobenzyl
phenyl	pyrimidinyl	
3,4-	2-amino-4-	2,6-dichlorobenzyl
dichlorophenyl	pyrimidinyl	
3,4-dimethyl	2-amino-4-	2,6-dichlorobenzyl
phenyl	pyrimidinyl	
2,4-	2-amino-4-	2,6-dichlorobenzyl
dichlorophenyl	pyrimidinyl	z, o dichiolobenzy i
2,4-dimethyl	2-amino-4-	2,6-dichlorobenzyl
phenyl	pyrimidinyl	z,o dichiolobenzyi
Phenyl	4-pyridyl	2-(2-chlorophenyl)
FILETIAL	4-byrrdyr	ethylamino
4 61	4	2-(2-chlorophenyl)
4-fluorophenyl	4-pyridyl	
	· · · · · · · · · · · · · · · · · · ·	ethylamino
3-fluorophenyl	4-pyridyl	2-(2-chlorophenyl)
		ethylamino
2-fluorophenyl	4-pyridyl	2-(2-chlorophenyl)
		ethylamino
4-chlorophenyl	4-pyridyl	2-(2-chlorophenyl)
		ethylamino
3-chlorophenyl	4-pyridyl	2-(2-chlorophenyl)
	1	ethylamino
2-chlorophenyl	4-pyridyl	2-(2-chlorophenyl)
	- 122-	ethylamino
4-tolvl	4-pyridyl	2-(2-chlorophenyl)
4 00191	- pyrrayr	ethylamino
3-tolvl	4-pyridyl	2-(2-chlorophenyl)
3-coryr	4-pyridyr	ethylamino
2-tolyl	4	
5-corAr	4-pyridyl	2-(2-chlorophenyl)
4	 	ethylamino
4-trifluoro-	4-pyridyl	2-(2-chlorophenyl)
methylphenyl		ethylamino
3-trifluoro-	4-pyridyl	2-(2-chlorophenyl)
methylphenyl		ethylamino
2,6-	4-pyridyl	2-(2-chloropheny1)
dichlorophenyl		ethylamino
dichlorophenyl		ethylamino

WO 98/24782

	41	
2,6-dimethyl	4-pyridyl	2-(2-chlorophenyl)
phenyl		ethylamino
3,4-	4-pyridyl	2-(2-chlorophenyl)
dichlorophenyl		ethylamino
3,4-dimethyl	4-pyridyl	2-(2-chlorophenyl)
phenyl		ethylamino
2,4-	4-pyridyl	2-(2-chlorophenyl)
dichlorophenyl		ethylamino
2,4-dimethyl	4-pyridyl	2-(2-chlorophenyl)
phenyl		ethylamino
4-fluorophenyl	4-pyridyl	3-(3-fluorophenyl)
		propylamino
4-fluorophenyl	2-amino-4-	3-(3-fluorophenyl)
	pyrimidinyl	propylamino
benzyl	4-pyridyl	3-phenylpropylamino
benzyl	4-pyridyl	2-(4-fluorophenyl)
		ethylamino
2-thienyl	4-pyridyl	3-phenylpropylamino
2-thienyl	4-pyridyl	2-(4-fluorophenyl)
		ethylamino
cyclohexyl	4-pyridyl	3-phenylpropylamino
cyclohexyl	4-pyridyl	2-(4-fluorophenyl)
		ethylamino
tert-butyl	4-pyridyl	3-phenylpropylamino
tert-butyl	4-pyridyl	2-(4-fluorophenyl)
		ethylamino
4-fluorophenyl	4- piperidinyl	3-phenylpropylamino
4-fluorophenyl	4-	2-(4-fluorophenyl)
	piperidinyl	ethylamino
4-fluorophenyl	4-pyranyl	3-phenylpropylamino
4-fluorophenyl	4-pyranyl	2-(4-fluorophenyl)
		ethylamino
Phenyl	2-amino-4-	2-(2-chlorophenyl)
	pyridyl	ethylamino
4-fluorophenyl	2-amino-4-	2-(2-chlorophenyl)
	pyridyl	ethylamino
3-fluorophenyl	2-amino-4-	2-(2-chlorophenyl)
	pyridyl	ethylamino
2-fluorophenyl	2-amino-4-	2-(2-chlorophenyl)
	pyridyl	ethylamino
4-chlorophenyl	2-amino-4-	2-(2-chlorophenyl)
	pyridyl	ethylamino
3-chlorophenyl	2-amino-4-	2-(2-chlorophenyl)
	pyridyl	ethylamino
2-chlorophenyl	2-amino-4-	2-(2-chlorophenyl)
	pyridyl	ethylamino
4-tolyl	2-amino-4-	2-(2-chlorophenyl)
	pyridyl	ethylamino
3-tolyl	2-amino-4-	2-(2-chlorophenyl)
	pyridyl	ethylamino
2-tolyl	2-amino-4-	2-(2-chlorophenyl)
1	pyridyl	ethylamino

4-trifluoro-	2-amino-4-	2-(2-chlorophenyl)
methylphenyl	pyridyl	ethylamino
3-trifluoro-	2-amino-4-	2-(2-chlorophenyl)
methylphenyl	pyridyl	ethylamino
2,6-	2-amino-4-	2-(2-chlorophenyl)
dichlorophenyl	pyridyl	ethylamino
2,6-dimethyl	2-amino-4-	2-(2-chlorophenyl)
phenyl	pyridyl	ethylamino
3,4-	2-amino-4-	2-(2-chlorophenyl)
dichlorophenyl	pyridyl	ethylamino
3,4-dimethyl	2-amino-4-	2-(2-chlorophenyl)
phenyl	pyridyl	ethylamino
2,4-	2-amino-4-	2-(2-chlorophenyl)
dichlorophenyl	pyridyl	ethylamino
2,4-dimethyl	2-amino-4-	2-(2-chlorophenyl)
phenyl	pyridyl	ethylamino
Phenyl	2-acetamido-	2-(2-chlorophenyl)
•	4-pyridyl	ethylamino
4-fluorophenyl	2-acetamido-	2-(2-chlorophenyl)
	4-pyridyl	ethylamino
3-fluorophenyl	2-acetamido-	2-(2-chlorophenyl)
	4-pyridyl	ethylamino
2-fluorophenyl	2-acetamido-	2-(2-chlorophenyl)
- Linesophion,	4-pyridyl	ethylamino
4-chlorophenyl	2-acetamido-	2-(2-chlorophenyl)
a chiciopheny:	4-pyridyl	ethylamino
3-chlorophenyl	2-acetamido-	2-(2-chlorophenyl)
3 chiolophon,i	4-pyridyl	ethylamino
2-chlorophenyl	2-acetamido-	2-(2-chlorophenyl)
2 chiolophenyi	4-pyridyl	ethylamino
4-tolyl	2-acetamido-	2-(2-chlorophenyl)
4 00131	4-pyridyl	ethylamino
3-tolyl	2-acetamido-	2-(2-chlorophenyl)
3 60191	4-pyridyl	ethylamino
2-tolyl	2-acetamido-	2-(2-chlorophenyl)
2-00191	4-pyridyl	ethylamino
4-trifluoro-	2-acetamido-	2-(2-chlorophenyl)
methylphenyl	4-pyridyl	ethylamino
3-trifluoro-	2-acetamido-	2-(2-chlorophenyl)
methylphenyl	4-pyridyl	
2,6-		ethylamino
dichlorophenyl	2-acetamido-	2-(2-chlorophenyl)
	4-pyridyl	ethylamino
2,6-dimethyl	2-acetamido-	2-(2-chlorophenyl)
phenyl	4-pyridyl	ethylamino
3,4-	2-acetamido-	2-(2-chlorophenyl)
dichlorophenyl	4-pyridyl	ethylamino
3,4-dimethyl	2-acetamido-	2-(2-chlorophenyl)
phenyl	4-pyridyl	ethylamino
2,4-	2-acetamido-	2-(2-chlorophenyl)
dichlorophenyl	4-pyridyl	ethylamino
2,4-dimethyl	2-acetamido-	2-(2-chlorophenyl)
phenyl	4-pyridyl	ethylamino
Phenyl	2-amino-4-	2-(2-chlorophenyl)
1	pyrimidinyl	ethylamino

WO 98/24782 PCT/US97/22390 43

4-fluorophenyl	2-amino-4-	2-(2-chlorophenyl)
	pyrimidinyl	ethylamino
3-fluorophenyl	2-amino-4-	2-(2-chlorophenyl)
	pyrimidinyl	ethylamino
2-fluorophenyl	2-amino-4-	2-(2-chlorophenyl)
	pyrimidinyl	ethylamino
4-chlorophenyl	2-amino-4-	2-(2-chlorophenyl)
	pyrimidinyl	ethylamino
3-chlorophenyl	2-amino-4-	2-(2-chlorophenyl)
	pyrimidinyl	ethylamino
2-chlorophenyl	2-amino-4-	2-(2-chlorophenyl)
	pyrimidinyl	ethylamino
4-tolyl	2-amino-4-	2-(2-chlorophenyl)
	pyrimidinyl	ethylamino
3-tolyl	2-amino-4-	2-(2-chlorophenyl)
	pyrimidinyl	ethylamino
2-tolyl	2-amino-4-	2-(2-chlorophenyl)
	pyrimidinyl	ethylamino
4-trifluoro-	2-amino-4-	2-(2-chlorophenyl)
methylphenyl	pyrimidinyl	ethylamino
3-trifluoro-	2-amino-4-	2-(2-chlorophenyl)
methylphenyl	pyrimidinyl	ethylamino
2,6-	2-amino-4-	2-(2-chlorophenyl)
dichlorophenyl	pyrimidinyl	ethylamino
2,6-dimethyl	2-amino-4-	2-(2-chlorophenyl)
phenyl	pyrimidinyl	ethylamino
3,4-	2-amino-4-	2-(2-chlorophenyl)
dichlorophenyl	pyrimidinyl	ethylamino
3,4-dimethyl	2-amino-4-	2-(2-chlorophenyl)
phenyl	pyrimidinyl	ethylamino
2,4-	2-amino-4-	2-(2-chlorophenyl)
dichlorophenyl	pyrimidinyl	ethylamino
2,4-dimethyl	2-amino-4-	2-(2-chlorophenyl)
phenyl	pyrimidinyl	ethylamino
Phenyl	4-pyridyl	2-(4-fluorophenyl)ethyl
		amino
4-fluorophenyl	4-pyridyl	2-(4-fluorophenyl)ethyl
		amino
3-fluorophenyl	4-pyridyl	2-(4-fluorophenyl)ethyl
		amino
2-fluorophenyl	4-pyridyl	2-(4-fluorophenyl)ethyl
		amino
4-chlorophenyl	4-pyridyl	2-(4-fluorophenyl)ethyl
	1	amino
3-chlorophenyl	4-pyridyl	2-(4-fluorophenyl)ethyl
	1	amino
2-chlorophenyl	4-pyridyl	2-(4-fluorophenyl)ethyl
-11-	1	amino
4-tolyl	4-pyridyl	2-(4-fluorophenyl)ethyl
1174	- 233	amino
3-tolyl	4-pyridyl	2-(4-fluorophenyl)ethyl
1	- 1	amino
2-tolyl	4-pyridyl	2-(4-fluorophenyl)ethyl
	1 - 11 - 141	amino

4-trifluoro-	4-pyridyl	2-(4-fluorophenyl)ethyl
methylphenyl		amino
3-trifluoro-	4-pyridyl	2-(4-fluorophenyl)ethyl
methylphenyl		amino
2,6-	4-pyridyl	2-(4-fluorophenyl)ethyl
dichlorophenyl		amino
2,6-dimethyl	4-pyridyl	2-(4-fluorophenyl)ethyl
phenyl		amino
3,4-	4-pyridyl	2-(4-fluorophenyl)ethyl
dichlorophenyl		amino
3,4-dimethyl	4-pyridyl	2-(4-fluorophenyl)ethyl
phenyl		amino
2,4-	4-pyridyl	2-(4-fluorophenyl)ethyl
dichlorophenyl		amino
2,4-dimethyl	4-pyridyl	2-(4-fluorophenyl)ethyl
phenyl		amino
Phenyl	2-amino-4-	2-(4-fluorophenyl)ethyl
	pyridyl	amino
4-fluorophenyl	2-amino-4-	2-(4-fluorophenyl)ethyl
	pyridyl	amino
3-fluorophenyl	2-amino-4-	2-(4-fluorophenyl)ethyl
	pyridyl	amino
2-fluorophenyl	2-amino-4-	2-(4-fluorophenyl)ethyl
1	pyridyl	amino
4-chlorophenvl	2-amino-4-	2-(4-fluorophenyl)ethyl
	pyridyl	amino
3-chlorophenyl	2-amino-4-	2-(4-fluorophenyl)ethyl
- one or opnoing r	pyridyl	amino
2-chlorophenyl	2-amino-4-	2-(4-fluorophenyl)ethyl
	pyridyl	amino
4-tolyl	2-amino-4-	2-(4-fluorophenyl)ethyl
-	pyridyl	amino
3-tolyl	2-amino-4-	2-(4-fluorophenyl)ethyl
	pyridyl	amino
2-tolyl	2-amino-4-	2-(4-fluorophenyl)ethyl
2 001,1	pyridyl	amino
4-trifluoro-	2-amino-4-	2-(4-fluorophenyl)ethyl
methylphenyl	pyridyl	amino
3-trifluoro-	2-amino-4-	2-(4-fluorophenyl)ethyl
methylphenyl	pyridyl	amino
2,6-	2-amino-4-	2-(4-fluorophenyl)ethyl
dichlorophenyl	pyridyl	amino
2,6-dimethyl	2-amino-4-	
phenyl	pyridyl	2-(4-fluorophenyl)ethyl amino
3,4-	2-amino-4-	
dichlorophenyl	pyridyl	2-(4-fluorophenyl)ethyl amino
3,4-dimethyl	2-amino-4-	
phenyl	pyridyl	2-(4-fluorophenyl)ethyl
2,4-		amino
	2-amino-4-	2-(4-fluorophenyl)ethyl
dichlorophenyl	pyridyl	amino
2,4-dimethyl	2-amino-4-	2-(4-fluorophenyl)ethyl
phenyl	pyridyl 2-acetamido-	amino
Phenyl	4-pyridyl	2-(4-fluorophenyl)ethyl amino

4-fluorophenyl	2-acetamido- 4-pyridyl	2-(4-fluorophenyl)ethyl amino
3-fluorophenyl	2-acetamido-	2-(4-fluorophenyl)ethyl
J ZZGOTOPHCH/Z	4-pyridyl	amino
2-fluorophenyl	2-acetamido-	2-(4-fluorophenyl)ethyl
	4-pyridyl	amino
4-chlorophenyl	2-acetamido- 4-pyridyl	2-(4-fluorophenyl)ethyl
3-chlorophenyl	2-acetamido-	2-(4-fluorophenyl)ethyl
	4-pyridyl	amino
2-chlorophenyl	2-acetamido-	2-(4-fluorophenyl)ethyl
	4-pyridyl	amino
4-tolyl	2-acetamido-	2-(4-fluorophenyl)ethyl
_	4-pyridyl	amino
3-tolv1	2-acetamido-	2-(4-fluorophenyl)ethyl
-	4-pyridyl	amino
2-tolyl	2-acetamido-	2-(4-fluorophenyl)ethyl
	4-pyridyl	amino
4-trifluoro-	2-acetamido-	2-(4-fluorophenyl)ethyl
methylphenyl	4-pyridyl	amino
3-trifluoro-	2-acetamido-	
methylphenyl	4-pyridyl	2-(4-fluorophenyl)ethyl amino
2,6-		
	2-acetamido-	2-(4-fluorophenyl)ethyl
dichlorophenyl	4-pyridyl	amino
2,6-dimethyl	2-acetamido-	2-(4-fluorophenyl)ethyl
phenyl	4-pyridyl	amino
3,4-	2-acetamido-	2-(4-fluorophenyl)ethyl
dichlorophenyl	4-pyridyl	amino
3,4-dimethyl	2-acetamido-	2-(4-fluorophenyl)ethyl
phenyl	4-pyridyl	amino
2,4-	2-acetamido-	2-(4-fluorophenyl)ethyl
dichlorophenyl	4-pyridyl	amino
2,4-dimethyl	2-acetamido-	2-(4-fluorophenyl)ethyl
phenyl	4-pyridyl	amino
Phenyl	2-amino-4-	2-(4-fluorophenyl)ethyl
	pyrimidinyl	amino
4-fluorophenyl	2-amino-4-	2-(4-fluorophenyl)ethyl
	pyrimidinyl	amino
3-fluorophenyl	2-amino-4-	2-(4-fluorophenyl)ethyl
2 -	pyrimidinyl	amino
2-fluorophenyl	2-amino-4-	2-(4-fluorophenyl)ethyl
	pyrimidinyl	amino
4-chlorophenyl	2-amino-4-	2-(4-fluorophenyl)ethyl
4 Chiciophenyi	pyrimidinyl	amino
3-chlorophenyl	2-amino-4-	2-(4-fluorophenyl)ethyl
2-curorobuenyr		
2 = 1 = = = 1	pyrimidinyl	amino
2-chlorophenyl	2-amino-4-	2-(4-fluorophenyl)ethyl
	pyrimidinyl	amino
4-tolyl	2-amino-4-	2-(4-fluorophenyl)ethyl
	pyrimidinyl	amino
3-tolyl	2-amino-4-	2-(4-fluorophenyl)ethyl
2-tolyl	pyrimidinyl	amino
2-coryr	2-amino-4- pyrimidinyl	2-(4-fluorophenyl)ethyl amino

4-trifluoro-	2-amino-4-	2-(4-fluorophenyl)ethyl
methylphenyl	pyrimidinyl	amino
3-trifluoro-	2-amino-4-	2-(4-fluorophenyl)ethyl
methylphenyl	pyrimidinyl	amino
2,6-	2-amino-4-	2-(4-fluorophenyl)ethyl
dichlorophenyl	pyrimidinyl	amino
2,6-dimethyl	2-amino-4-	2-(4-fluorophenyl)ethyl
phenyl	pyrimidinyl	amino
3,4-	2-amino-4-	2-(4-fluorophenyl)ethyl
dichlorophenyl	pyrimidinyl	amino
3,4-dimethyl	2-amino-4-	2-(4-fluorophenyl)ethyl
phenyl	pyrimidinyl	amino
2,4-	2-amino-4-	2-(4-fluorophenyl)ethyl
dichlorophenyl	pyrimidinyl	amino
2,4-dimethyl	2-amino-4-	2-(4-fluorophenyl)ethyl
phenyl	pyrimidinyl	amino
Phenyl	4-pyridyl	3-phenylpropylamino
4-fluorophenyl	4-pyridyl	3-phenylpropylamino
3-fluorophenyl	4-pyridyl	
		3-phenylpropylamino
2-fluorophenyl	4-pyridyl	3-phenylpropylamino
4-chlorophenyl	4-pyridyl	3-phenylpropylamino
3-chlorophenyl	4-pyridyl	3-phenylpropylamino
2-chlorophenyl	4-pyridyl	3-phenylpropylamino
4-tolyl	4-pyridyl	3-phenylpropylamino
3-tolyl	4-pyridyl	3-phenylpropylamino
2-tolyl	4-pyridyl	3-phenylpropylamino
4-trifluoro-	4-pyridyl	3-phenylpropylamino
methylphenyl		
3-trifluoro-	4-pyridyl	3-phenylpropylamino
methylphenyl		
2,6-	4-pyridyl	3-phenylpropylamino
dichlorophenyl		
2,6-dimethyl	4-pyridyl	3-phenylpropylamino
phenyl		
3,4-	4-pyridyl	3-phenylpropylamino
dichlorophenyl		
3,4-dimethyl	4-pyridyl	3-phenylpropylamino
phenyl		
2,4-	4-pyridyl	3-phenylpropylamino
dichlorophenyl		- p
2,4-dimethyl	4-pyridyl	3-phenylpropylamino
phenyl	1 pyrrwyr	5 phonyipropyramino
Phenyl	2-amino-4-	3-phenylpropylamino
THELLY I	pyridyl	2-buenarbrobaramino
4-fluorophenyl	2-amino-4-	3-phenylpropylamino
4-TIMOLODHEUAI		2-brienArbrobAramino
2 61	pyridyl	2 -4
3-fluorophenyl	2-amino-4-	3-phenylpropylamino
	pyridyl	
2-fluorophenyl	2-amino-4-	3-phenylpropylamino
	pyridyl	
4-chlorophenyl	2-amino-4-	3-phenylpropylamino
	pyridyl	
3-chlorophenyl	2-amino-4-	3-phenylpropylamino
	pyridyl	

2-amino-4- pyridyl	3-phenylpropylamino
2-amino-4- pyridyl	3-phenylpropylamino
pyridyl	3-phenylpropylamino
pyridyl	3-phenylpropylamino
2-amino-4- pyridyl	3-phenylpropylamino
2-amino-4- pyridyl	3-phenylpropylamino
pyridyl	3-phenylpropylamino
pyridyl	3-phenylpropylamino
4-pyridyl	3-phenylpropylamino
2-acetamido- 4-pyridyl	3-phenylpropylamino
	pyridyl 2-amino-4- pyridyl 2-acetamido-4- pyridyl

PCT/US97/22390

	40	
3,4-dimethyl	2-acetamido-	3-phenylpropylamino
phenyl	4-pyridyl	
2,4-	2-acetamido-	3-phenylpropylamino
dichlorophenyl	4-pyridyl	
2,4-dimethyl	2-acetamido-	3-phenylpropylamino
phenyl	4-pyridyl	
Phenyl	2-amino-4-	3-phenylpropylamino
	pyrimidinyl	
4-fluorophenyl	2-amino-4-	3-phenylpropylamino
	pyrimidinyl	
3-fluorophenyl	2-amino-4-	3-phenylpropylamino
	pyrimidinyl	
2-fluorophenyl	2-amino-4-	3-phenylpropylamino
	pyrimidinyl	
4-chlorophenyl	2-amino-4-	3-phenylpropylamino
	pyrimidinyl	
3-chlorophenyl	2-amino-4-	3-phenylpropylamino
	pyrimidinyl	
2-chlorophenyl	2-amino-4-	3-phenylpropylamino
	pyrimidinyl	
4-tolyl	2-amino-4-	3-phenylpropylamino
	pyrimidinyl	
3-tolyl	2-amino-4-	3-phenylpropylamino
	pyrimidinyl	
2-tolyl	2-amino-4-	3-phenylpropylamino
	pyrimidinyl	
4-trifluoro-	2-amino-4-	3-phenylpropylamino
methylphenyl	pyrimidinyl	
3-trifluoro-	2-amino-4-	3-phenylpropylamino
methylphenyl	pyrimidinyl	
2,6-	2-amino-4-	3-phenylpropylamino
dichlorophenyl	pyrimidinyl	
2,6-dimethyl	2-amino-4-	3-phenylpropylamino
phenyl	pyrimidinyl	
3,4-	2-amino-4-	3-phenylpropylamino
dichlorophenyl	pyrimidinyl	
3,4-dimethyl	2-amino-4-	3-phenylpropylamino
phenyl	pyrimidinyl	
2,4-	2-amino-4-	3-phenylpropylamino
dichlorophenyl	pyrimidinyl	
2,4-dimethyl	2-amino-4-	3-phenylpropylamino
phenyl	pyrimidinyl	
Phenyl	4-pyridyl	3-imidazolylpropylamino
4-fluorophenyl	4-pyridyl	3-imidazolylpropylamino
3-fluorophenyl	4-pyridyl	3-imidazolylpropylamino
2-fluorophenyl	4-pyridyl	3-imidazolylpropylamino
4-chlorophenyl	4-pyridyl	3-imidazolylpropylamino
3-chlorophenyl	4-pyridyl	3-imidazolylpropylamino
2-chlorophenyl	4-pyridyl	3-imidazolylpropylamino
4-tolyl	4-pyridyl	3-imidazolylpropylamino
3-tolyl	4-pyridyl	3-imidazolylpropylamino
2-tolyl	4-pyridyl 4-pyridyl	3-imidazolylpropylamino 3-imidazolylpropylamino
	4-pyridyl	3-imidazolylpropylamino 3-imidazolylpropylamino 3-imidazolylpropylamino

3-trifluoro	4-pyridyl	3-imidazolylpropylamino
methylphenyl		
2,6-	4-pyridyl	3-imidazolylpropylamino
dichlorophenyl	4	2 / 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
2,6-dimethyl	4-pyridyl	3-imidazolylpropylamino
phenyl		
3,4-	4-pyridyl	3-imidazolylpropylamino
dichlorophenyl		
3,4-dimethyl	4-pyridyl	3-imidazolylpropylamino
phenyl	4	
2,4-	4-pyridyl	3-imidazolylpropylamino
dichlorophenyl		
2,4-dimethyl	4-pyridyl	3-imidazolylpropylamino
phenyl	l	
Phenyl	2-amino-4-	3-imidazolylpropylamino
1 53	pyridyl	
4-fluorophenyl	2-amino-4-	3-imidazolylpropylamino
2 (2)	pyridyl	
3-fluorophenyl	2-amino-4-	3-imidazolylpropylamino
	pyridyl	
2-fluorophenyl	2-amino-4-	3-imidazolylpropylamino
	pyridyl	
4-chlorophenyl	2-amino-4-	3-imidazolylpropylamino
	pyridyl	
3-chlorophenyl	2-amino-4-	3-imidazolylpropylamino
	pyridyl	
2-chlorophenyl	2-amino-4-	3-imidazolylpropylamino
	pyridyl	
4-tolyl	2-amino-4-	3-imidazolylpropylamino
	pyridyl	
3-tolyl	2-amino-4-	3-imidazolylpropylamino
	pyridyl	
2-tolyl	2-amino-4-	3-imidazolylpropylamino
	pyridyl	
4-trifluoro-	2-amino-4-	3-imidazolylpropylamino
methylphenyl	pyridyl	
3-trifluoro-	2-amino-4-	3-imidazolylpropylamino
methylphenyl	pyridyl	
2,6-	2-amino-4-	3-imidazolylpropylamino
dichlorophenyl	pyridyl	
2,6-dimethyl	2-amino-4-	3-imidazolylpropylamino
phenyl	pyridyl	
3,4-	2-amino-4-	3-imidazolylpropylamino
dichlorophenyl	pyridyl	
3,4-dimethyl	2-amino-4-	3-imidazolylpropylamino
phenyl	pyridyl	
2,4-	2-amino-4-	3-imidazolylpropylamino
dichlorophenyl	pyridyl	1
2,4-dimethyl	2-amino-4-	3-imidazolylpropylamino
phenyl	pyridyl	
Phenyl	2-acetamido-	3-imidazolylpropylamino
	4-pyridyl	2-2-22-21111
4-fluorophenyl	2-acetamido-	3-imidazolylpropylamino
	4-pyridyl	
		

4-pyridyl	· · · · · · · · · · · · · · · · · · ·
4-pyridyl 3-imidazolyl 4-pyridyl 4-pyridyl 4-pyridyl 4-pyridyl 3-imidazolyl 4-pyridyl 4-pyridyl 4-pyridyl 3-imidazolyl 4-pyridyl 4-pyridyl 3-imidazolyl 4-pyridyl 4-pyridyl 3-imidazolyl 4-pyridyl 4-pyridyl 3-imidazolyl 4-pyridyl 4-pyridyl 3-imidazolyl 4-pyridyl 3-imidazolyl 4-pyridyl 4-pyridyl 3-imidazolyl 4-pyridyl 3-imidazolyl 4-pyridyl 3-imidazolyl 4-pyridyl 3-imidazolyl 4-pyridyl 3-imidazolyl 4-pyridyl 3-imidazolyl 4-pyridyl 4-pyridyl 3-imidazolyl 4-pyridyl 4-pyridyl 3-imidazolyl 4-pyridyl 4-pyrid	propylamino
4-chlorophenyl 2-acetamido- 4-pyridyl 3-imidazolyl 4-pyridyl 3-imidazolyl 4-pyridyl 3-imidazolyl 4-pyridyl 3-imidazolyl 4-tolyl 2-acetamido- 4-pyridyl 3-imidazolyl 4-tolyl 2-acetamido- 4-pyridyl 3-imidazolyl 4-pyridyl 3-imidazolyl 4-pyridyl 3-imidazolyl 4-trifluoro- 4-pyridyl 3-imidazolyl 4-trifluoro- 4-pyridyl 3-imidazolyl 4-trifluoro- 4-pyridyl 3-imidazolyl 4-pyrididinyl 3-imidazolyl 4-pyrimidinyl 3-imidazolyl 4-pyrimidinyl 3-imidazolyl 4-chlorophenyl 2-amino-4- 4-pyrimidinyl 3-imidazolyl 4-chlorophenyl 2-amino-4- 4-pyrimidinyl 3-imidazolyl 4-chlorophenyl 2-amino-4- 4-pyrimidinyl 3-imidazolyl	propylamino
2-acetamido- 4-pyridyl 3-imidazolyl 4-tolyl 2-acetamido- 3-imidazolyl 4-tolyl 2-acetamido- 3-imidazolyl 4-tolyl 2-acetamido- 3-imidazolyl 4-pyridyl 3-tolyl 2-acetamido- 3-imidazolyl 4-pyridyl 3-imidazolyl 4-pyridyl 3-trifluoro- 2-acetamido- 3-imidazolyl 4-pyridyl 3-trifluoro- 2-acetamido- 3-imidazolyl 4-pyridyl 3-trifluoro- 2-acetamido- 3-imidazolyl 4-pyridyl 4-pyridyl 3-imidazolyl 4-pyridyl 3-imidazolyl 4-pyridyl 3-imidazolyl 4-pyridyl 3-imidazolyl 3-imidazolyl 4-pyridyl 3-imidazolyl 3-imidazolyl 4-pyridyl 3-imidazolyl 3-imidazo	propylamino
2-acetamido-	propylamino
4-tolyl	propylamino.
4-pyridyl 2-acetamido-	propylamino
4-pyridyl 3-imidazolyl 3-imidazolyl 3-trifluoro-methylphenyl 4-pyridyl 2-acetamido-methylphenyl 3-imidazolymyrimidinyl 3-imidazoly	propylamino
4-trifluoro-methylphenyl 2-acetamido-methylphenyl 3-imidazolymyrimidinyl 3-imidazolymyrimidinyl 2-acetamido-methylphenyl 2-acetamido-methylphenyl 3-imidazolymyrimidinyl 3-imidazoly	propylamino
methylphenyl 4-pyridyl 2,6-d 2-acetamido-dichlorophenyl 3-imidazoly 2,6-dimethyl 2-acetamido-dichlorophenyl 3-imidazoly 4-pyridyl 3,4-dimethyl 2-acetamido-dichlorophenyl 3-imidazoly 3,4-dimethyl 2-acetamido-dichlorophenyl 3-imidazoly 2,4-dimethyl 2-acetamido-dichlorophenyl 3-imidazoly 2,4-dichlorophenyl 4-pyridyl Phenyl 2-acetamido-dichlorophenyl 3-imidazoly 4-pyridyl 4-pyridyl Phenyl 2-amino-4-pyrimidinyl 3-fluorophenyl 2-amino-4-pyrimidinyl 2-fluorophenyl 2-amino-4-pyrimidinyl 2-fluorophenyl 2-amino-4-pyrimidinyl 4-chlorophenyl 2-amino-4-pyrimidinyl 2-mino-4-pyrimidinyl 3-imidazoly 3-	lpropylamino
2-acetamido-	lpropylamino
2,6-dimethyl	lpropylamino
dichlorophenyl 4-pyridyl 3,4-dimethyl 2-acetamido- phenyl 4-pyridyl 2,4 2-acetamido- dichlorophenyl 4-pyridyl 2,4-dimethyl 2-acetamido- phenyl 4-pyridyl Phenyl 2-amino-4- pyrimidinyl 3-imidazoly 4-fluorophenyl 2-amino-4- pyrimidinyl 3-imidazoly 2-fluorophenyl 2-amino-4- pyrimidinyl 3-imidazoly 4-chlorophenyl 2-amino-4- pyrimidinyl 3-imidazoly 3-chlorophenyl 2-amino-4- pyrimidinyl 3-imidazoly 3-chlorophenyl 2-amino-4- pyrimidinyl 3-imidazoly 3-midazoly 3-imidazoly 3-midazoly 3-imidazoly 3-midazoly 3-imidazoly 3-midazoly 3-imidazoly 3-midazoly 3-imidazoly 3-imidazoly 3-imidazoly 3-imidazoly 3-imidazoly 3-imidazoly 3-imidaz	lpropylamino
2-acetamido-phenyl	lpropylamino
dichlorophenyl 4-pyridyl 3-imidazoly 2,4-dimethyl 2-acetamido- 3-imidazoly phenyl 2-amino-4- 3-imidazoly Phenyl 2-amino-4- 3-imidazoly pyrimidinyl 3-imidazoly 3-fluorophenyl 2-amino-4- 3-imidazoly pyrimidinyl 2-amino-4- 3-imidazoly pyrimidinyl 3-imidazoly 4-chlorophenyl 2-amino-4- 3-imidazoly pyrimidinyl 3-imidazoly 3-imidazoly yprimidinyl 3-imidazoly 3-imidazoly pyrimidinyl 3-imidazoly 3-imidazoly	lpropylamino
phenyl	lpropylamino
pyrimidinyl 2-amino-4	lpropylamino
pyrimidinyl 2-amino-4 3-imidazoly pyrimidinyl 2-fluorophenyl 2-amino-4 3-imidazoly pyrimidinyl 4-chlorophenyl 2-amino-4 pyrimidinyl 3-chlorophenyl 2-amino-4 3-imidazoly pyrimidinyl 3-imidazoly pyrimidinyl 3-imidazoly pyrimidinyl 3-imidazoly pyrimidinyl 3-imidazoly 3-imidazoly pyrimidinyl 3-imidazoly	lpropylamino
pyrimidinyl 2-fluorophenyl 2-amino-4 3-imidazoly 2-amino-4 3-imidazoly 2-amino-4 pyrimidinyl 3-chlorophenyl 2-amino-4 3-imidazoly pyrimidinyl 3-imidazoly 2-amino-4 pyrimidinyl 3-imidazoly 3-im	lpropylamino
2-fluorophenyl	lpropylamino
4-chlorophenyl 2-amino-4- pyrimidinyl 3-chlorophenyl 2-amino-4- pyrimidinyl 3-imidazoly pyrimidinyl	lpropylamino
3-chlorophenyl 2-amino-4- 3-imidazoly pyrimidinyl	lpropylamino
	lpropylamino
2-chlorophenyl 2-amino-4- 3-imidazoly	lpropylamino
	lpropylamino
	lpropylamino
	lpropylamino
	lpropylamino

3-trifluoro-	2-amino-4-	3-imidazolylpropylamino
methylphenyl	pyrimidinyl	
2,6-	2-amino-4-	3-imidazolylpropylamino
dichlorophenyl	pyrimidinyl	
2,6-dimethyl	2-amino-4-	3-imidazolylpropylamino
phenyl	pyrimidinyl	
3,4-	2-amino-4-	3-imidazolylpropylamino
dichlorophenyl	pyrimidinyl	
3,4-dimethyl	2-amino-4-	3-imidazolylpropylamino
phenyl	pyrimidinyl	
2,4-	2-amino-4-	3-imidazolylpropylamino
dichlorophenyl	pyrimidinyl	2 2 2 2
2,4-dimethyl	2-amino-4-	3-imidazolylpropylamino
phenyl	pyrimidinyl	
4-fluorophenyl	4-pyridyl	4-fluorobenzylamino
4-fluorophenyl	2-acetamido-	4-fluorobenzylamino
4 IIdolophenyi	4-pyridyl	4 IIdolobenzylamino
4-fluorophenyl	2-amino-4-	4-fluorobenzylamino
4-11dolophenyi	pyrimidinyl	4-11dolobenzylamino
4-fluorophenyl	4-pyridyl	2-(2-chlorophenyl-1-
4-IIdolophenyi	4-byrrdyr	methyl)ethyl)amino
4-fluorophenyl	2-acetamido-	2-(2-chlorophenvl-1-
4-IIuorophenyi		
4 63	4-pyridyl	methyl)ethyl)amino
4-fluorophenyl	2-amino-4-	2-(2-chlorophenyl-1-
	pyrimidinyl	methyl)ethyl)amino
4-fluorophenyl	4-pyridyl	(3-(4-fluorophenyl)-
	<u> </u>	propyl)amino
4-fluorophenyl	2-acetamido-	(3-(4-fluorophenyl)-
	4-pyridyl	propyl)amino
4-fluorophenyl	2-amino-4-	(3-(4-fluorophenyl)-
L	pyrimidinyl	propyl)amino
4-fluorophenyl	4-pyridyl	(3-(4-fluorophenyl)-1-
		methyl-propyl)amino
4-fluorophenyl	2-acetamido-	(3-(4-fluorophenyl)-1-
	4-pyridyl	methyl-propyl)amino
4-fluorophenyl	2-amino-4-	(3-(4-fluorophenyl)-1-
	pyrimidinyl	methyl-propyl)amino
4-fluorophenyl	4-pyridyl	(1,1-dimethyl-3-(4-fluoro
		phenyl)-propyl)amino
4-fluorophenyl	2-acetamido-	(1,1-dimethyl-3-(4-fluoro
	4-pyridyl	phenyl)-propyl)amino
4-fluorophenyl	2-amino-4-	(1,1-dimethyl-3-(4-fluoro
	pyrimidinyl	phenyl)-propyl)amino
4-fluorophenyl	4-pyridyl	(3-(2-fluorophenyl)-
photogram		propyl)amino
4-fluorophenyl	2-acetamido-	(3-(2-fluorophenyl)-
pnengi	4-pyridyl	propyl)amino
4-fluorophenvl	2-amino-4-	(3-(2-fluorophenyl)-
- Lincippinelly1	pyrimidinyl	propyl)amino
4-fluorophenyl	4-pyridyl	(3-methyl-3-
4-11dolobueny1	4-baridar	phenylpropyl)amino
4-fluorophenyl	2-acetamido-	(3-methyl-3-
4-ridorophenyi		
	4-pyridyl	phenylpropyl)amino

4-fluorophenyl	2-amino-4-	(3-methyl-3-
	pyrimidinyl	phenylpropyl)amino
4-fluorophenyl	4-pyridyl	(2-methyl-3-phenyl-
		propyl)amino
4-fluorophenyl	2-acetamido-	(2-methyl-3-phenyl-
	4-pyridyl	propyl)amino
4-fluorophenyl	2-amino-4-	(2-methyl-3-phenyl-
	pyrimidinyl	propyl)amino
3-fluorophenyl	4-pyridyl	(S)-tetrahydroisoquinol-
		3-ylmethylenamino
2-fluorophenyl	2-amino-4-	(S)-3-benzylpiperazinyl
	pyridyl	
3-chlorophenyl	2-acetamido-	(S)-2-N-isopropylamino-3-
	4-pyridyl	phenylpropylamino
2-chloropheny1	2-amino-4-	(S)-2-N-glycylamino-3-
	pyrimidinyl	phenylpropylamino
4-tolyl	4-pyridyl	(S)-2-amino-3-
<u> </u>	ļ	phenylpropylamino
3-tolyl	2-amino-4-	(R) -2-amino-3-
0 . 1 .	pyridyl	phenylpropylamino
2-tolyl	2-acetamido-	3-amino-3-
4 . 161	4-pyridyl	phenylpropylamino
4-trifluoro-	2-amino-4-	(S)-2-amino-3-(2-
methylphenyl	pyrimidinyl	fluorophenyl)propylamino
3-trifluoro-	4-pyridyl	(S)-2-amino-3-(2-
methylphenyl		methylphenyl)propylamino
2,6-	2-amino-4-	3-amino-3-(2-
dichlorophenyl	pyridyl	fluorophenyl)propylamino
2,6-dimethyl	2-acetamido-	3-amino-3-(2-
phenyl 3,4-	4-pyridyl 2-amino-4-	methylphenyl)propylamino
dichlorophenyl	2-amino-4- pyrimidinyl	2-amino-2-methyl-3-
3,4-dimethyl	4-pyrimidinyi	phenylpropylamino 3-amino-2-methyl-3-
phenyl	#-batraar	phenylpropylamino
3-fluorophenyl	2-amino-4-	(S)-2-amino-3-
2-TIGOLOPHENYI	pyridyl	phenylpropylamino
2-fluorophenyl	2-acetamido-	(S)-2-amino-3-(2-
- Tracrobuent	4-pyridyl	fluorophenyl)propylamino
3-chlorophenyl	2-amino-4-	(S)-2-amino-3-(2-
2 SHIOLODHEHAT	pyrimidinyl	methylphenyl)propylamino
2-chlorophenyl	4-pyridyl	(S)-2-N-isopropylamino-3-
2 cmicrophenyi	* PALICAL	phenylpropylamino
4-tolyl	2-amino-4-	(S)-2-N-glycylamino-3-
1	pyridyl	phenylpropylamino
3-tolyl	2-acetamido-	2-amino-2-methyl-3-
5 501,1	4-pyridyl	phenylpropylamino
2-tolyl	2-amino-4-	(R)-2-amino-3-
	pyrimidinyl	phenylpropylamino
4-trifluoro-	4-pyridyl	3-amino-3-
methylphenyl	l pyrrayr	phenylpropylamino
3-trifluoro-	2-amino-4-	3-amino-3-(2-
methylphenyl	pyridyl	fluorophenyl)propylamino
2,6-	2-acetamido-	3-amino-3-(2-
		methylphenyl)propylamino
dichlorophenyl	4-pyridyl	

2,6-dimethyl	2-amino-4-	3-amino-2-methy1-3-
phenyl	pyrimidinyl	phenylpropylamino
3,4-	4-pyridyl	(S)-tetrahydroisoguinol-
dichlorophenyl		3-ylmethylenamino
3,4-dimethyl	4-pyridyl	(S)-3-benzylpiperazinyl
phenyl	1	

and

wherein R^2 is -OH and R^{11} , R^{12} , and R^1 are one of the combinations given in the following table:

R ¹¹	R12	R,
Phenyl	4-pyridyl	4-pyridyl
4-fluorophenyl	4-pyridyl	4-pyridyl
3-fluorophenyl	4-pyridyl	4-pyridyl
2-fluorophenyl	4-pyridyl	4-pyridyl
4-chlorophenyl	4-pyridyl	4-pyridyl
3-chlorophenyl	4-pyridyl	4-pyridyl
2-chlorophenyl	4-pyridyl	4-pyridyl
4-tolyl	4-pyridyl	4-pyridyl
3-tolyl	4-pyridyl	4-pyridyl
2-toly1	4-pyridyl	4-pyridyl
4-trifluoro-	4-pyridyl	4-pyridyl
methylphenyl		1
3-trifluoro-	4-pyridyl	4-pyridyl
methylphenyl		
2,6-	4-pyridyl	4-pyridyl
dichlorophenyl		
2,6-dimethyl	4-pyridyl	4-pyridyl
phenyl		
3,4-	4-pyridyl	4-pyridyl
dichlorophenyl		
3,4-dimethyl	4-pyridyl	4-pyridyl
phenyl		
2,4-	4-pyridyl	4-pyridyl
dichlorophenyl		
2,4-dimethyl	4-pyridyl	4-pyridyl
phenyl	 	
Phenyl	2-amino-4-	4-pyridyl
	pyridyl	
4-fluorophenyl	2-amino-4-	4-pyridyl
2 fluore-ber-1	pyridyl	4
3-fluorophenyl	2-amino-4-	4-pyridyl
2-fluorophenvl	pyridyl	4
z-rruoropnenyr	2-amino-4-	4-pyridyl
	pyridyl	1

4-chlorophenyl	2-amino-4- pyridyl	4-pyridyl
3-chlorophenyl	2-amino-4- pyridyl	4-pyridyl
2-chlorophenyl	2-amino-4- pyridyl	4-pyridyl
4-tolyl	2-amino-4- pyridyl	4-pyridyl
3-tolyl	2-amino-4- pyridyl	4-pyridyl
2-tolyl	2-amino-4- pyridyl	4-pyridyl
4-trifluoro- methylphenyl	2-amino-4- pyridyl	4-pyridyl
3-trifluoro-	2-amino-4-	4-pyridyl
methylphenyl	pyridyl 2-amino-4-	4-pyridyl
dichlorophenyl 2,6-dimethyl phenyl	pyridyl 2-amino-4- pyridyl	4-pyridyl
3,4- dichlorophenyl	2-amino-4- pyridyl	4-pyridyl
3,4-dimethyl phenyl	2-amino-4- pyridyl	4-pyridyl
2,4- dichlorophenyl	2-amino-4- pyridyl	4-pyridyl
2,4-dimethyl phenyl	2-amino-4- pyridyl	4-pyridyl
Phenyl	2-acetamido- 4-pyridyl	4-pyridyl
4-fluorophenyl	2-acetamido- 4-pyridyl	4-pyridyl
3-fluorophenyl	2-acetamido- 4-pyridyl	4-pyridyl
2-fluorophenyl	2-acetamido- 4-pyridyl	4-pyridyl
4-chlorophenyl	2-acetamido- 4-pyridyl	4-pyridyl
3-chlorophenyl	2-acetamido- 4-pyridyl	4-pyridyl
2-chlorophenyl	2-acetamido- 4-pyridyl	4-pyridyl
4-tolyl	2-acetamido- 4-pyridyl	4-pyridyl
3-tolyl	2-acetamido- 4-pyridyl	4-pyridyl
2-toly1	2-acetamido- 4-pyridyl	4-pyridyl
4-trifluoro- methylphenyl	2-acetamido- 4-pyridyl	4-pyridyl
3-trifluoro- methylphenyl	2-acetamido- 4-pyridyl	4-pyridyl
2,6- dichlorophenyl	2-acetamido- 4-pyridyl	4-pyridyl

2,6-dimethyl	2-acetamido-	4-pyridyl
phenyl	4-pyridyl	
3,4-	2-acetamido-	4-pyridyl
dichlorophenyl	4-pyridyl	
3,4-dimethyl	2-acetamido-	4-pyridyl
phenyl	4-pyridyl	
2,4-	2-acetamido-	4-pyridyl
dichlorophenyl	4-pyridyl	
2,4-dimethyl	2-acetamido-	4-pyridyl
phenyl	4-pyridyl	
Phenyl	2-amino-4-	4-pyridyl
	pyrimidinyl	
4-fluorophenyl	2-amino-4-	4-pyridyl
	pyrimidinyl	
3-fluorophenyl	2-amino-4-	4-pyridyl
	pyrimidinyl	
2-fluorophenyl	2-amino-4-	4-pyridyl
	pyrimidinyl	
4-chlorophenyl	2-amino-4-	4-pyridyl
	pyrimidinyl	
3-chlorophenyl	2-amino-4-	4-pyridyl
	pyrimidinyl	
2-chlorophenyl	2-amino-4-	4-pyridyl
	pyrimidinyl	
4-tolyl	2-amino-4-	4-pyridyl
	pyrimidinyl	
3-tolyl	2-amino-4-	4-pyridyl
	pyrimidinyl	
2-tolyl	2-amino-4-	4-pyridyl
	pyrimidinyl	
4-trifluoro-	2-amino-4-	4-pyridyl
methylphenyl	pyrimidinyl	
3-trifluoro-	2-amino-4-	4-pyridyl
methylphenyl	pyrimidinyl	
2,6-	2-amino-4-	4-pyridyl
dichlorophenyl	pyrimidinyl	
2,6-dimethyl	2-amino-4-	4-pyridyl
phenyl	pyrimidinyl	
3,4-	2-amino-4-	4-pyridyl
dichlorophenyl	pyrimidinyl	
3,4-dimethyl	2-amino-4-	4-pyridyl
phenyl	pyrimidinyl	
2,4-	2-amino-4-	4-pyridyl
dichlorophenyl	pyrimidinyl	
2,4-dimethyl	2-amino-4-	4-pyridyl
phenyl	pyrimidinyl	
Phenyl	4-pyridyl	4-methyl sulfinylphenyl
4-fluorophenyl	4-pyridyl	4-methyl sulfinylphenyl
3-fluorophenyl	4-pyridyl	4-methyl sulfinylphenyl
2-fluorophenyl	4-pyridyl	4-methyl sulfinylphenyl
4-chlorophenyl	4-pyridyl	4-methyl sulfinylphenyl
3-chlorophenyl	4-pyridyl	4-methyl sulfinylphenyl
2-chlorophenyl	4-pyridyl	4-methyl sulfinylphenyl
4-tolyl	4-pyridyl	4-methyl sulfinylphenyl

2 5-1-1	A	14
3-tolyl	4-pyridyl	4-methyl sulfinylphenyl
2-tolyl	4-pyridyl	4-methyl sulfinylphenyl
4-trifluoro-	4-pyridyl	4-methyl sulfinylphenyl
methylphenyl	L	
3-trifluoro-	4-pyridyl	4-methyl sulfinylphenyl
methylphenyl		
2,6-	4-pyridyl	4-methyl sulfinylphenyl
dichlorophenyl		
2,6-dimethyl	4-pyridyl	4-methyl sulfinylphenyl
phenyl		
3,4-	4-pyridyl	4-methyl sulfinylphenyl
dichlorophenyl		
3,4-dimethyl	4-pyridyl	4-methyl sulfinylphenyl
phenyl		
2,4-	4-pyridyl	4-methyl sulfinylphenyl
dichlorophenyl		
2,4-dimethyl	4-pyridyl	4-methyl sulfinylphenyl
phenyl		
Phenyl	2-amino-4-	4-methyl sulfinylphenyl
1	pyridyl	1
4-fluorophenyl	2-amino-4-	4-methyl sulfinylphenyl
	pyridyl	
3-fluorophenvl	2-amino-4-	4-methyl sulfinylphenyl
1	pyridyl	
2-fluorophenyl	2-amino-4-	4-methyl sulfinylphenyl
	pyridyl	I mount bulling phony
4-chlorophenvl	2-amino-4-	4-methyl sulfinylphenyl
- chiciophony i	pyridyl	* Meenyl Bullingiphenyl
3-chlorophenyl	2-amino-4-	4-methyl sulfinylphenyl
1	pyridyl	
2-chlorophenyl	2-amino-4-	4-methyl sulfinylphenyl
	pyridyl	
4-tolyl	2-amino-4-	4-methyl sulfinylphenyl
	pyridyl	
3-tolyl	2-amino-4-	4-methyl sulfinylphenyl
	pyridyl	- mooning a carrying ipilony i
2-tolyl	2-amino-4-	4-methyl sulfinylphenyl
	pyridyl	* mccmir ballingiphengi
4-trifluoro-	2-amino-4-	4-methyl sulfinylphenyl
methylphenyl	pyridyl	- weenat sommitted
3-trifluoro-	2-amino-4-	4-methyl sulfinylphenyl
methylphenyl	pyridyl	* wecult surring thusing
2,6-	2-amino-4-	4-methyl sulfinylphenyl
dichlorophenyl	pyridyl	4-mechyi suilinyiphenyi
2,6-dimethyl	2-amino-4-	4 marbal aulfi
phenyl	pvridvl	4-methyl sulfinylphenyl
3.4-	2-amino-4-	4 mothyl gulfimilel
		4-methyl sulfinylphenyl
dichlorophenyl	pyridyl	1
3,4-dimethyl	2-amino-4-	4-methyl sulfinylphenyl
phenyl	pyridyl	1
2,4-	2-amino-4-	4-methyl sulfinylphenyl
dichlorophenyl	pyridyl	
2,4-dimethyl	2-amino-4-	4-methyl sulfinylphenyl
phenyl	pyridyl	

	3,	
Phenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
4-fluorophenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
3-fluorophenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
2-fluorophenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
4-chlorophenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
3-chlorophenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
2-chlorophenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
4-tolyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
3-tolyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
2-tolyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
4-trifluoro- methylphenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
3-trifluoro- methylphenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
2,6- dichlorophenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
2,6-dimethyl phenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
3,4- dichlorophenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
3,4-dimethyl phenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
2,4- dichlorophenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
2,4-dimethyl phenyl	2-acetamido- 4-pyridyl	4-methyl sulfinylphenyl
Phenyl	2-amino-4- pyrimidinyl	4-methyl sulfinylphenyl
4-fluorophenyl	2-amino-4- pyrimidinyl	4-methyl sulfinylphenyl
3-fluorophenyl	2-amino-4- pyrimidinyl	4-methyl sulfinylphenyl
2-fluorophenyl	2-amino-4- pyrimidinyl	4-methyl sulfinylphenyl
4-chlorophenyl	2-amino-4- pyrimidinyl	4-methyl sulfinylphenyl
3-chlorophenyl	2-amino-4- pyrimidinyl	4-methyl sulfinylphenyl
2-chlorophenyl	2-amino-4- pyrimidinyl	4-methyl sulfinylphenyl
4-tolyl	2-amino-4- pyrimidinyl	4-methyl sulfinylphenyl
3-tolyl	2-amino-4- pyrimidinyl	4-methyl sulfinylphenyl

2-tolyl	2-amino-4- pyrimidinyl	4-methyl sulfinylphenyl
4-trifluoro-	2-amino-4-	4-methyl sulfinylphenyl
methylphenyl	pyrimidinyl	
3-trifluoro-	2-amino-4-	4-methyl sulfinylphenyl
methylphenyl	pyrimidinyl	- manage and any agriculture
2,6-	2-amino-4-	4-methyl sulfinylphenyl
dichlorophenyl	pyrimidinyl	a meenya bullingiphenyi
2.6-dimethyl	2-amino-4-	4-methyl sulfinylphenyl
phenyl	pyrimidinyl	4-methyl sullinylphenyl
3,4-	2-amino-4-	4 (11 16: 13 1
		4-methyl sulfinylphenyl
dichlorophenyl	pyrimidinyl 2-amino-4-	
3,4-dimethyl		4-methyl sulfinylphenyl
phenyl	pyrimidinyl	
2,4-	2-amino-4-	4-methyl sulfinylphenyl
dichlorophenyl	pyrimidinyl	
2,4-dimethyl	2-amino-4-	4-methyl sulfinylphenyl
phenyl	pyrimidinyl	·
Phenyl	4-pyridyl	2,6-dichlorobenzyl
4-fluorophenyl	4-pyridyl	2,6-dichlorobenzyl
3-fluorophenyl	4-pyridyl	2,6-dichlorobenzyl
2-fluorophenyl	4-pyridyl	2,6-dichlorobenzyl
4-chlorophenyl	4-pyridyl	2,6-dichlorobenzyl
3-chlorophenyl		
	4-pyridyl	2,6-dichlorobenzyl
2-chlorophenyl	4-pyridyl	2,6-dichlorobenzyl
4-tolyl	4-pyridyl	2,6-dichlorobenzyl
3-tolyl	4-pyridyl	2,6-dichlorobenzyl
2-tolyl	4-pyridyl	2,6-dichlorobenzyl
4-trifluoro-	4-pyridyl	2,6-dichlorobenzyl
methylphenyl		
3-trifluoro- methylphenyl	4-pyridyl	2,6-dichlorobenzyl
2.6-	4-pyridyl	2,6-dichlorobenzyl
dichlorophenyl	1 2722072	270 dromrozowomaji
2,6-dimethyl	4-pyridyl	2,6-dichlorobenzyl
phenyl		
3,4-	4-pyridyl	2,6-dichlorobenzyl
dichlorophenyl		
3,4-dimethyl	4-pyridyl	2,6-dichlorobenzyl
phenyl		
2,4-	4-pyridyl	2,6-dichlorobenzyl
dichlorophenyl		
2,4-dimethyl	4-pyridyl	2,6-dichlorobenzyl
phenyl	1	•
Phenyl	2-amino-4-	2,6-dichlorobenzyl
	pyridyl	1,0 4,011,011,011,011,011
4-fluorophenyl	2-amino-4-	2,6-dichlorobenzyl
4 LIGOTOPHENYI	pyridyl	2,0 dichiolobelizyi
2 61		2 6 45 -1-1
3-fluorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyridyl	
2-fluorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyridyl	
4-chlorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyridyl	

3-chlorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyridyl	
2-chlorophenyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
4-tolyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
3-tolyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
2-tolyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
4-trifluoro- methylphenyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
3-trifluoro- methylphenyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
2,6- dichlorophenyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
2,6-dimethyl phenyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
3,4- dichlorophenyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
3,4-dimethyl phenyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
2,4- dichlorophenyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
2,4-dimethyl phenyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
Phenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
4-fluorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
3-fluorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
2-fluorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
4-chlorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
3-chlorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
2-chlorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
4-tolyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
3-tolyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
2-tolyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
4-trifluoro- methylphenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
3-trifluoro- methylphenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
2,6- dichlorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
2,6-dimethyl phenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl

3,4-	2-acetamido-	2,6-dichlorobenzyl
dichlorophenyl	4-pyridyl	
3,4-dimethyl	2-acetamido-	2,6-dichlorobenzyl
phenyl	4-pyridyl	
2,4-	2-acetamido-	2,6-dichlorobenzyl
dichlorophenyl	4-pyridyl	
2,4-dimethyl	2-acetamido-	2,6-dichlorobenzyl
phenyl	4-pyridyl	
Phenyl	2-amino-4-	2,6-dichlorobenzyl
	pyrimidinyl	
4-fluorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyrimidinyl	
3-fluorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyrimidinyl	
2-fluorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyrimidinyl	
4-chlorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyrimidinyl	_
3-chlorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyrimidinyl	
2-chlorophenyl	2-amino-4-	2,6-dichlorobenzyl
	pyrimidinyl	
4-tolyl	2-amino-4-	2,6-dichlorobenzyl
	pyrimidinyl	*
3-tolyl	2-amino-4-	2,6-dichlorobenzvl
_	pyrimidinyl	
2-tolyl	2-amino-4-	2,6-dichlorobenzyl
-	pyrimidinyl	1 1
4-trifluoro-	2-amino-4-	2,6-dichlorobenzyl
methylphenyl	pyrimidinyl	
3-trifluoro-	2-amino-4-	2,6-dichlorobenzyl
methylphenyl	pyrimidinyl	1
2,6-	2-amino-4-	2,6-dichlorobenzyl
dichlorophenyl	pyrimidinyl	_
2,6-dimethyl	2-amino-4-	2,6-dichlorobenzyl
phenyl	pyrimidinyl	
3,4-	2-amino-4-	2,6-dichlorobenzyl
dichlorophenyl	pyrimidinyl	
3,4-dimethyl	2-amino-4-	2,6-dichlorobenzyl
phenyl	pyrimidinyl	_, = ==================================
2.4-	2-amino-4-	2,6-dichlorobenzyl
dichlorophenyl	pyrimidinyl	
2,4-dimethyl	2-amino-4-	2,6-dichlorobenzyl
phenyl	pyrimidinyl	
Phenyl	4-pyridyl	2-(4-fluorophenyl)
	P11-	ethylamino
4-fluorophenyl	4-pyridyl	2-(4-fluorophenyl)
	- P/110/1	ethylamino
3-fluorophenyl	4-pyridyl	2-(4-fluorophenvl)
	1. PALLOAL	ethylamino
2-fluorophenyl	4-pyridyl	2-(4-fluorophenyl)
" TIMOTOPHENYI	- barraar	ethylamino
4-chlorophenyl	4-pyridyl	2-(4-fluorophenyl)
- curorobuenar	- barraar	ethylamino
		I ecuivamitino

	ρŢ	
3-chlorophenyl	4-pyridyl	2-(4-fluorophenyl)
		ethylamino
2-chlorophenyl	4-pyridyl	2-(4-fluorophenyl)
		ethylamino
4-tolyl	4-pyridyl	2-(4-fluorophenyl)
		ethylamino
3-tolyl	4-pyridyl	2-(4-fluorophenyl)
		ethylamino
2-tolyl	4-pyridyl	2-(4-fluorophenyl)
		ethylamino
4-trifluoro-	4-pyridyl	2-(4-fluorophenyl)
methylphenyl		ethylamino
3-trifluoro-	4-pyridyl	2-(4-fluorophenyl)
methylphenyl		ethylamino
2.6-	4-pyridyl	2-(4-fluorophenyl)
dichlorophenyl		ethylamino
2,6-dimethyl	4-pyridyl	2-(4-fluorophenyl)
phenyl		ethylamino
3,4-	4-pyridyl	2-(4-fluorophenyl)
dichlorophenyl	. pjrrajr	ethylamino
3,4-dimethyl	4-pyridyl	2-(4-fluorophenyl)
phenyl	4 pyridyr	ethylamino
2,4-	4-pyridyl	2-(4-fluorophenyl)
dichlorophenyl	" pyrrayr	ethylamino
2,4-dimethyl	4-pyridyl	2-(4-fluorophenyl)
phenyl	4-DYLIGYI	ethylamino
Phenyl	2-amino-4-	2-(4-fluorophenyl)
I Helly I	pyridyl	ethylamino
4-fluorophenyl	2-amino-4-	2-(4-fluorophenyl)
4-11dolophenyi	pyridyl	ethylamino
3-fluorophenyl	2-amino-4-	2-(4-fluorophenyl)
3-11dot obitetivi	pyridyl	ethylamino
2-fluorophenyl	2-amino-4-	2-(4-fluorophenvl)
z-iidolophenyi		
4-chlorophenyl	pyridyl	ethylamino 2-(4-fluorophenyl)
4-chiorophenyi	2-amino-4-	
2 1 1	pyridyl 2-amino-4-	ethylamino
3-chlorophenyl		2-(4-fluorophenyl)
	pyridyl	ethylamino
2-chlorophenyl	2-amino-4-	2-(4-fluorophenyl)
	pyridyl	ethylamino
4-tolyl	2-amino-4-	2-(4-fluorophenyl)
	pyridyl	ethylamino
3-tolyl	2-amino-4-	2-(4-fluorophenyl)
	pyridyl	ethylamino
2-tolyl	2-amino-4-	2-(4-fluorophenyl)
	pyridyl	ethylamino
4-trifluoro-	2-amino-4-	2-(4-fluorophenyl)
methylphenyl	pyridyl	ethylamino
3-trifluoro-	2-amino-4-	2-(4-fluorophenyl)
methylphenyl	pyridyl	ethylamino
2,6-	2-amino-4-	2-(4-fluorophenyl)
dichlorophenyl	pyridyl	ethylamino
2,6-dimethyl	2-amino-4-	2-(4-fluorophenyl)
phenyl	pyridyl	ethylamino

	62	
3,4-	2-amino-4-	2-(4-fluorophenyl)
dichlorophenyl	pyridyl	ethylamino
3,4-dimethyl	2-amino-4-	2-(4-fluorophenyl)
phenyl	pyridyl	ethylamino
2,4-	2-amino-4-	2-(4-fluorophenyl)
dichlorophenyl	pyridyl	ethylamino
2,4-dimethyl	2-amino-4-	2-(4-fluorophenyl)
phenyl	pyridyl	ethylamino
Phenyl	2-acetamido-	2-(4-fluorophenyl)
	4-pyridyl	ethylamino
4-fluorophenyl	2-acetamido-	2-(4-fluorophenyl)
	4-pyridyl	ethylamino
3-fluorophenyl	2-acetamido-	2-(4-fluorophenyl)
	4-pyridyl	ethylamino
2-fluorophenyl	2-acetamido-	2-(4-fluorophenyl)
	4-pyridyl	ethylamino
4-chlorophenyl	2-acetamido-	2-(4-fluorophenyl)
	4-pyridyl	ethylamino
3-chlorophenyl	2-acetamido-	2-(4-fluorophenyl)
	4-pyridyl	ethylamino
2-chlorophenyl	2-acetamido-	2-(4-fluorophenyl)
	4-pyridyl	ethylamino
4-tolyl	2-acetamido-	2-(4-fluorophenyl)
	4-pyridyl	ethylamino
3-tolyl	2-acetamido-	2-(4-fluorophenyl)
	4-pyridyl	ethylamino
2-tolyl	2-acetamido-	2-(4-fluorophenyl)
	4-pyridyl	ethylamino
4-trifluoro-	2-acetamido-	2-(4-fluorophenyl)
methylphenyl	4-pyridyl	ethylamino
3-trifluoro-	2-acetamido-	2-(4-fluorophenyl)
methylphenyl	4-pyridyl	ethylamino
2,6-	2-acetamido-	2-(4-fluorophenyl)
dichlorophenyl	4-pyridyl	ethylamino
2,6-dimethyl	2-acetamido-	2-(4-fluorophenyl)
phenyl	4-pyridyl	ethylamino
3,4-	2-acetamido-	2-(4-fluorophenyl)
dichlorophenyl	4-pyridyl	ethylamino
3,4-dimethyl	2-acetamido-	2-(4-fluorophenyl)
phenyl	4-pyridyl	ethylamino
2,4-	2-acetamido-	2-(4-fluorophenyl)
dichlorophenyl	4-pyridyl	ethylamino
2,4-dimethyl	2-acetamido-	2-(4-fluorophenyl)
phenyl	4-pyridyl	ethylamino
Phenyl	2-amino-4-	2-(4-fluorophenyl)
	pyrimidinyl	ethylamino
4-fluorophenyl	2-amino-4-	2-(4-fluorophenyl)
	pyrimidinyl	ethylamino
3-fluorophenyl	2-amino-4-	2-(4-fluorophenyl)
	pyrimidinyl	ethylamino
2-fluorophenyl	2-amino-4-	2-(4-fluorophenyl)
	pyrimidinyl	ethylamino
4-chlorophenyl	2-amino-4-	2-(4-fluorophenyl)
1	pyrimidinyl	ethylamino

2 chlorophor-1	2-amino-4-	2-(4-fluorophenyl)
3-chlorophenyl		
2-chlorophenyl	pyrimidinyl 2-amino-4-	ethylamino 2-(4-fluorophenyl)
2-cnioropnenyi		
4 5 7 - 7	pyrimidinyl 2-amino-4-	ethylamino
4-tolyl		2-(4-fluorophenyl)
2 . 7 7	pyrimidinyl	ethylamino
3-tolyl	2-amino-4-	2-(4-fluorophenyl)
	pyrimidinyl	ethylamino
2-tolyl	2-amino-4-	2-(4-fluorophenyl)
	pyrimidinyl	ethylamino
4-trifluoro-	2-amino-4-	2-(4-fluorophenyl)
methylphenyl	pyrimidinyl	ethylamino
3-trifluoro-	2-amino-4-	2-(4-fluorophenyl)
methylphenyl	pyrimidinyl	ethylamino
2,6-	2-amino-4-	2-(4-fluorophenyl)
dichlorophenyl	pyrimidinyl	ethylamino
2,6-dimethyl	2-amino-4-	2-(4-fluorophenyl)
phenyl	pyrimidinyl	ethylamino
3,4-	2-amino-4-	2-(4-fluorophenyl)
dichlorophenyl	pyrimidinyl	ethylamino
3,4-dimethyl	2-amino-4-	2-(4-fluorophenyl)
phenyl	pyrimidinyl	ethylamino
2,4-	2-amino-4-	2-(4-fluorophenyl)
dichlorophenyl	pyrimidinyl	ethylamino
2,4-dimethyl	2-amino-4-	2-(4-fluorophenyl)
phenyl	pyrimidinyl	ethylamino
Phenyl	4-pyridyl	3-phenyl-propylamino
4-fluorophenyl	4-pyridyl	3-phenyl-propylamino
3-fluorophenyl	4-pyridyl	3-phenyl-propylamino
2-fluorophenyl	4-pyridyl	3-phenyl-propylamino
4-chlorophenyl	4-pyridyl	3-phenyl-propylamino
3-chlorophenyl	4-pyridyl	3-phenyl-propylamino
2-chlorophenyl	4-pyridyl	3-phenyl-propylamino
4-tolyl	4-pyridyl	3-phenyl-propylamino
3-tolyl	4-pyridyl	3-phenyl-propylamino
2-tolyl	4-pyridyl	3-phenyl-propylamino
4-trifluoro-	4-pyridyl	3-phenyl-propylamino
methylphenyl	4-pyridyi	3-phenyi-propyramino
3-trifluoro-	4-pyridyl	3-phenyl-propylamino
methylphenyl	a pyridyr	3-biletili-brobliguino
2,6-	4-pyridyl	3-phenyl-propylamino
dichlorophenyl	4-pyridyi	3-phenyi-propyiamino
2,6-dimethyl	4	3-phenyl-propylamino
	4-pyridyl	3-phenyi-propyiamino
phenyl 3.4-	4	2 1 2 2
	4-pyridyl	3-phenyl-propylamino
dichlorophenyl	14 / 2 .2	12 1 2 2
3,4-dimethyl	4-pyridyl	3-phenyl-propylamino
phenyl	I	1
2,4-	4-pyridyl	3-phenyl-propylamino
dichlorophenyl	1	1
2,4-dimethyl	4-pyridyl	3-phenyl-propylamino
phenyl		1
Phenyl	2-amino-4-	3-phenyl-propylamino
	pyridyl	

	3-phenyl-propylamino
2-amino-4-	3-phenyl-propylamino
2-amino-4- pyridyl	3-phenyl-propylamino
pyridyl	3-phenyl-propylamino
2-amino-4- pyridyl	3-phenyl-propylamino
2-acetamido- 4-pyridyl	3-phenyl-propylamino
2-acetamido-	3-phenyl-propylamino
	pyridyl 2-amino-4- pyridyl 2-acetamido-4- pyridyl

4-trifluoro-	2-acetamido-	3-phenyl-propylamino
methylphenyl	4-pyridyl	
3-trifluoro-	2-acetamido-	3-phenyl-propylamino
methylphenyl	4-pyridyl	
2,6-	2-acetamido-	3-phenyl-propylamino
dichlorophenyl	4-pyridyl	
2,6-dimethyl	2-acetamido-	3-phenyl-propylamino
phenyl	4-pyridyl	
3,4-	2-acetamido-	3-phenyl-propylamino
dichlorophenyl	4-pyridyl	
3,4-dimethyl	2-acetamido-	3-phenyl-propylamino
phenyl	4-pyridyl	
2,4-	2-acetamido-	3-phenyl-propylamino
dichlorophenyl	4-pyridyl	- F
2.4-dimethyl	2-acetamido-	3-phenyl-propylamino
phenyl	4-pyridyl	- promise propriation
Phenvl	2-amino-4-	3-phenyl-propylamino
I Helly I	pyrimidinyl	5 phonyr propyramino
4-fluorophenyl	2-amino-4-	3-phenyl-propylamino
4-11dol oblieny1	pyrimidinyl	3-phenyi-propyramino
3-fluorophenyl	2-amino-4-	3-phenyl-propylamino
3-11dolophenyi	pyrimidinyl	3-piletry1-propyramilito
2-fluorophenyl	2-amino-4-	3-phenyl-propylamino
z-fidol Ophenyi	pyrimidinyl	3-phenyi-propyramino
4-chlorophenyl	2-amino-4-	2 mb-myl mannylamina
4-chiolophenyi		3-phenyl-propylamino
3-chlorophenyl	pyrimidinyl 2-amino-4-	3-phenyl-propylamino
3-Chrorophenyi		2-buenAT-brobATawino
2-chlorophenyl	pyrimidinyl 2-amino-4-	3-phenyl-propylamino
z-eniorophenyi	pyrimidinyl	3-phenyi-propyramino
4-tolyl	2-amino-4-	3-phenyl-propylamino
4-00191	pyrimidinyl	3-phenyi-propyramino
3-tolyl	2-amino-4-	3-phenyl-propylamino
3-COIYI	pyrimidinyl	3-phenyi-propyramino
2-tolyl	2-amino-4-	2 -2111111
Z-COTĂT		3-phenyl-propylamino
4-trifluoro-	pyrimidinyl 2-amino-4-	2 -111
		3-phenyl-propylamino
methylphenyl 3-trifluoro-	pyrimidinyl	3 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
	2-amino-4-	3-phenyl-propylamino
methylphenyl	pyrimidinyl	2 1 2
2,6-	2-amino-4-	3-phenyl-propylamino
dichlorophenyl	pyrimidinyl	
2,6-dimethyl	2-amino-4-	3-phenyl-propylamino
phenyl	pyrimidinyl	
3,4-	2-amino-4-	3-phenyl-propylamino
dichlorophenyl	pyrimidinyl	
3,4-dimethyl	2-amino-4-	3-phenyl-propylamino
phenyl	pyrimidinyl	*
2,4-	2-amino-4-	3-phenyl-propylamino
dichlorophenyl	pyrimidinyl	
2,4-dimethvl	2-amino-4-	3-phenyl-propylamino
phenyl	pyrimidinyl	
	pyrimidinyl 4-pyridyl	(1-methyl-3- phenyl)propylamino

4-fluorophenyl	4-pyridyl	(1-methy1-3-
		phenyl)propylamino
3-fluorophenyl	4-pyridyl	(1-methyl-3-
2 61	1	phenyl)propylamino
2-fluorophenyl	4-pyridyl	(1-methyl-3-
	 	phenyl)propylamino
4-chlorophenyl	4-pyridyl	(1-methy1-3-
	 	phenyl)propylamino
3-chlorophenyl	4-pyridyl	(1-methy1-3-
		phenyl)propylamino
2-chlorophenyl	4-pyridyl	(1-methy1-3-
4 5 2 2 2	4	phenyl)propylamino
4-tolyl	4-pyridyl	(1-methy1-3-
2 - 1 - 1	4	phenyl)propylamino
3-toly1	4-pyridyl	(1-methy1-3-
2 + - 1 1	4	phenyl)propylamino
2-tolyl	4-pyridyl	(1-methy1-3-
4-trifluoro-	4	phenyl)propylamino (1-methyl-3-
	4-pyridyl	
methylphenyl 3-trifluoro-	4	phenyl)propylamino (1-methyl-3-
methylphenyl	4-pyridyl	
metnyipnenyi 2.6-	4	phenyl)propylamino
	4-pyridyl	(1-methy1-3-
dichlorophenyl		phenyl)propylamino
2,6-dimethyl	4-pyridyl	(1-methyl-3-
phenyl	·	phenyl) propylamino
3,4-	4-pyridyl	(1-methy1-3-
dichlorophenyl		phenyl)propylamino
3,4-dimethyl	4-pyridyl	(1-methy1-3-
phenyl	4	phenyl) propylamino
2,4- dichlorophenyl	4-pyridyl	(1-methy1-3-
2,4-dimethyl	4-pyridyl	phenyl)propylamino (1-methyl-3-
phenyl	#-DALIGAT	phenyl)propylamino
Phenyl	2-amino-4-	(1-methy1-3-
PHEHYI	pyridyl	phenyl)propylamino
4-fluorophenyl	2-amino-4-	(1-methy1-3-
4 TIGOTOPHENYI	pvridvl	phenyl)propylamino
3-fluorophenyl	2-amino-4-	(1-methy1-3-
5 114010pheny1	pyridyl	phenyl)propylamino
2-fluorophenyl	2-amino-4-	(1-methy1-3-
2-11dolopheny1	pyridyl	phenyl)propylamino
4-chlorophenvl	2-amino-4-	(1-methyl-3-
4 CHIOLOPHENYI	pyridyl	phenyl)propylamino
3-chlorophenv1	2-amino-4-	(1-methy1-3-
2 curorobuent	pyridyl	phenyl)propylamino
2-chlorophenyl	2-amino-4-	(1-methy1-3-
z chiorophenyi	pyridyl	phenyl)propylamino
4-tolyl	2-amino-4-	(1-methyl-3-
3 20131	pyridyl	phenyl)propylamino
3-toly1	2-amino-4-	(1-methyl-3-
3 30191	pyridyl	phenyl)propylamino
2-tolyl	2-amino-4-	(1-methy1-3-
2 20171	pyridyl	phenyl)propylamino
	1-1-1-41-	F/-/-/P/

4-trifluoro-	2-amino-4-	(1-methyl-3-
methylphenyl	pyridyl	phenyl)propylamino
3-trifluoro-	2-amino-4-	(1-methyl-3-
methylphenyl	pyridyl	phenyl)propylamino
2,6-	2-amino-4-	(1-methyl-3-
dichlorophenyl	pyridyl	phenyl)propylamino
2,6-dimethyl	2-amino-4-	(1-methyl-3-
phenyl	pyridyl	phenyl)propylamino
3,4-	2-amino-4-	(1-methyl-3-
dichlorophenyl	pyridyl	phenyl)propylamino
3.4-dimethyl	2-amino-4-	(1-methyl-3-
phenyl	pyridyl	phenyl)propylamino
2,4-	2-amino-4-	(1-methyl-3-
dichlorophenyl	pyridyl	phenyl)propylamino
2,4-dimethyl	2-amino-4-	(1-methyl-3-
phenyl	pyridyl	phenyl)propylamino
Phenyl	2-acetamido-	(1-methyl-3-
FREITY	4-pyridyl	phenyl)propylamino
4-fluorophenyl	2-acetamido-	(1-methyl-3-
4-11dolobueny1	4-pyridyl	phenyl)propylamino
2 61	2-acetamido-	(1-methyl-3-
3-fluorophenyl		
0 61	4-pyridyl	phenyl)propylamino
2-fluorophenyl	2-acetamido-	(1-methyl-3-
	4-pyridyl	phenyl)propylamino
4-chlorophenyl	2-acetamido-	(1-methyl-3-
	4-pyridyl	phenyl)propylamino
3-chlorophenyl	2-acetamido-	(1-methy1-3-
	4-pyridyl	phenyl)propylamino
2-chlorophenyl	2-acetamido-	(1-methyl-3-
	4-pyridyl	phenyl)propylamino
4-tolyl	2-acetamido-	(1-methyl-3-
	4-pyridyl	phenyl)propylamino
3-tolyl	2-acetamido-	(1-methyl-3-
	4-pyridyl	phenyl)propylamino
2-tolyl	2-acetamido-	(1-methyl-3-
	4-pyridyl	phenyl)propylamino
4-trifluoro-	2-acetamido-	(1-methyl-3-
methylphenyl	4-pyridyl	phenyl)propylamino
3-trifluoro-	2-acetamido-	(1-methyl-3-
methylphenyl	4-pyridyl	phenyl)propylamino
2,6-	2-acetamido-	(1-methyl-3-
dichlorophenyl	4-pyridyl	phenyl)propylamino
2,6-dimethyl	2-acetamido-	(1-methyl-3-
phenyl	4-pyridyl	phenyl)propylamino
3,4-	2-acetamido-	(1-methyl-3-
dichlorophenyl	4-pyridyl	phenyl)propylamino
3,4-dimethyl	2-acetamido-	(1-methyl-3-
phenyl	4-pyridyl	phenyl)propylamino
2,4-	2-acetamido-	(1-methyl-3-
dichlorophenyl	4-pyridyl	phenyl)propylamino
2,4-dimethyl	2-acetamido-	(1-methyl-3-
phenyl	4-pyridyl	phenyl)propylamino
Phenyl	2-amino-4-	(1-methyl-3-
1	pyrimidinyl	phenyl) propylamino
		I F

4-fluorophenyl	2-amino-4-	(1-methyl-3-
2 63	pyrimidinyl	phenyl)propylamino
3-fluorophenyl	2-amino-4-	(1-methy1-3-
	pyrimidinyl	phenyl)propylamino
2-fluorophenyl	2-amino-4-	(1-methy1-3-
	pyrimidinyl	phenyl)propylamino
4-chlorophenyl	2-amino-4-	(1-methyl-3-
	pyrimidinyl	phenyl)propylamino
3-chlorophenyl	2-amino-4-	(1-methy1-3-
	pyrimidinyl	phenyl)propylamino
2-chlorophenyl	2-amino-4-	(1-methyl-3-
	pyrimidinyl	phenyl)propylamino (1-methyl-3-
4-tolyl	2-amino-4-	(1-methyl-3-
	pyrimidinyl	phenyl)propylamino
3-tolyl	2-amino-4-	(1-methyl-3-
	pyrimidinyl	phenyl)propylamino
2-tolyl	2-amino-4-	(1-methy1-3-
	pyrimidinyl	phenyl) propylamino
4-trifluoro-	2-amino-4-	(1-methyl-3-
methylphenyl	pyrimidinyl	phenyl)propylamino
3-trifluoro-	2-amino-4-	(1-methyl-3-
methylphenyl	pyrimidinyl	phenyl)propylamino
2,6-	2-amino-4-	(1-methyl-3-
dichlorophenyl	pyrimidinyl	phenyl)propylamino
2,6-dimethyl	2-amino-4-	(1-methv1-3-
phenyl	pyrimidinyl	phenyl)propylamino
3,4-	2-amino-4-	(1-methyl-3-
dichlorophenyl	pyrimidinyl	phenyl)propylamino
3,4-dimethyl	2-amino-4-	(1-methy1-3-
phenyl	pyrimidinyl	phenyl)propylamino
2,4-	2-amino-4-	(1-methyl-3-
dichlorophenyl	pyrimidinyl	phenyl)propylamino
2,4-dimethyl	2-amino-4-	(1-methyl-3-
phenyl	pyrimidinyl	phenyl)propylamino
4-fluorophenyl	4-pyridyl	4-fluorobenzylamino
4-fluorophenyl	2-acetamido-	4-fluorobenzylamino
	4-pyridyl	_
4-fluorophenyl	2-amino-4-	4-fluorobenzylamino
	pyrimidinyl	-
4-fluorophenyl	4-pyridylnyl	(2-(4-fluorophenvl)-1-
		methyl-ethyl)amino
4-fluorophenyl	2-acetamido-	(2-(4-fluorophenyl)-1-
	4-pyridyl	methyl-ethyl)amino
4-fluorophenyl	2-amino-4-	(2-(4-fluorophenyl)-1-
	pyrimidinyl	methyl-ethyl)amino
4-fluorophenyl	4-pyridyl	(1,1-dimethyl-2-(4-
	222-	fluorophenyl) -ethyl) amino
4-fluorophenyl	2-acetamido-	(1,1-dimethyl-2-(4-
	4-pyridyl	fluorophenyl) -ethyl) amino
4-fluorophenyl	2-amino-4-	(1,1-dimethyl-2-(4-
	pyrimidinyl	fluorophenyl) -ethyl) amino
4-fluorophenyl	4-pyridyl	2-(4-fluorophenyl)-2-
	- pyridyi	methyl-ethylamino
		I meeting a configuration

4-fluorophenyl	2-acetamido-	(2-(4-fluorophenyl)-2-
	4-pyridyl	methyl-ethyl)amino
4-fluorophenyl	2-amino-4-	(2-(4-fluorophenyl)-2-
	pyrimidinyl	methyl-ethyl)amino
4-fluorophenyl	4-pyridyl	(2-methyl-2-
		phenylethyl)amino
4-fluorophenyl	2-acetamido-	(2-methyl-2-
	4-pyridyl	phenylethyl)amino
4-fluorophenyl	2-amino-4-	(2-methy1-2-
	pyrimidinyl	phenylethyl)amino
4-fluorophenyl	4-pyridyl	methyl-(2-
		phenylethyl)amino
4-fluorophenyl	2-acetamido-	methyl-(2-
	4-pyridyl	phenylethyl)amino
4-fluorophenyl	2-amino-4-	methyl-(2-
	pyrimidinyl	phenylethyl)amino
4-fluorophenyl	4-pyridyl	(2-(4-trifluoromethyl
1 -		phenyl)ethyl)amino
4-fluorophenyl	2-acetamido-	(2-(4-trifluoromethyl
	4-pyridyl	phenyl)ethyl)amino
4-fluorophenyl	2-amino-4-	(2-(4-trifluoromethyl
	pyrimidinyl	phenyl)ethyl)amino
4-fluorophenyl	4-pyridyl	2-(4-toly1)ethylamino
4-fluorophenvl	2-acetamido-	2-(4-tolyl)ethylamino
	4-pyridyl	2 (4 coly1, conylamino
4-fluorophenyl	2-amino-4-	2-(4-tolyl)ethylamino
	pyrimidinyl	2 (1 coly 1) cony lamino
4-fluorophenyl	4-pyridyl	(2-(3-fluorophenyl)
	- 211-	ethyl)amino
4-fluorophenyl	2-acetamido-	(2-(3-fluorophenvl)
	4-pyridyl	ethyl)amino
4-fluorophenyl	2-amino-4-	(2-(3-fluorophenyl)
	pyrimidinyl	ethyl)amino
4-fluorophenyl	4-pyridyl	(2-(2-fluorophenyl)
	- P1-1-1-	ethyl)amino
4-fluorophenyl	2-acetamido-	(2-(2-fluorophenyl)
	4-pyridyl	ethyl)amino
4-fluorophenyl	2-amino-4-	(2-(2-fluorophenyl)
	pyrimidinyl	ethyl)amino
4-fluorophenyl	4-pyridyl	methyl-(2-(2-
- Limolophonji	- 21-1-01-	pyridyl)ethyl)amino
4-fluorophenyl	2-acetamido-	methyl-(2-(2-
- LIGOLOPHCHYI	4-pyridyl	pyridyl) ethyl) amino
4-fluorophenyl	2-amino-4-	methyl-(2-(2-
- Tracrobuenyr	pyrimidinyl	pyridyl)ethyl)amino
4-fluorophenyl	4-pyridyl	(1,1-dimethyl-3-phenyl-
4 11401Opheny1	= pyriayi	propyl)amino
4-fluorophenyl	2-acetamido-	(1,1-dimethyl-3-phenyl-
4 Lingiophenyi	4-pyridyl	propyl)amino
4-fluorophenyl	2-amino-4-	(1,1-dimethyl-3-phenyl-
- Lidorophenyi	pyrimidinyl	propyl)amino
4-fluorophenyl	4-pyridyl	(3-(4-fluorophenyl)-
* TraorobuenAr	# DATIMAT	propyl)amino
	<u> </u>	I Drobar) amirino

	Co. Cr.	
4-fluorophenyl	2-acetamido-	(3-(4-fluorophenyl)-
	4-pyridyl	propyl)amino
4-fluorophenyl	2-amino-4-	(3-(4-fluorophenyl)-
	pyrimidinyl	propyl)amino
4-fluorophenyl	4-pyridyl	(3-(4-fluorophenyl)-1-
		methyl-propyl)amino
4-fluorophenyl	2-acetamido-	(3-(4-fluorophenyl)-1-
	4-pyridyl	methyl-propyl)amino
4-fluorophenyl	2-amino-4-	(3-(4-fluorophenyl)-1-
	pyrimidinyl	methyl-propyl)amino
4-fluorophenyl	4-pyridyl	(1,1-dimethyl-3-(4-fluoro
		phenyl)-propyl)amino
4-fluorophenyl	2-acetamido-	(1,1-dimethyl-3-(4-fluoro
	4-pyridyl	phenyl)-propyl)amino
4-fluorophenyl	2-amino-4-	(1,1-dimethyl-3-(4-fluoro
	pyrimidinyl	phenyl)-propyl)amino
4-fluorophenyl	4-pyridyl	(3-(2-fluorophenyl)-
		propyl)amino
4-fluorophenyl	2-acetamido-	(3-(2-fluorophenyl)-
	4-pyridyl	propyl)amino
4-fluorophenyl	2-amino-4-	(3-(2-fluorophenyl)-
	pyrimidinyl	propyl)amino
4-fluorophenyl	4-pyridyl	(3-methyl-3-phenyl-
		propyl)amino
4-fluorophenyl	2-acetamido-	(3-methyl-3-phenyl-
	4-pyridyl	propyl)amino
4-fluorophenyl	2-amino-4-	(3-methyl-3-phenyl-
	pyrimidinyl	propyl)amino
4-fluorophenyl	4-pyridyl	(2-methyl-3-phenyl-
L		propyl)amino
4-fluorophenyl	2-acetamido-	(2-methyl-3-phenyl-
	4-pyridyl	propyl)amino
4-fluorophenyl	2-amino-4-	(2-methyl-3-phenyl-
	pyrimidinyl	propyl)amino
4-fluorophenyl	4-pyridyl	(3,3-dimethylbutyl)amino
4-fluorophenyl	2-acetamido-	(3,3-dimethylbutyl)amino
	4-pyridyl	
4-fluorophenyl	2-amino-4-	(3,3-dimethylbutyl)amino
	pyrimidinyl	
4-fluorophenyl	4-pyridyl	isoamylamino
4-fluorophenyl	2-acetamido-	isoamylamino
	4-pyridyl	
4-fluorophenyl	2-amino-4-	isoamylamino
	pyrimidinyl	
4-fluorophenyl	4-pyridyl	amylamino
4-fluorophenyl	2-acetamido-	amylamino
	4-pyridyl	
4-fluorophenyl	2-amino-4-	amylamino
	pyrimidinyl	
4-fluorophenyl	4-pyridyl	(2,5-dimethyl)pentylamino
4-fluorophenyl	2-acetamido-	(2,5-dimethyl)pentylamino
	4-pyridyl	
4-fluorophenyl	2-amino-4-	(2,5-dimethyl)pentylamino
1	pyrimidinyl	1

4-fluorophenyl	4-pyridyl	piperazinyl
4-fluorophenyl	2-acetamido-	piperazinvl
	4-pyridyl	1
4-fluorophenvl	2-amino-4-	piperazinyl
•	pyrimidinyl	1
4-fluorophenyl	4-pyridyl	(3-(3-fluorophenvl)-
		propyl)amino
4-fluorophenyl	2-acetamido-	(3-(3-fluorophenvl)-
	4-pyridyl	propyl)amino
4-fluorophenyl	2-amino-4-	(3-(3-fluorophenyl)-
1 radorophichyr	pyrimidinyl	propyl)amino
benzyl	4-pyridyl	3-phenylpropylamino
benzvl	4-pyridyl	2-(4-fluorophenyl)
Bellayi	4 pyridyr	ethylamino
2-thienyl	4-pyridyl	3-phenylpropylamino
2-thienyl	4-pyridyl	2-(4-fluorophenvl)
2-chienyi	4-byridyi	
	4	ethylamino
cyclohexyl	4-pyridyl	3-phenylpropylamino
cyclohexyl	4-pyridyl	2-(4-fluorophenyl)
		ethylamino
tert-butyl	4-pyridyl	3-phenylpropylamino
tert-butyl	4-pyridyl	2-(4-fluorophenyl)
		ethylamino
4-fluorophenyl	4-	3-phenylpropylamino
	piperidinyl	
4-fluorophenyl	4-	2-(4-fluorophenyl)
	piperidinyl	ethylamino
4-fluorophenyl	4-pyranyl	3-phenylpropylamino
4-fluorophenyl	4-pyranyl	2-(4-fluorophenyl)
		ethylamino
Phenyl	4-pyridyl	3-phenyl-2-amino-
		propylamino
4-fluorophenyl	4-pyridyl	3-pheny1-2-amino-
		propylamino
3-fluorophenyl	4-pyridyl	3-phenyl-2-amino-
		propylamino
2-fluorophenyl	4-pyridyl	3-phenyl-2-amino-
		propylamino
4-chlorophenyl	4-pyridyl	3-phenv1-2-amino-
	- 223-	propylamino
3-chlorophenyl	4-pyridyl	3-phenyl-2-amino-
o omronophichy i	- pjilaji	propylamino
2-chlorophenyl	4-pyridyl	3-phenyl-2-amino-
- SHEOLOPHCHY!	- barraar	propylamino
4-tolvl	4-pyridyl	3-phenyl-2-amino-
4-coryr	4-byridyi	propylamino
3-tolyl	4-pyridyl	
2 COTAT	#-DALIGAT	3-phenyl-2-amino-
2-tolyl	4	propylamino
√-corAT	4-pyridyl	3-phenyl-2-amino-
1		propylamino
4-trifluoro-	4-pyridyl	3-phenyl-2-amino-
methylphenyl		propylamino
3-trifluoro-	4-pyridyl	3-phenyl-2-amino-
methylphenyl	1	propylamino

2,6-	4-pyridyl	3-phenyl-2-amino-
dichlorophenyl		propylamino
2,6-dimethyl	4-pyridyl	3-phenyl-2-amino-
phenyl		propylamino
3,4-	4-pyridyl	3-phenyl-2-amino-
dichlorophenyl		propylamino
3,4-dimethyl	4-pyridyl	3-phenyl-2-amino-
phenyl		propylamino
2,4-	4-pyridyl	3-phenyl-2-amino-
dichlorophenyl		propylamino
2,4-dimethyl	4-pyridyl	3-pheny1-2-amino-
phenyl		propylamino
Phenyl	4-pyridyl	3-phenyl-3-amino-
-		propylamino
4-fluorophenyl	4-pvridvl	3-phenyl-3-amino-
<i>p</i>	- 233-	propylamino
3-fluorophenyl	4-pyridyl	3-phenyl-3-amino-
	- 533-	propylamino
2-fluorophenyl	4-pyridyl	3-phenyl-3-amino-
z riudiophenyi	4 pyrrayr	propylamino
4-chlorophenyl	4-pvridvl	3-phenvl-3-amino-
4-curorophenyr	4-pyridyi	propylamino
3 abla	4	3-phenyl-3-amino-
3-chlorophenyl	4-pyridyl	
		propylamino
2-chlorophenyl	4-pyridyl	3-phenyl-3-amino-
		propylamino
4-tolyl	4-pyridyl	3-phenyl-3-amino-
		propylamino
3-tolyl	4-pyridyl	3-phenyl-3-amino-
		propylamino
2-tolyl	4-pyridyl	3-phenyl-3-amino-
		propylamino
4-trifluoro-	4-pyridyl	3-phenyl-3-amino-
methylphenyl		propylamino
3-trifluoro-	4-pyridyl	3-phenyl-3-amino-
methylphenyl		propylamino .
2,6-	4-pyridyl	3-phenyl-3-amino-
dichlorophenyl	- 233-	propylamino
2,6-dimethyl	4-pyridyl	3-phenyl-3-amino-
phenyl	. 2311031	propylamino
3,4-	4-pyridyl	3-phenyl-3-amino-
dichlorophenyl	4 pyrrayr	propylamino
3,4-dimethyl	A marrial days	3-phenyl-3-amino-
	4-pyridyl	
phenyl	 	propylamino
2,4-	4-pyridyl	3-phenyl-3-amino-
dichlorophenyl	1	propylamino
2,4-dimethyl	4-pyridyl	3-phenyl-3-amino-
phenyl		propylamino
3-fluorophenyl	4-pyridyl	(S)-tetrahydroisoquinol-
		3-ylmethylenamino
2-fluorophenyl	2-amino-4- pyridyl	(S)-3-benzylpiperazinyl
3-chlorophenyl	2-acetamido-	(S)-2-N-isopropylamino-3

2-chlorophenyl	2-amino-4-	(S)-2-N-glycylamino-3-
z-chrorophenyi	pyrimidinyl	phenylpropylamino
4-tolyl .	4-pyridyl	(S)-2-amino-3-
4-colyl .	4-pyridyl	
2		phenylpropylamino
3-tolyl	2-amino-4-	(R)-2-amino-3-
	pyridyl	phenylpropylamino
2-tolyl	2-acetamido-	3-amino-3-
	4-pyridyl	phenylpropylamino
4-trifluoro-	2-amino-4-	(S)-2-amino-3-(2-
methylphenyl	pyrimidinyl	fluorophenyl)propylamino
3-trifluoro-	4-pyridyl	(S)-2-amino-3-(2-
methylphenyl		methylphenyl)propylamino
2,6-	2-amino-4-	3-amino-3-(2-
dichlorophenyl	pyridyl	fluorophenyl)propylamino
2,6-dimethyl	2-acetamido-	3-amino-3-(2-
phenyl	4-pyridyl	methylphenyl)propylamino
3,4-	2-amino-4-	2-amino-2-methyl-3-
dichlorophenyl	pyrimidinyl	phenylpropylamino
3,4-dimethyl	4-pyridyl	3-amino-2-methyl-3-
phenyl		phenylpropylamino
3-fluorophenyl	2-amino-4-	(S)-2-amino-3-
1	pyridyl	phenylpropylamino
2-fluorophenyl	2-acetamido-	(S)-2-amino-3-(2-
1	4-pyridyl	fluorophenyl)propylamino
3-chlorophenyl	2-amino-4-	(S)-2-amino-3-(2-
1 1	pyrimidinyl	methylphenyl)propylamino
2-chlorophenyl	4-pyridyl	(S)-2-N-isopropylamino-3-
	- 133-	phenylpropylamino
4-tolvl	2-amino-4-	(S)-2-N-glycylamino-3-
. 00171	pyridyl	phenylpropylamino
3-tolvl	2-acetamido-	2-amino-2-methyl-3-
0 00030	4-pyridyl	phenylpropylamino
2-tolv1	2-amino-4-	(R)-2-amino-3-
2 00171	pyrimidinyl	phenylpropylamino
4-trifluoro-	4-pyridyl	3-amino-3-
methylphenyl	- pyrrayr	phenylpropylamino
3-trifluoro-	2-amino-4-	3-amino-3-(2-
methylphenyl	pyridyl	fluorophenyl)propylamino
2.6-	2-acetamido-	3-amino-3-(2-
dichlorophenyl	4-pyridyl	methylphenyl)propylamino
2,6-dimethyl	2-amino-4-	3-amino-2-methyl-3-
phenyl	pyrimidinyl	phenylpropylamino
3,4-		
	4-pyridyl	(S)-tetrahydroisoquinol-
dichlorophenyl	I	3-ylmethylenamino
3,4-dimethyl	4-pyridyl	(S)-3-benzylpiperazinyl
phenyl	1	

Additional preferred compounds are listed in the Examples, infra.

As utilized herein, the following terms shall have the following meanings:

"Alkyl", alone or in combination, means a straight-chain or branched-chain alkyl radical containing preferably 1-15 carbon atoms (C1-C15), more preferably 1-8 carbon 5 atoms (C1-C8), even more preferably 1-6 carbon atoms (C1-C6), yet more preferably 1-4 carbon atoms (C1-C4), still more preferably 1-3 carbon atoms (C1-C3), and most preferably 1-2 carbon atoms (C1-C2). Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, 10 n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, hexyl, octvl and the like.

"Hydroxyalkyl", alone or in combination, means an alkyl radical as defined above wherein at least one hydrogen 15 radical is replaced with a hydroxyl radical, preferably 1-3 hydrogen radicals are replaced by hydroxyl radicals, more preferably 1-2 hydrogen radicals are replaced by hydroxyl radicals, and most preferably one hydrogen radical is replaced by a hydroxyl radical. Examples of such radicals include hydroxymethyl, 1-, 2-hydroxyethyl, 1-, 2-, 3-hydroxypropyl, 1,3-dihydroxy-2-propyl, 1,3-dihydroxybtyl, 1,2,3,4,5,6-hexahydroxy-2-hexyl and the like.

"Alkenyl", alone or in combination, means a straight-chain or branched-chain hydrocarbon radical having one or more double bonds, preferably 1-2 double bonds and more preferably one double bond, and containing preferably 2-15 carbon atoms (C2-C15), more preferably
2-8 carbon atoms (C2-C6), even more preferably 2-6 carbon atoms (C2-C6), yet more preferably 2-4 carbon atoms (C2-C4), and still more preferably 2-3 carbon atoms (C2-C3). Examples of such alkenyl radicals include ethenyl, propenyl, 2-methylpropenyl, 1,4-butadienyl and the like.

"Alkoxy", alone or in combination, means a radical of the type "R-O-" wherein "R" is an alkyl radical as defined above and "O" is an oxygen atom. Examples of such alkoxy radicals include methoxy, ethoxy, n-propoxy, 5 isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tertbutoxy and the like.

"Alkoxycarbony1", alone or in combination, means a radical of the type "R-O-C(0)-" wherein "R-O-" is an alkoxy radical as defined above and "C(0)" is a carbonyl radical.

"Alkoxycarbonylamino", alone or in combination, means a radical of the type "R-O-C(0)-NH-" wherein "R-O-C(0)" is an alkoxycarbonyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.

20 "Alkylthio", alone or in combination, means a radical of the type "R-S-" wherein "R" is an alkyl radical as defined above and "S" is a sulfur atom. Examples of such alkylthio radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, 25 sec-butylthio, tert-butylthio and the like.

"Alkylsulfinyl", alone or in combination, means a radical of the type "R-S(0)-" wherein "R" is an alkyl radical as defined above and "S(0)" is a mono-oxygenated sulfur atom. Examples of such alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, isopropylsulfinyl, n-butylsulfinyl, iso-butylsulfinyl, sec-butylsulfinyl, tert-butylsulfinyl and the like.

35 "Alkylsulfonyl", alone or in combination, means a radical of the type "R-S(O)₂-" wherein "R" is an alkyl radical as defined above and "S(O)," is a di-oxygenated sulfur atom. Examples of such alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl, n-propylsulfonyl. isopropylsulfonyl, n-butylsulfonyl, iso-butylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl and the like.

5

10

- "Aryl", alone or in combination, means a phenyl or biphenyl radical, which is optionally benzo fused or heterocyclo fused and which is optionally substituted with one or more substituents selected from alkyl. alkoxy, halogen, hydroxy, amino, azido, nitro, cyano, haloalkyl, carboxy, alkoxycarbonyl, cycloalkyl, alkanoylamino, amido, amidino, alkoxycarbonylamino, Nalkylamidino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, N-alkylamido, N.N-15 dialkylamido, aralkoxycarbonylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, oxo and the like. Examples of arvl radicals are phenvl, o-tolvl, 4methoxyphenyl, 2-(tert-butoxy)phenyl, 3-methyl-4methoxyphenyl, 2-CF3-phenyl, 2-fluorophenyl, 2-
- 20 chlorophenyl, 3-nitrophenyl, 3-aminophenyl, 3acetamidophenyl, 2-amino-3-(aminomethyl)phenyl, 6methyl-3-acetamidophenyl, 6-methyl-2-aminophenyl, 6methyl-2,3-diaminophenyl, 2-amino-3-methylphenyl, 4,6dimethyl-2-aminophenyl, 4-hydroxyphenyl, 3-methyl-4-25 hydroxyphenyl, 4-(2-methoxyphenyl)phenyl, 2-amino-1
 - naphthyl, 2-naphthyl, 3-amino-2-naphthyl, 1-methyl-3amino-2-naphthyl, 2,3-diamino-1-naphthyl, 4,8-dimethoxy-2-naphthyl and the like.
- 3.0 "Aralkyl" and "arylalkyl", alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyl, 1-, 2phenylethyl, dibenzylmethyl, hydroxyphenylmethyl, methylphenylmethyl, diphenylmethyl,
 - dichlorophenylmethyl, 4-methoxyphenylmethyl and the like.

- "Aralkoxy", alone or in combination, means an alkoxy radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyloxy, 1-, 2-phenylethoxy, dibenzylmethoxy, hydroxyphenylmethoxy, methylphenylmethoxy, dichlorophenylmethoxy, 4-methoxyphenylmethoxy and the like.
- "Aralkoxycarbony1", alone or in combination, means a radical of the type "R-O-C(0)-" wherein "R-O-" is an aralkoxy radical as defined above and "-C(0)-" is a carbonyl radical.
- "Alkanoyl", alone or in combination, means a radical of the type "R-C(0)-" wherein "R" is an alkyl radical as defined above and "-C(0)-" is a carbonyl radical. Examples of such alkanoyl radicals include acetyl, trifluoroacetyl, hydroxyacetyl, propionyl, butyryl,
- 20 valeryl, 4-methylvaleryl, and the like.
- "Alkanoylamino", alone or in combination, means a radical of the type "R-C(0)-NH-" wherein "R-C(0)-" is an alkanoyl radical as defined above, wherein the amino 25 radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.
- "Aminocarbonyl", alone or in combination, means an amino substituted carbonyl (carbamoyl) radical, wherein the amino radical may optionally be mono- or di-substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, alkoxycarbonyl, aralkoxycarbonyl and the like.
 - "Aminosulfonyl", alone or in combination, means an amino substituted sulfonyl radical.

25

3.0

"Benzo", alone or in combination, means the divalent radical CgH4= derived from benzene. "Benzo fused" forms a ring system in which benzene and a cycloalkyl or aryl group have two carbons in common, for example tetrahydronaphthylene and the like.

"Bicyclic" as used herein is intended to include both fused ring systems, such as naphthyl and \$-carbolinyl, and substituted ring systems, such as biphenyl, phenylpyridyl and diphenylpiperazinyl.

"Cycloalkyl", alone or in combination, means a saturated

or partially saturated, preferably one double bond,
monocyclic, bicyclic or tricyclic carbocyclic alkyl
radical, preferably monocyclic, containing preferably 512 carbon atoms (C5-C12), more preferably 5-10 carbon
atoms (C5-C10), even more preferably 5-7 carbon atoms
(C5-C7), which is optionally benzo fused or heterocyclo
fused and which is optionally substituted as defined
herein with respect to the definition of aryl. Examples
of such cycloalkyl radicals include cyclopentyl,
cyclohexyl, dihydroxycyclohexyl.

ethylenedioxycyclohexyl, cycloheptyl, octahydronaphthyl, tetrahydronaphthyl, octahydroquinolinyl, dimethoxytetrahydronaphthyl, 2,3-dihydro-lH-indenyl, azabicyclof3.2.1loctvl and the like.

"Heteroatoms" means nitrogen, oxygen and sulfur heteroatoms

"Heterocyclo fused" forms a ring system in which a heterocyclyl or heteroaryl group of 5-6 ring members and a cycloalkyl or aryl group have two carbons in common,

35 for example indole, isoquinoline, tetrahydroquinoline, methylenedioxybenzene and the like. "Heterocyclyl" means a saturated or partially unsaturated, preferably one double bond, monocyclic or bicyclic, preferably monocyclic, heterocycle radical containing at least one, preferably 1 to 4, more

- 5 preferably 1 to 3, even more preferably 1-2, nitrogen, oxygen or sulfur atom ring member and having preferably 3-8 ring members in each ring, more preferably 5-8 ring members in each ring and even more preferably 5-6 ring members in each ring. "Heterocyclyl" is intended to
- include sulfone and sulfoxide derivatives of sulfur ring members and N-oxides of tertiary nitrogen ring members, and carbocyclic fused, preferably 3-6 ring carbon atoms and more preferably 5-6 ring carbon atoms, and benzo fused ring systems. "Heterocycly1" radicals may
- optionally be substituted on at least one, preferably 1-4, more preferably 1-3, even more preferably 1-2, carbon atoms by halogen, alkyl, alkoxy, hydroxy, oxo, thioxo, aryl, aralkyl, heteroaryl, heteroaralkyl, amidino, N-alkylamidino, alkoxycarbonylamino, alkylsulfonylamino
- and the like, and/or on a secondary nitrogen atom by hydroxy, alkyl, aralkoxycarbonyl, alkanoyl, alkoxycarbonyl, heteroaralkyl, aryl or aralkyl radicals. More preferably, "heterocyclyl", alone or in combination, is a radical of a monocyclic or bicyclic
- 25 saturated heterocyclic ring system having 5-8 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals. Examples of
- 30 such heterocyclyl radicals include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, 4-benzyl-piperazin-1-yl, pyrimidinyl, tetrahydrofuryl, pyrazolidonyl, pyrazolinyl, pyridazinonyl, pyrrolidonyl, tetrahydrothienyl and its sulfoxide and sulfone
- 35 derivatives, 2,3-dihydroindolyl, tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-1-

oxo-isoquinolinyl, 2,3-dihydrobenzofuryl, benzopyranyl, methylenedioxyphenyl, ethylenedioxyphenyl and the like.

- "Heteroaryl" means a monocyclic or bicyclic, preferably
 5 monocyclic, aromatic heterocycle radical, having at
 least one, preferably 1 to 4, more preferably 1 to 3,
 even more preferably 1-2, nitrogen, oxygen or sulfur
 atom ring members and having preferably 5-6 ring members
 in each ring, which is optionally saturated carbocyclic
 10 fused, preferably 3-4 carbon atoms (C3-C4) to form 5-6
 ring membered rings and which is optionally substituted
 as defined above with respect to the definitions of
 aryl. Examples of such heteroaryl groups include
 imidazolyl, 1-benzyloxycarbonylimidazol-4-yl, pyrrolyl,
- pyrazolyl, pyridyl, 3-(2-methyl)pyridyl, 3-(4trifluoromethyl)pyridyl, pyrimidinyl, 5-(4trifluoromethyl)pyrimidinyl, pyrazinyl, triazolyl,
 furyl, thienyl, oxazolyl, thiazolyl, indolyl,
 quinolinyl, 5,6,7,8-tetrahydroquinolyl,
- 20 5,6,7,8-tetrahydroisoquinolinyl, quinoxalinyl, benzothiazolyl, benzofuryl, benzimidazolyl, benzoxazolyl and the like.
- "Heteroaralky1" and "heteroarylalky1," alone or in combination, means an alky1 radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by a heteroaryl radical as defined above, such as 3-furylpropyl, 2-pyrrolyl propyl, chloroquinolinylmethyl, 2-thienylethyl, pyridylmethyl,
- 30 1-imidazolylethyl and the like.
 - "Halogen" and "halo", alone or in combination, means fluoro, chloro, bromo or iodo radicals.
- 35 "Haloalkyl", alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-3, is replaced by a halogen radical,

more preferably fluoro or chloro radicals. Examples of such haloalkyl radicals include 1,1,1-trifluoroethyl, chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl,

5 bis(trifluoromethyl)methyl and the like.

"4(3H)-pyrimidinone" (A) and "4-hydroxy-pyrimidine" (B) are names of two tautomers of the same compound which may be used interchangeably. It is intended that the use of one of these terms inherently includes the other.

$$\begin{array}{c}
0\\
N\\
N
\end{array}$$
(A)
(B)

"Pharmacologically acceptable salt" means a salt prepared by conventional means, and are well known by 15 those skilled in the art. The "pharmacologically acceptable salts" include basic salts of inorganic and organic acids, including but not limited to hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulfonic acid, malic acid, 20 acetic acid, oxalic acid, tartaric acid, citric acid, lactic acid, fumaric acid, succinic acid, maleic acid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid and the like. When compounds of the invention include an acidic function such as a carboxy 25 group, then suitable pharmaceutically acceptable cation pairs for the carboxy group are well known to those skilled in the art and include alkaline, alkaline earth, ammonium, quaternary ammonium cations and the like. For additional examples of "pharmacologically acceptable 30 salts," see infra and Berge et al. J. Pharm. Sci. 66. 1 (1977).

"Cytokine" means a secreted protein that affects the functions of other cells, particularly as it relates to the modulation of interactions between cells of the immune system or cells involved in the inflammatory response. Examples of cytokines include but are not

- response. Examples of cytokines include but are no limited to interleukin 1 (IL-1), preferably IL-16, interleukin 6 (IL-6), interleukin 8 (IL-8) and TNF, preferably TNF- α (tumor necrosis factor- α).
- "TNF, IL-1, IL-6, and/or IL-8 mediated disease or disease state" means all disease states wherein TNF, IL-1, IL-6, and/or IL-8 plays a role, either directly as TNF, IL-1, IL-6, and/or IL-8 itself, or by TNF, IL-1, IL-6, and/or IL-8 inducing another cytokine to be released. For example, a disease state in which IL-1 plays a major role, but in which the production of or action of IL-1 is a result of TNF, would be considered mediated by TNF.
- "Leaving group" generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.
- "Protecting group" generally refers to groups well known
 in the art which are used to prevent selected reactive
 groups, such as carboxy, amino, hydroxy, mercapto and the
 like, from undergoing undesired reactions, such as
 nucleophilic, electrophilic, oxidation, reduction and the
 like. Preferred protecting groups are indicated herein
 where appropriate. Examples of amino protecting groups
 include, but are not limited to, aralkyl, substituted
 aralkyl, cycloalkenylalkyl and substituted cycloalkenyl

alkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like. Examples of aralkyl include, but are not limited to, benzyl, orthomethylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as phosphonium and ammonium salts. Examples of arvl groups include phenyl, naphthyl, indanyl, anthracenyl, 9-(9-phenylfluorenyl), phenanthrenyl, durenyl and the like. 10 Examples of cycloalkenylalkyl or substituted cycloalkylenylalkyl radicals, preferably have 6-10 carbon atoms, include, but are not limited to, cyclohexenyl methyl and the like. Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl, t-15 butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, tri-fluoroacetyl, tri-chloro acetyl, phthaloyl and the like. A mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected by both an

aralkyl group and an aralkoxycarbonyl group. Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example, 1,2-bis(methylene)benzene, phthalimidyl, succinimidyl, maleimidyl and the like and where these heterocyclic

groups can further include adjoining aryl and cycloalkyl rings. In addition, the heterocyclic groups can be mono-, di- or tri-substituted, such as nitrophthalimidyl. Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an addition salt, such as hydrochloride, toluenesulfonic

addition salt, such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like. Many of the amino protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups. For example, aralkyl groups. Alkyl groups are also sutiable groups

35 for protecting hydroxy and mercapto groups, such as tertbutyl.

chemistry.

Silvl protecting groups are silicon atoms optionally substituted by one or more alkyl, aryl and aralkyl groups. Suitable silvl protecting groups include, but are not limited to, trimethylsilyl, triethylsilyl, tri-isopropylsilyl, tertbutyldimethylsilyl, dimethylphenylsilyl, 1,2bis(dimethylsilyl)benzene, 1,2-bis(dimethylsilyl)ethane and diphenylmethylsilyl. Silylation of an amino groups provide mono- or di-silylamino groups. Silylation of 10 aminoalcohol compounds can lead to a N,N,O-tri-silvl derivative. Removal of the silvl function from a silvl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium flouride reagent, either as a discrete reaction step or in situ during a reaction with the alcohol group. 15 Suitable silvlating agents are, for example, trimethylsilyl chloride, tert-buty-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethyl silyl chloride or their combination products with imidazole or DMF. Methods for silvlation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well 25 known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol

Protecting groups are removed under conditions which will not affect the remaining portion of the 30 molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a 35 suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. A t-butoxycarbonyl protecting group can be removed utilizing an increanic

or organic acid, such as ECl or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be neutralized to yield the free amine. Carboxy protecting group, such as methyl, ethyl, benzyl, tert-butyl, 4-methoxyphenylmethyl and the like, can be removed under hydroylsis and hydrogenolysis conditions well known to those skilled in the art.

The symbols used above have the following meanings:

$$-CR^{\times}R^{Y} - = \begin{array}{c} R^{\times} & R^{Y} \\ -C(0) - = \\ R^{\times} & -C(0) - = \end{array}$$

$$-NR^{\times}R^{Y} = \begin{array}{c} R^{\times} & -C(NR) - = \\ R^{\times} & -C(NR) - = \\ -NR - = \end{array}$$

10

Prodrugs of the compounds of this invention are also contemplated by this invention. A prodrug is an active or inactive compound that is modified chemically through in vivo physicological action, such as hydrolysis, metabolism and the like, into a compound of 15 this invention following adminstration of the prodrug to a patient. The suitability and techniques involved in making and using prodrugs are well known by those skilled in the art. For a general discussion of 20 prodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p-25 methoxybenzyl), and alkylcarbonyloxyalkyl (for example,

pivaloyloxymethyl). Amines have been masked as

15

2.0

25

30

arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as 5 imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers. EP 039,051 (Sloan and Little, 4/11/81) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.

Compounds according to the invention can be synthesized according to one or more of the following methods. It should be noted that the general procedures are shown as it relates to preparation of compounds having unspecified stereochemistry. However, such procedures are generally applicable to those compounds of a specific stereochemistry, e.g., where the stereochemistry about a group is (S) or (R). In addition, the compounds having one stereochemistry (e.g., (R)) can often be utilized to produce those having opposite stereochemistry (i.e., (S)) using wellknown methods, for example, by inversion.

Pyrimidines:

A general method for the preparation of compounds of formula I involves the condensation of an 1.3dicarbonyl intermediate IV with an N-C-N containing structure such as an amidine V, a quanidine VI or urea VII (Scheme 1: for a review of synthetic methods see D.J. Brown, Heterocyclic Compounds: the Pyrimidines, Chapter 3, 1994, John Wiley & Sons).

87

Scheme 1

Additionally, as a 1,3-dicarbonyl synthon, a b-dimethylamino-a,b-unsaturated ketone IX can be reacted with amidines V or guanidines VI as described (G.B. Bennett et al., J. Med. Chem. 21, 623-628, 1978). (Scheme 2). Such b-dimethylamino-a,b-unsaturated ketones IX can be prepared by aminoformylation of an active methylene ketone VIII with Bredereck's reagent, namely, bis(dimethylamino)methoxymethane (H. Bredereck et al., Chem. Ber. 101, 41-50 (1968); G. B. Bennett et al., J. Org. Chem. 43, 221-225 (1977)).

Scheme 2

1.0

15

2.0

$$\begin{array}{c} \underline{\text{Scheme 3}} \\ \underline{\text{Me}_2N} \\ \underline{\text{OMe}} \\ \underline{\text{NN}} \\ \underline{\text{N$$

According to this approach, Scheme 3 illustrates the conversion of 2-(4-fluorophenyl)-1-(4-pyridyl)ethanone (VIII; Sheldrake, Synthetic Communications 23, 1967 (1993)) into the enamine IX. Intermediate IX may be condensed with a variety of amidines V and guanidines VI to provide 2-substituted 5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidines I.

Further ketones VIII may be prepared (e.g., according to Sheldrake, Synthetic communications 23, 1967-1971 (1993)), by employing other heteroaryl carboxaldehydes as the starting material, such as 2-methylpyridine-4-carboxaldehyde, 2,6-dimethylpyridine-4-carboxaldehyde (Mathes and Sauermilch, Chem. Ber. 88, 1276-1283 (1955)), quinoline-4-carboxaldehyde, pyrimidine-4-carboxaldehyde, 6-methylpyrimidine-4-carboxaldehyde, 2-methylpyrimidine-4-carboxaldehyde, 2,6-dimethylpyrimidine-4-carboxaldehyde (Bredereck et al., Chem. Ber. 97, 3407-3417 (1964)). Furthermore, 2-nitropyridin-4-carboxaldehyde may be prepared from 2-nitro-4-methylpyridine (Stanonis, J. Org. Chem. 22, 475 (1957)) by oxidation of the methyl group (Venemalm et al., Tet. Lett. 34, 5495-5496 (1993)). Its further

conversion via a ketone VIII would lead to a 2-nitro-4pyridyl derivative I (Scheme 4). Catalytic reduction of the nitro group to an amino group would provide a derivative of I with R¹¹ represented by a 2-amino-4pyridyl group. Conventional acetylation of the amino group then leads to the 2-acetamido-4-pyridyl derivative.

As displayed in Scheme 5, intermediate IX may also be condensed with urea VII to give the 2(1H) - pyrimidinone derivative X. X is transformed into chloride XI by reaction with a halogenating agent such as phosphorous oxychloride. Treatment of chloride XI with primary and secondary amines, thiolates or alcoholates allows the preparation of further pyrimidines I with Ri represented by a substituted N, S or O groups, as recited above. Likewise, hydrazines may be reacted with chloride XI to provide 2-hydrazino substituted pyrimidines I.

10

 $R^{-} = NH_{2}$ $R^{1} = NR^{22}C(0)R^{21}$ $R^{1} = NR^{22}SO_{2}R^{20}$

Palladium or nickel catalyzed cross couplings of chloride XI with arylboronic acids or arylzinc halides provide compounds of formula I wherein R' is aryl or heteroaryl.

Scheme 6 illustrates the reaction of intermediate IX with guanidine VI to give 2-amino substituted I. 2-Amino I is a useful intermediate for further acylations

15

2.0

25

and sulfonylations of the 2-amino group to give acylamido and sulfonamido derivatives.

For the synthesis of 4-hydroxy-pyrimidines II, the approach displayed in Scheme 7 may be followed (for a review of synthetic methods see: D.J. Brown, Heterocyclic Compounds: the Pyrimidines, supra). This approach involves the cyclization reaction between an acrylic acid ester XII and an amidine V followed by oxidation of the resulting dihydropyrimidinone XIII to give II.

For the synthesis of 2-substituted 5-(4-fluorophenyl)-6-(4-pyridyl)-4-hydroxy-pyrimidines II (Scheme 8), the disubstituted acrylic acid ester XII may be prepared conveniently by condensation of pyridine-4-carboxaldehyde with 4-fluorophenylacetic acid followed by esterification. XII may be reacted with a variety of amidines V at elevated temperature. As a dehydrogenating agent for the conversion of XIII to II, sodium nitrite/acetic acid is suitable.

Accordingly, further compounds of formula II may be obtained in which R¹² is any other heteroaryl ring within the definition of R¹² by the appropriate choice of starting material. Such starting materials include but are not limited to 2-methylpyridine-4-carboxaldehyde, 2,6-dimethylpyridine-4-carboxaldehyde (Mathes and Sauermilch, Chem. Ber. 88, 1276-1283 (1955)), quinoline-4-carboxaldehyde, pyrimidine-4-carboxaldehyde, 6-methylpyrimidine-4-carboxaldehyde, 2-methylpyrimidine-4-carboxaldehyde, 2,6-dimethylpyrimidine-4-carboxaldehyde, 2,6-dimethylpyrimidine-4-car

(1964)). The use of 2-nitropyridine-4-carboxaldehyde would lead to a derivative of formula II with R¹² represented by a 2-nitro-4-pyridyl group. Catalytic reduction of the nitro to an amino group would provide the 2-amino-4-pyridyl derivative of II. The approach displayed in Scheme 8 is applicable to the use of other aryl acetic acids leading to compounds of formula II with different aryl groups as R¹¹.

Another approach (Scheme 9) leading to 5,6-diaryl4-hydroxy-pyrimidines involves the cyclization of the bketo ester XIV with thiourea to give the thiouracil
derivative XV. XV can be S-monomethylated to XVI.

Reaction of XVI with primary and secondary amines leads
to 2-amino substituted 4-hydroxy-pyrimidines II.
Further 2-thioether derivatives of II with R¹ = SR²¹ can
be obtained, for example by alkylation of XV with alkyl
halides. Treatment of XV or XVI with Raney nickel and
Treatment of SV or XVI with Raney nickel and
Whyprovides compounds of structure II wherein R¹ is H.

Although Scheme 9 illustrates syntheses in which R12 is 4-pyridyl, this approach may be equally applied to any other heteroaryl ring within the definition of R12 by the appropriate choice of the starting material. Such starting materials include but are not limited to ethyl 2-methyl isonicotinate (Efimovsky and Rumpf, Bull. Soc. Chim. FR. 648-649 (1954)), methyl pyrimidine-4-10 carboxylate, methyl 2-methylpyrimidine-4-carboxylate, methyl 6-methylpyrimidine-4-carboxylate and methyl 2,6dimethylpyrimidine-4-carboxylate (Sakasi et al., Heterocycles 13, 235 (1978)). Likewise, methyl 2nitroisonicotinate (Stanonis, J. Org. Chem. 22, 475 (1957)) may be reacted with an aryl acetic acid ester 1.5 followed by cyclization of the resultant b-keto ester with thiourea analogously to Scheme 9. Subsequent catalytic reduction of the nitro group to an amino group would give a 4-hydroxy-pyrimidine II in which R^{12} is represented by a 2-amino-4-pyridyl group (Scheme 10).

Furthermore, methyl 2-acetamido isonicotinate (Scheme 11) may be reacted analogously to Scheme 9 after appropriate protection of the amide nitrogen with e.g. a tert-butyldimethylsilyloxymethyl group (Benneche et al., Acta Chem. Scand. B 42 384-389 (1988)), a tert-

butyldimethylsilyl group, a benzyloxymethyl group, a benzyl group or the like (P.).

5

Removal of the protecting group P, of the resulting
pyrimidine II with a suitable reagent (e.g.,
tetrabutylammonium fluoride in the case where P, is tbutyldimethyl-silyloxymethyl) would then lead to a
pyrimidine II with R" represented by a 2-acetamido-4pyridyl group. Needless to say, ethyl p-fluorophenyl
acetate may be substituted by any alkyl arylacetate in
the procedure illustrated in Scheme 9 thus providing
compounds of formula II with different R" aryl
substituents.

In a further process, compounds of pyrimidines II

25 may be prepared by coupling a suitable derivative of

XVIII (L is a leaving group, such as halogen radical and

10

15

20

the like, and P2 is a protecting group, such as benzyl and the like) with an appropriate aryl equivalent.

TTTVX

Such arvl/heteroarvl couplings are well known to those skilled in the art and involve an organic-metallic component for reaction with a reactive derivative, e.g., a halogeno derivative, of the second compound in the presence of a catalyst. The metallo-organic species may be provided either by the pyrimidinone in which case the aryl component provides the reactive halogen equivalent or the pyrimidinone may be in the form of a reactive 5halogeno derivative for reaction with a metallo organic aryl compound. Accordingly, 5-bromo and 5-iodo derivatives of XVIII (L = Br, I) may be treated with arvlalkyl tin compounds, e.g., trimethylstannylbenzene, in an inert solvent such as tetrahydrofuran in the presence of a palladium catalyst, such as di (triphenylphosphine) palladium (II) dichloride. et al., J. Heterocyclic Chem. 27, 2165-2173, (1990). Alternatively, the halogen derivative of XVIII may be converted into a trialkyltin derivative (L = Bu,Sn) by reaction with e.g. tributylstannyl chloride following lithiation with butvllithium and may then be reacted 25 with an aryl halide in the presence of a catalyst. (Sandosham and Undheim, Acta Chem. Scand. 43, 684-689 (1989). Both approaches would lead to pyrimidines II in which R" is represented by aryl and heteroaryl groups.

As reported in the literature (Kabbe, Lieb, Ann. Chem. 704, 144 (1967); German Patent 1271116 (1968)) and 3.0 displayed in Scheme 12, 5-arvl-2,6-dipyridyl-4-hydroxypyrimidines II may be prepared in a one step synthesis by reaction of the cyanopyridine with an arylacetyl

ester, such as ethyl phenylacetate in the presence of sodium methoxide.

Scheme 12

$$\bigcap_{N}^{CN} \qquad \bigcap_{R^{11} \subset CO_2Et}^{R^{11}} \bigcap_{N}^{OH}$$

Analogously, as reported (Kabbe, supra) and displayed in Scheme 13, 4-amino-5-(aryl)-2,6-dipyridyl-pyrimidines XIX are obtained in a one step synthesis by reaction of cyanopyridine with arylacetonitrile, such as 4-fluorophenylacetonitrile.

10 Scheme 13

Modification at the 4-position (R2 of formula I) of pyrimidine II is possible by conversion into the chloro derivative XX by reaction with phosphorous oxychloride 15 (Scheme 14). A 4-alkoxy derivative XXI may be prepared from chloro derivative XX by nucleophilic substitution with alkoxide. Alternatively, in stead of the chloro group, other leaving groups, such as tosylates, mesylates and the like, can be used. Also, such leaving groups can also be displaced by amino, thiolates, 20 alcoholates, and the like nucleophiles. For example, the chloro derivative XX may be reduced by catalytic hydrogenation to give a pyrimidine I where R2 is H, or may be reacted with an alkyl or arvl boronic acid or an 25 alkyl or aryl zinc halide to provide a pyrimidine I where R2 is alkyl or aryl.

15

20

25

$$R^{11} \longrightarrow R^{1}$$

$$R^{12} \longrightarrow R^{1}$$

$$R^{13} \longrightarrow R^{1}$$

$$R^{12} \longrightarrow R^{1}$$

$$R^{1$$

In Scheme 15, compounds of the present invention of formula XXX can be readily prepared by reacting the methylthio intermediate XXXI with the amine NHR*R**, for example by heating the mixture preferably at a temperature greater than 100°C, more preferably 150-210°C. Alternatively, compounds of formula XXX can be readily prepared by reacting the methylsulfonyl intermediate XXXII with the amine NHR*R**, for example by heating the mixture preferably at a temperature greater than 40°C, more preferably 50-210°C.

Scheme 15

Amines of formula NHR'R" are commercially available or can be readily prepared by those skilled in the art from commercially available starting materials. For example, an amide, nitro or cyano group can be reduced under reducing conditions, such as in the prescence of a reducing agent like lithium aluminum hydride and the like, to form the corresponding amine. Alkylation and acylation of amino groups are well known in the art. Chiral and achiral substituted amines can be prepared from chiral amino acids and amino acid amides (for example, alkyl, aryl, heteroaryl, cycloalkyl, arylalkyl,

WO 98/24782 PCT/US97/22390 98

heteroarylalkyl, cycloalkylalkyl and the like substituted glycine, ß-alanine and the like) using methods well known in the art, such as H. Brunner, F. Hankofer, U. Holzinger, B. Treittinger and H.

- 5 Schoenenberger, Eur. J. Med. Chem. 25, 35-44, 1990; M. Freiberger and R. B. Hasbrouck, J. Am. Chem. Soc. 82, 696-698, 1960; Dornow and Fust, Chem. Ber. 87, 984, 1954; M. Kojima and J. Fujita, Bull. Chem. Soc. Jpn. 55, 1454-1459, 1982; W. Wheeler and D. O'Bannon, Journal of Labelled Compounds and Radiopharmaceuticals XXXI, 306, 1992; and S. Davies, N. Garrido, O. Ichihara and I.
 - Walters, J. Chem. Soc., Chem. Commun. 1153, 1993.

99

The following Examples are presented for illustrative purposes only and are not intended, nor should they be construed, as limiting the invention in any manner. Those skilled in the art will appreciate 5 that modifications and variations of the compounds disclosed herein can be made without violating the spirit or scope of the present invention.

EXAMPLES

Example 1

10 General procedure for the preparation of 2-substituted 5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidines a. 3-(Dimethylamino)-2-(4-fluorophenyl)-1-(4-pyridyl)-

3-propene-1-one: (According to Bennett et al., J. Org. Chem. 43, 221 (1977)).

A mixture of 2-(4-fluorophenyl)-1-(4-pyridinyl)ethanone (300 mg, 1.39 mmol) and bis(dimethylamino)methoxymethane (300 mml, 1.95 mmol) was heated at 110°C for 1.5 h under argon. It was evaporated and the yellow, crystallizing residue dried in an oil pump vacuum before used in the succeeding reaction. MS (m/z): 270.8 (M+H); C,H,FN,O requir. 270.3. H-NMR (CDCl₃): d 8.57, 7.25 (2m, each 2H, Pyrid.), 7.36 (s, 1H, CH=), 7.13, 6.99 (2m, each 2H, PhF), 3.00 (bs, 6H, 2CH,).

b. General procedure:

15

20

25

(According to Bennett et al., J. Med. Chem. 21, 623 (1978)).

A solution of 3-(dimethylamino)-2-(4-fluorophenyl)-1-(4-pyridinyl)-3-propene-1-one (1.39 mmol) in absol. ethanol (9 ml) was transferred into a solution of the R'-C(NH)NH, 5 (1.67 mmol) in ethanol (2 ml) prepared from sodium (1.67 mmol) and the amidine or guanidine hydrochloride (1.67 mmol). After heating under reflux for 1.5 to 24 h, it was evaporated and the resulting material was applied either directly to a column of silica gel (1-5% methanol/dichloromethane) or was taken up in dichloromethane followed by washing with water, drying of the organic solution and evaporation prior to column chromatography.

The following pyrimidines were prepared according to this general procedure by reacting 3-(dimethylamino)-2-(4-fluorophenyl)-1-(4-pyridinyl)-3-propene-1-one with amidines:

- 1-1 5-(4-Fluorophenyl)-2-methyl-4-(4-pyridyl)pyrimidine: MS (m/z): 266.0 (M+H); C₁₆H₁₂FN, requir.

 20 265.3. 'H-NMR (CDCl₂): d 8.70 (d, 1H, H-6, Pyrim.),
 8.59, 7.32 (2m, each 2H, Pyrid.), 7.20-7.00 (m, 4H,
 PhF), 2.88 (s, 3H, CH₂).

 R, = CH₂-
- 1-2 5-(4-Fluorophenyl)-2-isopropyl-4-(4-pyridyl)25 pyrimidine: MS (m/z): 294.4 (M+H)*; C₁₈H₁₈FN, requir.
 293.4. 'H-NMR (CDCl₃): d 8.73 (s, 1H, H-6, Pyrim.),
 8.60, 7.35 (2m, each 2H, Pyrid.), 7.20-7.04 (m, 4H,
 PhF), 3.37 (m, 1H, CH(CH₃)₂), 1.50, 1.47 (2s, each 3H,
 2CH₃).

 $R_1 = (CH_3)_2CH$

15

101

1-3 2-tert-Butyl-5-(4-fluorophenyl)-4-(4-pyridyl)pyrimidine: MS (m/z): 307.8 (M+H); C₁₃H_mFN, requir.
307.4. ³H-NMR (CDCl₃): d 8.72 (s, 1H, H-6, Pyrim.),
8.59, 7.38 (2m, each 2H, Pyrid.), 7.21-7.06 (m, 4H,
5 PhF), 1.52 (s, 9H, 3CH₃).

 $R_{i} = (CH_{i})_{i}C-$

- 1-4 2-(1-Chloro-2-methoxyethyl)-5-(4-fluorophenyl)-4(4-pyridyl)-pyrimidine: MS (m/z): 344.2 (M+H)*;

 C₁₄H₁₅ClFN₅O requir. 343.8. ¹H-NNR (CDCl₂): d 8.81 (s, 1H, 10 H-6, Pyrim.), 8.61, 7.35 (2m, each 2H, Pyrid.), 7.227.08 (m, 4H, PhF), 5.29 (dd, 1H, CHCl), 4.31, 4.04 (2dd, each 1H, CH₂O), 3.47 (s, 3H, CH₃O).

 R. = CHOCH.CH(Cl)-
- 1-5 2-(Cyclopropyl)-5-(4-fluorophenyl)-4-(4-pyridyl)15 pyrimidine: MS (m/z): 292.0 (M+H); C₁₄H₁₄FN, requir.
 291.3. ¹H-NMR (CDCl₁): d 8.60 (s, 1H, H-6, Pyrim.),
 8.57, 7.32 (2d, each 2H, Pyrid.), 7.16-7.00 (m, 4H,
 PhF), 2.32 (m, 1H, -CH-), 1.2, 1.1 (2m, each 2H, 2CH₂).
 R1 =
- 20 1-6 2-(Adamant-1-vl)-5-(4-fluorophenvl)-4-(4-pvridyl)pvrimidine: MS (m/z): 386.0 (M+H)'; C_{3x}H₂₄FN₃ requir.

 385.5. ¹H-NMR (CDCl₃): d 8.76 (s, 1H, H-6, Pyrim.),

 8.61, 7.51 (2m, each 2H, Pyrid.), 7.22-7.08 (m, 4H,
 PhF), ~1.9-1.5 (broad, 15H, CH₂, CH).

R1 =

25

1-7 <u>2-Benzyl-5-(4-fluorophenyl)-4-(4-pyridyl)-</u>
<u>pyrimidine:</u> MS (m/z): 342.2 (M+H)*; C₂₂H₁₆FN, requir.
341.4. 'H-MMR (CDCl₁): d 8.71 (s, 1H, H-6, Pyrim.),

8.60, 7.48 (2m, each 2H, Pyrid.), 7.42-7.04 (m, 9H, PhF,

30 Ph), 4.42 (s, 2H, $\mathrm{CH_2Ph})$.

102

1-8 2-(2,6-Dichlorobenzyl)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 410.2 (M), C_{1,2}H_{1,6}Cl,FN, requir. 410.3. 'h-NNR (CDCl₁): d 8.68 (s, 1H, H-6, Fyrim.), 8.57 (d, 2H, Pyrid.), 7.44-7.03 (m, 9H, Pyrid., PhF, PhCl₁), 4.93 (s, 2H, CH₁).

1-9 5-(4-Fluorophenyl)-2-phenoxymethyl-4-(4-pyridyl)pyrimidine: MS (m/z): 358.2 (M+H); C₂:H₁:FN₀ requir.

357.4. 'H-NMR (CDCl₃): d 8.83 (s, 1H, H-6, Pyrim.), 8.60
(m, 2H, Pyrid.), 7.36-6.98 (m, 11H, Pyrid., PhF, Ph),

5.43 (s, 2H, CH₃).

1-10 5-(4-Fluorophenyl)-2-phenylthiomethyl-4-(4-pyridinyl)-pyrimidine: MS (m/z): 374.2 (M+H)'; C₂H₁FN,S requir. 373.5. 'H-NMR (CDCl₃): d 8.72 (s, 1H, H-6, Pyrim.), 8.56, 7.49 (2m each 2H, Pyrid.), 7.32-7.02 (m, 9H, PhF, Ph), 4.50 (s, 2H, CH₃).

1-12 5-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-4-(4pyridyl) -pyrimidine: MS (m/z): 344.2 (M+H)*; C.H.FN.O requir. 343.4. H-NMR (DMSO-d_e): d 10.2 (bs, 1H, OH), 8.90 (s, 1H, H-6, Pyrim., Pyrim.), 8.60, 7.42 (2m, each 5 2H, Pyrid.), 8.35, 7.40-6.92 (m, 8H, PhF, PhOH).

1-13 5-(4-Fluorophenyl)-2-(4-aminophenyl)-4-(4-pyridyl)pyrimidine: MS (m/z): 343.2 (M+H); C,H,FN, requir. 342.4. H-NMR (CDCl₂): d 8.75 (s, 1H, H-6, Pyrim.), 8.60.

10 7.41 (2m, each 2H, Pyrid.), 8,40, 7.22-6.79 (m. 8H, PhF. Ph), 4.00 (bs, 2H, NH.).

$$R1 = H_2N$$

1-14 5-(4-Fluorophenyl)-2-(3-pyridyl)-4-(4-pyridyl)pyrimidine: MS (m/z): 329.0 (M+H)*; C.H.FN requir. 15 328.4. 'H-NMR (CDCl₁): d 9.80 (bs, H-2, 3-Pyrid.), 8.90 (s, 1H, H-6, Pyrim.), 8.84, 8.80 (2m, each 1H, 3-Pyrid.), 8.66, 7.45 (2m, each 2H, 4-Pyrid.), 7.50 (m, 1H, 3-Pyrid.), 7.28-7.10 (m, 4H, PhF).

$$R1 = N$$

1-15 5-(4-Fluorophenyl)-2-(2-pyridyl)-4-(4-pyridyl)pyrimidine: MS (m/z): 329.0 (M+H)*; C20H11FN requir. 328.4. H-NMR (CDCl.): d 9.01 (s, 1H, H-6, Pyrim.), 8.92, 8.66, 7.94, 7.48 (4m, each 1H, 2-Pyrid.), 8.66, 7.47 (2m, each 2H, 4-Pyrid.), 7.26, 7.14 (2m, each 2H, 25 PhF).

$$R1 = N$$

1-16 5-(4-Fluorophenyl)-2-(2-pyrazinyl)-4-(4-pyridyl)pyrimidine: MS (m/z): 330.2 (M+H); C,H,FN, requir.

329.3. 'H-NMR (CDCl₃): 9.84 (m, 1H, H-3, Pyraz.), 9.01 (s, 1H, H-6, Pyrim.), 8.84, 8.76 (2m, each 1H, H-5, H-6, Pyraz.), 8.65, 7.44 (2m, each 2H, Pyrid.), 7.26, 7.13 (2m, each 2H, PhF).

1-17 5-(4-Fluorophenyl)-2-(2-methylthiazol-4-yl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 349.0 (M+H)*; C₁₆H₁₅FN₁S requir. 348.4. 'H-MMR (CDCl₁): d 8.90 (s, 1H, H-6, Pyrim.), 8.63, 7.42 (2m, each 2H, Pyrid.), 8.32 (s, 1H, H-5, Thiaz.), 7.22, 7.10 (2m, each 2H, FhF), 2.88 (s, 3H, CH.).

- 20 The following pyrimidines were prepared according to the general procedure by reacting 3-(dimethylamino)-2-(4fluorophenyl)-1-(4-pyridinyl)-3-propene-1-one with guanidines:
- 1-19 <u>2-Amino-5-(4-fluorophenyl)-4-(4-pyridyl)-</u>
 25 <u>pyrimidine:</u> MS (m/z): 267.0 (M+H); C₁₅H₁₁FN₄ requir.
 266.3. ¹H-NNR (DMSO-d₄): d 8.54, 7.26 (2m, each 2H,
 Pyrid.), 8.35 (s, 1H, H-6, Pyrim.), 7.22-7.12 (m, 4H,
 PhF), 6.97 (s, 2H, NH₂).
 R1 = NH₂

1-20 <u>2-Ethylamino-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine:</u> MS (m/z): 295.0 (M+H)*; C₁,H₁,FN₄ requir. 294.3. ¹H-MMR (CDCl₃): d 8.56, 7.32 (m, each 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.12-6.99 (m, 4H, 5 PhF), 5.33 (unresolv.t, 1H, NH), 3.58 (m, 2H, CH₂), 1.32 (t, 3H, CH₃).

R1 = CH.CH.-NH-

1-21 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(2-sulfoethylamino)-pyrimidine: MS (m/z): 375.2 (M+H);

10 C₁,H₁,FN₂O₃S requir. 374.4. 'H-NNR (DMSO-d₄): d 8.51, 7.25 (2d, each 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.32 (t, 1H, NH), 7.2-7.1 (m, 4H, PhF), 3.62 (q, 2H, CH₂N), 2.72 (t, 2H, CH₂).

R1 = HO,S-CH,-CH,-NH-

- 15 1-22 2-(2-Diethylaminoethylamino)-5-(4-fluorobhenyl)-4(4-pyridyl)-pyrimidine: MS (m/z): 365.8 (M+H)*, C₁,H₂,FN,
 requir. 365.5. ¹H-MMR (CDCl₃): d 8.55, 7.28 (2m, each
 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.08, 7.01 (2m,
 each 2H, PhF), 5.95 (bs, 1H, NH), 3.60 (q, 2H, CH₂N),
 20 2.76 (t, 2H, CH₂), 2.65 (q, 4H, 2CH₂CH₃), 1.08 (t, 6H,
 2CH₃).
- 1-23 (4-Fluorophenyl)-4-(4-pyridyl)-2-(thioureido)pyrimidine: MS (m/z): 326.2 (M+H)*; C_{1,H1};FN,S requir. 25 325.4. ¹H-NMR (DMSO-d_e): d 10.84, 10.11, 9.20 (3s, each 1H, NH, SH), 8.75 (s, 1H, H-6, Pyrim.), 8.59, 7.32 (2m, each 2H, Pyrid.), 7.28, 7.21 (2m, each 2H, Ph)F.

$$R1 = H_2N N N N$$

 $R1 = (CH, CH_1), NCH_2CH_3NH-$

1-24 2-(2,6-Dichlorophenylamino)-5-(4-fluorophenyl)-430 (4-pvridyl)-pvrimidine: MS (m/z): 410.8 (M); C₁,H₁,Cl₂FN₄
requir. 411.3. 'H-MMR (CDCl₃): d 8.54, 7.30 (2m, each
2H, Pyrid.), 8.45 (s, 1H, H-6, Pyrim.), 7.45 (d, 2H,
PhCl₃), 7.21 (t, 1H, PhCl₂), 7.12, 7.04 (2m, each 2H,
PhF).

106

$$R1 = \begin{bmatrix} CI & H \\ N & N \end{bmatrix}$$

$$R1 = Me H N$$

$$Me$$

1-26 5-(4-Fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS
) (m/z): 373.0 (M+H)^r; C₂H₁FN₀ requir. 372.4. H-NNR
(CDCl₁): d 8.62, 7.40 (2m, each 2H, Pyrid.), 8.60 (m,
1H, PhOMe), 8.52 (s, 1H, H-6, Pyrim.), 7.99 (s, 1H, NH),
7.18-6.94 (m, 7H, PhF, PhOMe), 3.96 (s, 3H, CHO).

15 1-27 5-(4-Fluorophenvl)-2-(4-fluorophenvlamino)-4-(4pyridyl)-pyrimidine: MS (m/z): 361.0 (M+H)*, C₁₁H₁F₁N₄ requir. 360.4. 'H-NMR (CDCl₁): d 8.58, 7.32 (m, 2H, Pyrid.), 8.46 (s, 1H, H-6, Pyrim.), 7.62 (m, 2H, PhF), 7.24 (bs, 1H, NH), 7.13-7.00 (m, 6H, PhF).

20

1-28 2-(4-Ethylphenylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 371.2 (M+H); C₃H₁,FN₄ requir. 370.4. 'H-NMR (CDCl₃): d 8.61, 7.41 (2m, each 2H, Pyrid.), 8.49 (s, 1H, H-6, Pyrim.), 7.60, 7.23 (2d,

WO 98/24782 PCT/US97/22390

107

each 2H, PhEth), ~ 7.28 (NH), 7.13, 7.06 (2m, each 2H, PhF), 2.67 (q, 2H, CH_2), 1.27 (t, 3H, CH_3).

$$R1 = \underbrace{\begin{array}{c} H \\ N \end{array}}$$

1-29 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(3-

5 trifluoromethylphenylamino)-pyrimidine: MS (m/z): 411.0 (M+H); C₂₂H₁₄F₄N₄ requir. 410.4. 'H-NMR (CDCl₃): d 8.60, 7.35 (2m, each 2H, Pyrid.), 8.52 (s, 1H, H-6, Pyrim.), 8.23, 7.73, 7.46 (s, dd, t, each 1H, PhCF₃), 7.44 (s, 1H, NH), 7.31 (dd, 1H, PhCF₃), 7.13, 7.05 (2m, each 2H, PhF).

$$R1 = \bigcap_{CF_2}^{H} \bigvee_{N=1}^{N}$$

$$R1 = NH$$

1-31 5-(4-Fluorophenyl)-2-(2-phenylethylamino)-4-(4-20 pyridyl)-pyrimidine: MS (m/z): 371.0 (M+H); C₂₂H₁₇FN₁ requir. 370.4. H-NMR (CDCl₁): d 8.56 (m, 2H, Pyrid.), 8.35 (s, 1H, H-6, Pyrim.), 7.38-7.22 (m, 7H, Ph, Pyrid.), 7.08, 7.02 (2m, each 2H, PhF), 5.32 (t, 1H, NN), 3.80 (q, 2H, CH,N), 2.92 (t, 2H, CH₂).

25

1-32 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-pyrrolidinopyrimidine: MS (m/z): 321.2 (M+H)*; C_n,H,FN, requir. 32.4. 'H-MMR (CDCl₁): d 8.54, 7.32 (2d, each 2H, Pyrid.), 8.37 (s, 1H, H-6, Pyrim.), 7.06, 7.00 (2m, each 5 2H, PhF), 3.68, 2.05 (2m, each 4H, 4CH₂).

1-33 5-(4-Fluorophenyl)-2-morpholino-4-(4-pyridyl)pyrimidine: MS (m/z): 337.2 (M+H); C₁₉H₁₇FN₁O requir. 336.4. ¹H-NMR (CDCl₁): d 8.56, 7.31 (2m, each 2H,

10 Pyrid.), 8.40 (s, 1H, H-6, Pyrim.), 7.10, 7.03 (2m, each 2H, PhF), 3.94, 3.83 (2m, each 4H, 4CH₂).

1-34 2-(3,5-Dimethylpyrazolyl)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 346.0 (M+H); C₁₀H₁₀FN₂

15 requir. 345.4. 'H-NMR (CDCl₁): d 8.80 (s, 1H, H-6, Pyrim.), 8.60, 7.35 (2m, each 2H, Pyrid.), 7.18, 7.08 (2m, each 2H, PhF), 6.08 (s, 1H, Pyraz.), 2.70, 2.30 (2s, each 3H, 2CH₁).

20 1-35 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(3,5bis(trifluoromethyl)benzenesulfamoyl)-pyrimidine: MS
(m/z): 542.8 (M+H)*; C₃H₁₁F,N₂O₅ requir. 542.4. 'H-NMR
(DMSO-d₄): d 8.63 (s, 1H, H-6, Pyrim.), 8.56 (m, 2H,
Pyrid.), 8.49, 8.43 (2s, 2H, 1H, Ph(CF₃)₂), 7.26-7.15 (m,
25 6H, PhF, Pyrid.).

1-36 2-(4-Aminobenzenesulfamoyl)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 421.8 (M+H): C.H., FN,O,S requir. 421.5. H-NMR (DMSO-d): d 8.58 (s, 1H, H-6, Pyrim.), 8.575 (m, 2H, Pyrid.), 7.64, 6.56 (2d. 5 each 2H, PhNH,), 7.28-7.15 (m, 6H, PhF, Pyrid.), 5.99 (s. 2H. NH.).

$$R1 = \frac{0}{100} \frac{0}{100} \frac{0}{100}$$

1-37 2-(2-Dimethylaminoethylthio)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine was prepared according to the 10 general procedure by reacting 3-(dimethylamino)-2-(4fluorophenyl)-1-(4-pyridinyl)-3-propene-1-one with S-(2dimethylaminoethyl)isothiourea. MS (m/z): 355.2 (M+H)*: C, H, FN, S requir. 354.5. H-NMR (CDC1,): d 8.59, 7.32 (2m, each 2H, Pyrid.), 8.58 (s, 1H, H-6, Pyrim.), 7.16, 7.08 15 (2m, each 2H, PhF), 3.40, 2.76 (2m, each 2H, 2CH₂), 2.37 (s, 6H, 2CH,).

 $R1 = (CH_s)_sNCH_sCH_sS-$

2.5

Example 2

20 General procedure for the preparation of 2-N substituted 2-amino-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidines a. 5-(4-Fluorophenyl)-4-(4-pyridyl)-2(1H)-pyrimidinone:

Urea (0.67 g, 11.15 mmol) was added to a stirred ethanolic 0.62 N sodium ethoxide solution (15 ml). An ethanolic solution (60 ml) of 3-(dimethylamino)-2-(4fluorophenyl)-1-(4-pyridinyl)-3-propene-1-one (9.29

mmol) was added and the mixture was refluxed overnight. It was evaporated followed by column chromatography (5% methanol/dichloromethane to 100% methanol). Crystals (presumably urea) obtained on treating the resultant product with dichloromethane/methanol were filtered. The filtrate was evaporated and the remainder rechromatographed on a column of silica gel (chloroform/methanol/water = 70:20:1) to yield the title compound as a yellowish foam.

0 MS (m/z): 268.2 (M+H)'; C₁₈H₁₆FN,0 requir. 267.3. 'H-NMR (DMSO-d_e): d 8.55, 7.24 (2m, each 2H, Pyrid.), 8.22 (bs, 1H, H-6, Pyrim.), 7.20-7.10 (m, 4H, PhF).

b. 2-Chloro-5-(4-fluorophenyl)-4-(4-pyridyl)pyrimidine:

$$\bigcap_{N \to \infty} \bigcap_{N \to \infty} \bigcap_{N$$

A mixture of 5-(4-fluorophenyl)-4-(4-pyridyl)-2-(1H)pyrimidinone (2.41 mmol) and phosphorus oxychloride (3
ml) was heated at reflux for 45 min. It was evaporated
to dryness at a bath temperature of >50° C. The flask
was cooled in an ice-bath and ice-water was added. If
the pH value was found still acidic, then the mixture
was neutralized with aqueous 5% ammonium hydroxide. It
was extracted with dichloromethane, followed by washing
of the organic solution with aqueous sodium chloride,
drying and evaporation to yield the title compound as a

25 drying and evaporation to yield the title compound as a yellowish foam which was used without further purification.

MS (m/z): 286.1 (M+H)*; $C_{15}H_{19}C1FN_1$, requir. 285.7. 1H -NMR (CDCl₃): d 8.68 (s, 1H, H-6, Pyrim.), 8.62, 7.42 (2m, each 2H, Pyrid.), 7.23-7.10 (m, 4H, PhF).

Alternatively, 2-chloro-5-(3-methylphenyl)-4-(4pyridyl)-pyrimidine (MS (m/z): 282 (M+H)+; C16H12ClN3 requir. 281.7) and 2-chloro-4-(4-pyridyl)-5-(3-trifluoro methylphenyl)-pyrimidine (MS (m/z): 336.0 (M)+; 5 C16H9ClF3N3 requir. 335.7) have been synthesized by the same reaction sequence, but starting from 2-(3-methyl phenyl)-1-(4-pyridinyl)ethanone (prepared according to: I. Lantos et al., J. Org. Chem. 53, 4223-4227, 1988) and 1-(4-pyridinyl)-2-(3-trifluoromethylphenyl)ethanone (prepared according to: P.W. Sheldrake, Synth, Commun. 23 (24), 1967-1971, 1993); and WO 97/12876). Also, thionyl chloride/N, N-dimethylformamide (excess/3 equivalents, reflux) can be used instead of phosphorus oxvchloride.

15 c. General procedure:

10

20

2.5

Typically, a mixture of 2-chloro-5-(4-fluoro phenyl)-4-(4-pyridyl)-pyrimidine (50-120 mg, 0.18-0.42 mmol) and the amine, HNR⁵R²¹, (0.5-5.5 mmol) was heated at 50-100°C for 5-60 min (thin layer chromatography check). The mixture was applied directly to a column of silica gel which was developed with dichloromethane/ methanol or dichloromethane/methanol/conc. ammonium hydroxide.

An alternate procedure using ethanol as a solvent was used in case of Examples 2-6, 2-11, 2-12, 2-20 and 2-26 as described.

The following pyrimidines were prepared according to this procedure using the appropriate amine and 30 substituted 2-chloropyrimidine:

WO 98/24782 PCT/US97/22390

112

- 2-1 2-(2-Aminoethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 310.2 (M+H); C,H,rFN,-HCl requir. 309.4+36.5. H-NMR (CD,OD): d 8.84, 8.10 (2m, each 2H, Pyrid.), 8.58 (s, 1H, H-6, Pyrim.), 7.28, 7.15 (2m, each 2H, PhF), 3.83 (t, 2H, CH,), 3.27 (t, 2H, CH,). R1 = NH,CH,CH,NH-
- 2-2 <u>2-(3-Aminopropylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride:</u> MS (m/z): 324.0 10 (M+H)^{*}, C_{1,H1,FN3}-Hcl requir. 323.4+36.5. [†]H-NMR (CD₃OD): d 8.85, 8.10 (m, 2H, Pyrid.), 8.54 (s, 1H, H-6, Pyrim.), 7.27, 7.14 (2m, each 2H, PhF), 3.84, 3.68 (2t, each 2H, 2CH,N), 2.18 (m, 2H, CH₂). R1 = NH₂CH₂CH₂NH-
- 15 2-3 2-(4-Aminobutylamino)-5-(4-fluorophenyl)-4-(4-<u>pyridyl)-pyrimidine hydrochloride:</u> MS (m/z): 338.0 (M+H); C₁,H₂,FN₁-HCl requir. 337.4+36.5. ¹H-NMR (CD₃OD): d 8.80, 8.05 (2m, each 2H, Pyrid.), 8.50 (s, 1H, H-6, Pyrim.), 7.25, 7.14 (2m, each 2H, PhF), 3.58 (bt, 2H, 20 CH₂), 3.02 (bt, 1H, CH₂), 1.80 (m, 4H, 2CH₂). R1 = NH.CH.CH.CH.CH.NH-
- 2-4 2-(2-Dimethylaminoethylamino)-5-(4-fluorophenyl)-4-(4-DYRIGY1)-DYRIMIGINE: MS (m/z): 338.2 (M+H)*; C_{1,}H_{1,}FN₁ requir. 337.4. ¹H-NMR (CDCl₂): d 8.57, 7.30 (2m, each 25 2H, Pyrid.), 8.37 (s, 1H, H-6, Pyrim.), 7.10, 7.03 (2m, each 2H, PhF), 6.00 (t, 1H, NH), 3.66 (q, 2H, CH₂), 2.71 (t, 2H, CH₂), 2.41 (s, 6H, 2CH₃). R1 = (CH₂),NCH₂CH,NH-
- 2-5 <u>5-(4-Fluorophenyl)-2-(2-phenylaminoethylamino)-4-</u>
 30 (4-pyridyl)-pyrimidine: MS (m/z): 386 (M+H); C₂₁H₁₂FN₃ requir. 385.5. ¹H-MMR (CDCl₃): d 8.57, 7.28 (m, 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.18 (t, 2H, Ph), 7.08, 7.02 (2m, each 2H, PhF), 6.73 (t, 1H, Ph), 6.64 (d, 2H, Ph), 5.62 (bt, 1H, NH), 3.80 (q, 2H, CH₂), 3.47 (t, 2H, CH).

$$R1 = \begin{bmatrix} H \\ N \\ H \end{bmatrix}$$

2-6 5-(4-Fluorophenyl)-2-(2-(4-fluorophenylamino)-ethylamino)-4-(4-pyridyl)-pyrimidine: A solution of 2-chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine (103 mg, 0.36 mmol) and N-(4-fluorophenyl)ethylendiamine (1 ml) in ethanol (1 ml) was heated to reflux for 3 h. Evaporation was followed by column chromatography (3% methanol/dichloromethane) to provide the title compound as a yellowish solid. MS (m/z): 404.2 (M+H); C₂H₁,F₂N, requir. 403.4. H-NMR (CDCl₃): 8.60 7.31 (2m, each 2H, Pyrid.), 8.40 (s, 1H, H-6, Pyrim.), 7.11-7.02 (2m, each 2H, PhF), 6.90, 6.60 (t, dd, each 2H, PhF), 5.62 (t, 1H, NH), 3.82 (q, 2H, CH₂), 3.44 (t, 2H, CH₂).

$$R1 = \prod_{H} \prod_{H} N$$

15 2-7 5-(4-Fluorophenyl)-2-(4-methylbenzylamino)-4-(4-pyridyl)-pyrimidine; MS (m/z): 371.2 (M+H)'; C₃,H,;FN, requir. 370.4. 'H-NMR (CDCl₁): d 8.55, 7.34 (2m, each 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.30, 7.18 (2d, each 2H, PhMe), 7.08, 7.02 (2m, each 2H, PhF), 5.69 (bs, 2H, NH), 4.69 (d, 2H, CH₁), 2.36 (s, 3H, CH₁)

$$R1 = Me$$
 Me
 N
 H

2-8 5-(4-Fluorophenyl)-2-(2-(4-fluorophenyl)ethylamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 389.2 (M+H); C₁H₁F₂N₁ requir. 388.4. 'H-NMR (CDCl₃): d 8.57 (m, 25 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.32-7.20, 7.12-6.98 (2m, 10H, 2PhF, Pyrid.), 5.37 (bt, 1H, NH), 3.79 (q, 2H, CH,N), 2.97 (t, 2H, CH₃).

2-9 2-(2-(4-Chlorophenyl)-ethylamino)-5-(4-

fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 405.0 (M+H)'; C₂₃H₁₆ClFN, requir. 404.9. ^hH-NMR (CDCl₃): d 8.56 (bs, 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.29 (m, d, 4H, Pyrid., PhCl), 7.20 (d, 2H, PhCl), 7.08, 7.02 (2m, each 2H, PhF), 5.35 (t, 1H, NH), 3.78 (q, CH₂N), 2.96 (t, 2H, CH₃)

10 2-10 2-(2-(4-Bromophenyl)-ethylamino)-5-(4-

20

2-11 5-(4-Fluorophenyl)-2-(2-(4-hydroxyphenyl)-

ethylamino)-4-(4-pyridyl)-pyrimidine: A mixture of 2-chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine (61 mg, 0.21 mmol), tyramine hydrochloride (186 mg, 1.01 mmol) and sodium hydrogencarbonate (90 mg, 1.07 mmol) in aqueous ethanol (1 ml) was heated to reflux for 1 h. Solvent evaporation and subsequent column chromatography

(5% methanol/dichloromethane) provided the title

6.69 (2d, each 2H, PhOH), 3.52 (q, 2H, CH_2N), 2.78 (t, 2H, CH):

2-12 2-(2-(4-Aminophenyl)-ethylamino)-5-(4-

5 fluorophenyl)-4-(4-pyridyl)-pyrimidine: A solution of 2-chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine (71 mg, 0.25 mmol) and 2-(4-aminophenyl)ethylamine (0.5 ml, 3.80 mmol) in ethanol (1.5 ml) was heated to reflux for 20 min. Evaporation and subsequent chromatography on a column of silica gel (2% methanol/dichloromethane) provided the title compound as a yellow syrup. MS (m/z): 386.4 (M+H); C_{3,H₂,FN₃ requir. 385.5. H-NMR (CDCl₃): d 8.56, 7.32 (2m, each 2H, Pyrid.), 8.35 (s, 1H, H-6, Pyrim.), 7.12-6.99 (m, 6H, PhF, PhNH₂), 6.68 (d, 2H, PhNH₂), 5.37 (t, 1H, NH), 3.75 (q, 2H, CH,N), 2.88 (t, 2H, CH₂).}

$$R1 = H_2N$$

$$R1 = F$$

25 2-14 2-(2-(2-Chlorophenyl)-ethylamino))-5-(4fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 405.0 (M+H)'; C₃H₁₈ClFN₄ requir. 404.9. 'H-NMR (CDCl₃): d 8.57 (m, 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.40-7.00 $(m, 10H, PhF, PhCl₂, Pyrid.), 5.44 (bt, 1H, NH), 3.84 (q, 2H, <math>CH_2N)$, 3.15 (t, 2H, CH_2).

2-15 5-(4-Fluorophenyl)-2-(2-(2-methoxyphenyl)-

5 <u>ethylamino)-4-(4-pyridyl)-pyrimidine;</u> MS (m/z): 401.2 (M+H); C₃,H₃;PN₀Orequir. 400.5 ³H-NMR (CDCl₃): d 8.56, 7.30 (2m, each 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.24, 7.08, 7.02, 6.92 (4m, each 2H, PhF, PhOMe), 5.50 (bt, 1H, NH), 3.87 (s, 3H, CH₃), 3.78 (q, 2H, CH₃N), 3.02 (t, 2H, CH₃).

$$R1 = OMe^{\frac{H}{N}}$$

2-16 2-(2-(2,4-Dichlorophenyl)-ethylamino)-5-(4-

fluorophenvl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 439.0 (M), C₂H,Cl,FN, requir. 439.3 H-MMR (CDCl₃): 8.56 (bs, 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.37 (s, 1H, PhCl), 7.30 (bd, 2H, Pyrid.), 7.22-7.15 (m, 2H, PhCl), 7.08, 7.05 (2m, each 2H, PhF), 5.40 (t, 1H, NH), 3.80 (q, 2H, CH,N), 3.10 (t, 2H, CH₃).

$$R1 = \frac{H}{Cl}$$

$$R1 = \begin{array}{c} CI & H \\ N & N \end{array}$$

2-18 5-(4-Fluorophenyl)-2-(2-(3-methoxyphenyl)-

5 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.32-7.22, 7.11-6.98, 6.89-6.77 (3m, 10H, PhF, PhOMe, Pyrid.), 5.38 (t, 1H, NH), 3.82 (m, 5H, CH,N, CH,), 2.96 (t, 2H, CH,).

2-19 <u>2-(2-(3-Chlorophenyl)-ethylamino))-5-(4-</u>

10 <u>fluorophenvl</u>)-4-(4-pyridyl)-pyrimidine: MS (m/z): 405.4 (M+H)'; C₂₁H₁₈ClFN₄ requir. 404.9. h-NMR (CDCl₃): d 8.60 (d, 2H, Pyrid.), 8.38 (s, 1H, H-6, Pyrim.), 7.32-7.24 (m, 5H, Pyrid., PhCl), 7.18 (m, 1H, PhCl), 7.11, 7.04 (2m, each 2H, PhF), 5.35 (t, 1H, NH), 3.83 (q, 2H, 15 CH,N), 3.00 (t, 2H, CH₃).

$$R1 = N$$

2-20 5-(4-Fluorophenyl)-2-((2-hydroxy-2-phenyl)-ethylamino)-4-(4-pyridyl)-pyrimidine: A mixture of 2-chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine (87 cm, 0.31 mmol) and 2-amino-1-phenylethanol (300 mg, 2.19 mmol) in ethanol (2 ml) was heated to reflux for 2 h.

Evaporation and subsequent chromatography on a column of silica gel (4% methanol/dichloromethane) provided the

title compound as as yellow foam. MS (m/z): 387.0

25 (M+H)*; C₃H₃FN₄O requir. 386.4. ¹H-NMR (CDCl₃): d 8.58 (d, 2H, Pyrid.), 8.38 (s, 1H, H-6, Pyrim.), 7.47 (d, 2H,

Ph), 7.41 (t, 2H, Ph), 7.34 (t, 1H, Ph), 7.28 (d, 2H, Pyrid.), 7.10, 7.02 (2m, 2H, PhF), 5.72 (t, 1H, NH), 5.06 (m CHOH)), 4.02-3.92 (m, 2H, OH, 1CH₂), 3.72 (ddd, 1H, 1CH₃).

2-21 5-(4-Fluorophenyl)-2-(methyl-(2-phenylethyl)-

$$R1 = \begin{array}{c} CH_3 \\ N \end{array}$$

2-22 5-(4-Fluorophenyl)-2-((3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 385.2 (M+H)*; C₂₄H₁₁FN₄
15 requir. 384.5. ¹H-NMR (CDCl₃): d 8.56 (m, 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.34-7.20 (m, 7H, Ph, Pyrid.), 7.08, 7.01 (2m, each 2H, PhF), 5.38 (t, 1H, NH), 3.58 (q, 2H, CH₂N), 2.78 (t, 2H, CH₂), 2.03 (m, 2H, CH₃).

$$R1 = N H$$

CH_), 1.34 (d, 3H, CH_).

20

2-23 5-(4-Fluorophenyl)-2-((1-methyl-3-phenylpropyl)amino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 399.0 (M+H)*;
C,H3,FN,requir. 398.5. H-NMR (CDCl₃): d 8.56 (m, 2H,
Pyrid.), 8.32 (s, 1H, H-6, Pyrim.), 7.32-7.17 (m, 7H,
25 Pyrid., Ph), 7.09-7.02 (2m, each 2H, PhF), 5.16 (d, 1H,
NH), 4.28 (m, 1H, CH), 2.77 (m, 2H, CH), 1.94 (m, 2H,

2-24 5-(4-Fluorophenvl) -2-((3-imidazolvlpropvl)-amino)4-(4-pyridyl)-pyrimidine: MS (m/z): 375.0 (M+H); C₂
H₁,FN_e requir. 374.4. ¹H-NMR (CDCl₃): d 8.57, 7.26 (2m,
5 each 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.56 (s,
1H, Imid.), 7.16-6.96 (m, 6H, PhF, Imid.), 5.38 (bt, 1H,
NH), 4.12 (t, 2H, CH₂N), 3.56 (q, 2H, CH₂NH), 2.20 (m,
2H, CH₃).

$$R1 = N$$

10 2-25 5-(4-Fluorophenyl)-2-((4-phenyl-n-butyl)-amino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 399.0 (M+H); C₂₂H₂₂FN₄ requir. 398.5. 'H-MMR (CDCl₃): d 8.56 (m, 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.33-7.17 (m, 7H, Ph, Pyrid.), 7.08, 7.02 (2m, each 2H, PhF), 5.33 (bt, 1H, 15 NH), 3.56 (q, 2H, CH₂N), 2.71 (t, 2H, CH₂), 1.76 (m, 4H, 2CH.).

2-26 5-(4-Fluorophenyl)-2-(1-piperazinyl)-4-(4-pyridyl)pyrimidine: A mixture of 2-chloro-5-(4-fluorophenyl)-420 (4-pyridyl)-pyrimidine (71 mg, 0.25 mmol) and piperazine
(214 mg, 2.48 mmol) in ethanol (1 ml) was heated to
reflux for 5 min. Evaporation and subsequent
chromatography on a column of silica gel (5%
methanol/dichloromethane) provided the title compound as
25 as yellow solid. MS (m/z): 336.2 (M+H); C₁H₁FN, requir.
335.4. 'H-NMR (CDCl₃): d 8.54, 7.29 (2m, each 2H,
Pyrid.), 8.37 (s, 1H, H-6, Pyrim.), 7.08, 7.00 (2m, each
2H, PhF), 3.95 (t, 4H, 2CH₂), 3.01 (t, 4H, 2CH₂).

2-27 5-(4-Fluorophenv1)-2-(1-piperidinv1)-4-(4-pvridv1)pvrimidine: MS (m/z): 335.2 (M+H); C_mH_sFN_s requir. 334.4. 'H-NMR (CDC1_s): d 8.55, 7.30 (2m, each 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.08, 7.01 (2m, 2H, PhF), 3.91 (t, 4H, 2CH_sN), 1.74, 1.68 (2m, 6H, 3CH_s).

$$R1 = N$$

2-28 <u>5-(4-Fluorophenyl)-2-(4-methyl-1-piperazinyl)-4-(4-pyridyl)-pyrimidine:</u> MS (m/z): 350.0 (M+H); C₂₂H₂₀FN₅

10 requir. 349.4. 'H-NMR (CDCl₁): d 8.58, 7.32 (2m, each
2H, Pyrid.), 8.40 (s, 1H, H-6, Pyrim.), 7.10, 7.04 (2m,
each 2H, PhF), 4.00 (t, 4H, 2CH₂), 2.57 (t, 4H, 2CH₂),
2.42 (s, 3H, CH₁).

$$R1 = H_3C-N$$
 $N-$

15 2-29 5-(4-Fluorophenvl)-2-(4-phenvl-1-piperazinvl)-4-(4-pyridvl)-pyrimidine: MS (m/z): 412.2 (M+H)'; C₂:H₂:FN₂ requir. 411.5. 'H-NMR (CDCl₁): d 8.58 (bd, 2H, Pyrid.), 8.42 (s, 1H, H-6, Pyrim.), 7.38-7.30 (m, 4H, Pyrid., Ph), 7.15-7.00 (m, 6H, PhF, Ph), 6.94 (t, 1H, Ph), 4.13
20 (t, 4H, 2CH₁), 3.33 (t, 4H, 2CH₁).

25

2CH.).

2-30 5-(4-Fluorophenyl)-2-(2-morpholinoethylamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 380.4 (M+H)*; C₂₁H₂₂FN₃O requir. 379.4. ¹H-NMR (CDCl₃): d 8.58, 7.30 (2m, each 2H, Pyrid.), 8.38 (s, 1H, H-6,Pyrim.), 7.10, 7.03 (2m, each 2H, PhF), 5.91 (bs, 1H, NH), 3.79 (bs, 4H, 2CH₂), 3.66 (bs, 2H, CH₂), 2.71 (bs, 2H, CH₂), 2.59 (bs, 4H,

$$R1 = O N$$

2-31 5-(4-Fluorophenyl)-2-(2-piperidinoethylamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 378.2 (M+H); C₂₂H₂FN₃ requir. 377.5 H-NMR (CDCl₃): d 8.54, 7.27 (2d, each 2H, 5 Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.06, 7.00 (2m, each 2H, PhF), 6.04 (bt, 1H, NH), 3.66 (q, 2H, CH₃NH), 2.74 (t, 2H, CH₂), 2.61 (bs, 4H, 2CH₂), 1.68 (m, 4H, 2CH₂), 1.50 (m, 2H, CH₃).

$$R1 = N$$

10 2-32 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(2-pyrrolidinoethylamino)-pyrimidine: MS (m/z): 364.0 (M+H); C₁₁H₂₁FN₃ requir. 363.4 'H-NMR (CDCl₃): d 8.55, 7.28 (2m, each 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.08, 7.02 (2m, each 2H, PhF), 6.28 (t, 1H, NH), 3.86 (q, 2H, 15 CH,NH), 3.18 (t, 2H, CH,N), 3.10 (bs, 4H, 2CH,N), 2.02 (bs, 4H, 2CH,).

$$R1 = N^{-N}$$

2-33 5-(4-Fluorophenyl)-2-(3-morpholinopropylamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 394.2 (M+H)*; C₂₂H_{x2}FN₂O 20 requir. 393.5. 'H-NMR (CDCl₃): d 8.54, 7.27 (2m, each 2H, Pyrid.), 8.33 (s, 1H, H-6, Pyrim.), 7.06, 7.00 (2m, each 2H, PhF), 6.00 (t, 1H, NH), 3.76 (t, 4H, 2CH₂O), 3.60 (q, 2H, CH₂NH), 2.52 (t, 2H, CH₂N), 2.50 (m, 4H, CH₂N), 1.86 (m, 2H, CH₂).

25

2-34 5-(4-Fluorophenyl)-2-(3-(2-pyrrolidinon-1-yl)-propylamino)-4-(4-pyridyl)-pyrimidine:

20

MS (m/z): 392.2 (M+H)²; C₂₂H₂₂FN₃O requir. 391.5. ¹H-NMR (CDCL₃): d 8.58, 7.30 (m, 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.10, 7.04 (m, 2H, PhF), 5.88 (t, 1H, NH), 3.56 (q, 2H, CH₂NH), 3.48, 3.45 (2t, each 2H, 2CH₂), 2.46 (t, 2H, CH₃), 2.08 (m, 2H, CH₃), 1.90 (m, 2H, CH₃).

$$R1 = \begin{pmatrix} 0 \\ N \end{pmatrix} \begin{pmatrix} H \\ N \end{pmatrix}$$

2-35 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride:
MS (m/z): 400.1 (M+H)+; C24H22FN5 requir. 399.5 (free base).

$$R1 = NH_2$$

2-36 2-(((S)-2-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride: 2-Chloro-4-(4-pyridyl)-5-(3-

15 trifluoromethylphenyl)-pyrimidine and (S)-1,2benzylethylendiamine were reacted according to the
General Procedure, Step C (70°C for 75 min) to give the
title compound. MS (m/z): 450.4 (M+H)+; C25H22F3N5
requir. 4449.5 (free base).

2-37 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine hydrochloride:
2-Chloro-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine and
(S)-1,2-benzylethylendiamine were reacted according to
the General Procedure, Step C (100°C for 20 min) to give
the title compound. MS (m/z): 396.2 (M+H)⁺; C25H25N5
requir. 395.5 (free base).

$$R1 = NH_2$$

2-38 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: 2-Chloro-5(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine and (S)-2-N,Ndimethylamino-3-phenylpropylamine were reacted according
to the General Procedure, Step C (100°C for 45 min) to
give the title compound. MS (m/z): 427.8 (M+H)+;
C₁₆H_MFN, requir. 427.5.

2-39 2-(((S)-2-N.N-Dimethylamino-3-phenylpropyl)-amino)10 5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine: 2-Chloro-5(3-methylphenyl)-4-(4-pyridyl)-pyrimidine and (S)-2-N.Ndimethylamino-3-phenylpropylamine were reacted according
to the General Procedure, Step C (100°C for 30 min) to
give the title compound. MS (m/z): 424.2 (M+H)+;
15 C₂H₂FN, requir. 423.6.

2-40 2-((3-Amino-3-phenylpropyl)-amino)- 5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: 2-chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine and 1-phenyl-1,3-propanediamine were reacted according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 4001. (M+H)+; C₂,H₂,FN, requir. 399.5 (free base).

25 2-41 2-((3-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride: 2-Chloro-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)pyrimidine and 1-phenyl-1,3-propanediamine were reacted according to the General Procedure, Step C (100°C for 1 h) to give the title compound. MS (m/z): 450.3 $(M+H)^+$; $C_{\alpha}H_{\alpha}F_{\alpha}N_{\alpha}$ requir. 449.5 (free base).

2-42 2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride: 2-Chloro-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine and 1-(2-fluorophenyl)-1,3-propanediamine were reacted according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 468.4 (M+H)+; C,H,F,N, requir. 467.5 (free base).

2-43 2-((3-Amino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine hydrochloride:

15 2-Chloro-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine and 1-phenyl-1,3-propanediamine were reacted according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 396.1 (M+H)+; C₃₅H₃₂N₃, requir. 395.5 (free base).

$$R1 = NH_2$$

20

2-44 2-((2-Amino-2-methyl-3-phenylpropyl)-amino)- 5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: 2-Chloro-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine and 2-amino-2-methyl-3-phenylpropylamine were reacted

25 according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 410.2

(M+H)+; C,H,N, requir. 409.5 (free base).

$$R1 = H_2N CH_3 H$$

2-45 2-((3-Hydroxy-3-phenylpropyl)-amino) 5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine: 2-Chloro-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine and 3-hydroxy-3-phenylpropylamine were reacted according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 397.2 (M+H)+; C₂,H₂,N₄O requir. 396.5.

10 2-46 2-(((2R,3R)-3-Amino-2-methyl-3-phenylpropyl)amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)pyrimidine hydrochloride: 2-Chloro-4-(4-pyridyl)-5-(3trifluoromethylphenyl)-pyrimidine and (1R,2R)-2-methyl1-phenyl-1,3-propanediamine were reacted according to

15 the General Procedure, Step C (50°C for 1 h) to give the
title compound. MS (m/z): 464.4 (M+H)+; C26H24F3N5
requir. 463.5 (free base).

$$R1 = \begin{array}{c} \frac{NH_2}{\overline{\tau}} \\ CH_3 \end{array}$$

2-47 2-(((2S,3S)-3-Amino-2-methyl-3-phenylpropyl)amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)pyrimidine hydrochloride: 2-chloro-4-(4-pyridyl)-5-(3trifluoromethylphenyl)-pyrimidine and (1S,2S)-2-methyl1-phenyl-1,3-propanediamine were reacted according to
the General Procedure, Step C (90°C for 45 min) to give

25 the title compound. MS (m/z): 464.1 (M+H)+; C26H24F3N5
requir. 463.5 (free base).

$$R1 = \begin{bmatrix} NH_2 \\ \frac{1}{2} \\ CH_3 \end{bmatrix}$$

2-48 2-((S)-3-Benzylpiperazinyl)- 4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride: 2-Chloro-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)5 pyrimidine and (S)-2-benzylpiperazine were reacted according to the General Procedure, Step C (70°C for 30 min) to give the title compound. MS (m/z): 475.5

(M-H)+; C27H2AF3Ns requir, 476.1 (free base).

10 2-49 4-(4-Pvridy1)-2-(((S)-tetrahydroisoquinol-3-ylmethylen)amino)-5-(3-trifluoromethylpheny1)-pyrimidine hydrochloride: 2-Chloro-4-(4-pyridy1)-5-(3-trifluoromethylpheny1)-pyrimidine and (S)-tetrahydroisoquinol-3-ylmethylenamine were reacted

15 according to the General Procedure, Step C (50°C for 1.5 h) to give the title compound. MS (m/z): 462.4 (M+H)+; C26H22F3N5 requir. 461.5 (free base).

2-50 5-(3-Methylphenyl)-4-(4-pyridyl)-2-(((S)-

20 tetrahvdroisoguinol-3-ylmethylen)amino)-pyrimidine hvdrochloride: 2-Chloro-5-(3-methylphenyl)-4-(4pyridyl)-pyrimidine and (S)-tetrahydroisoguinol-3ylmethylenamine were reacted according to the General Procedure, Step C (100°C for 45 min) to give the title

25 compound. MS (m/z): 408.2 (M+H)+; C26H25N5 requir. 407.5 (free base).

Example 3

General procedure for the preparation of 2-acylamino-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidines

 $R = R^{21}$, OR^{20} or NR^5R^{21}

The chlorocarbonyl R-C(0)Cl (0.57 mmol) was added dropwise to a solution of 2-amino-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine (0.38 mmol) in pyridine (3 ml) at ice-bath temperature. It was stirred for 3 h at room temperature, monitored by thin layer chromatography, poured into ice-water, extracted with dichloromethane, dried and evaporated. The crude product can be purified by silica gel column chromatography (hexane-acetone) and 15 recrystallized from a suitable solvent such as ethyl acetate.

The following compounds were prepared using the appropriate acid chloride according to this procedure: 3-1 2-Acetamido-5-(4-fluorophenyl)-4-(4-pyridyl)pyrimidine: MS (m/z): 309.0 (M+H)*; C,,H,FN,O requir. 308.3. H-NMR (CDCl₃): d 8.63 (s, 1H, H-6, Pyrim.), 8.60, 7.29 (2m, each 2H, Pyrid.), 8.26 (bs, 1H, NH), 7.14, 7.08 (2m, each 2H, PhF), 2.58 (s, 3H, CH,CO). R = CH,-

25 3-2 2-Butyramido-5-(4-fluorophenyl)-4-(4-pyridyl)pyrimidine: MS (m/z): 337.2 (M+H); C19H17FN4O requir. 336.4. ¹H-NMR (CDCl₃): d 8.64, (s, 1H, H-6, Pyrim.), 8.60, 7.31 (2m, each 2H, Pyrid.), 8.17 (bs, 1H, NH), 7.14, 7.08 (2m, each 2H, PhF), 2.80 (t, 2H, CH₂CO), 1.82 (m, 2H, CH,), 1.06 (t, 3H, CH3). 30

R = CH,CH,CH,-

- 3-3 5-(4-Fluorophenyl)-2-pivalamido-4-(4-pyridyl)pyrimidine: MS (m/z): 351.0 (M+H)'; C₂₀H₁₉FN₁O requir.
 350.4. 'H-NMR (CDCl₂): d 8.69 (s, 1H, H-6, Pyrim.),
 8.60, 7.35 (2m, each 2H, Pyrid.), 8.25 (bs, 1H, NH),
 7.15, 7.08 (2m, each 2H, PhF), 1.4 (s, 9H, 3CH₁).
 R = (CH₁),C-
- 3-4 <u>2-Benzamido-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine:</u> MS (m/z): 371.0 (M+H); C₂₁H₁₅FN₄O requir.

 10 370.4. ¹H-NMR (CDCl₃): d 8.75 (s, 2H, NH, H-6, Pyrim.), 8.61, 7.36 (2m, each 2H, Pyrid.), 8.00, 7.63, 7.55 (d, t, t, 2H, 1H, 2H, Ph), 7.18, 7.10 (2m, each 2H, PhF).

3-5 5-(4-Fluorophenyl)-2-phenylacetamido-4-(4-pyridyl)15 pyrimidine: MS (m/z): 385.0 (M+H)*; C₃H₁,FN₄O requir.
384.4. ¹H-NMR (CDCl₃): d 8.66 (s, 1H, H-6, Pyrim.),
8.59, 7.28 (2m, each 2H, Pyrid.), 8.21 (bs, 1H, NH),
7.43-7.30 (m, 5H, Ph), 7.14, 7.08 (2m, each 2H, PhF),
4.13 (s, 2H, CH₂).

20

3-6 5-(4-Fluorophenyl)-2-hydrocinnamamido-4-(4-pyridyl)-pyrimidine: MS (m/z): 399.2 (M+H)'; C₂₈H₁₅FN₄O requir. 398.4. 'H-MMR (CDCL₃): d 8.60 (s, 1H, H-6, Pyrim.), 8.54 (m, 2H, Pyrid.), 8.20 (bs, 1H, NH), 7.31-7.16 (m, 7H, Ph, Pyrid.), 7.11, 7.05 (2m, each 2H, PhF), 3.20, 3.09 (2t, each 2H, 2CH).

Example 4

General procedure for the preparation of 2-substituted 5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidones

5 a. 2-(4-Fluorophenyl)-3-(4-pyridyl)-acrylic acid: A mixture of 4-fluorophenylacetic acid (9 g, 58.4 mmol), 4-pyridinecarboxaldehyde (5.6 ml, 58.6 mmol), pyridine (6 ml) and acetic anhydride (6 ml) was heated at 150°C for 1 h followed by evaporation and co-distillation with water. The resulting material crystallized on addition of ethanol. The solids were filtered and washed with ethanol and ethyl acetate to provide the title compound. MS (m/z): 244.0 (M+H)'; C₁₅H₁₅FNO₃ requir. 243.2 'H-NMR (DMSO-d₈): d 8.43, 6.98 (2d, each 2H, Pyrid.), 7.73 (s, 15 LH, CH=), 7.21 (d, 4H, PhF).

b. Ethyl 2-(4-fluorophenyl)-3-(4-pyridyl)-acrylate:
Conc. sulfuric acid (2.2 ml) was added carefully to a
suspension of 2-(4-fluorophenyl)-3-(4-pyridyl)-acrylic
acid (6.7 g, 27.5 mmol) in ethanol (120 ml) and the

mixture was heated at reflux for 24 h. The solvent was
evaporated, the remainder was taken up in
dichloromethane and the organic solution was washed with
aqueous sodium hydrogencarbonate and water, followed by
drying and evaporation. Flash column chromatography on

silica gel (hexane-acetone = 2:1) provided the pure title compound. MS (m/z): 271.8 (M+H); C₁₄H₁₇PNO₂ requir. 271.3 ¹H-NMR (CDCl₃): 8.44, 6.88 (2m, each 2H, Pyrid.), 7.72 (s, 1H, CH=), 7.16, 7.06 (2m, each 2H, PhF), 4.28 (g. 2H, CH.), 1.28 (t. 3H, CH.).

c. General procedure: A stirred mixture of ethyl 2-(4fluorophenyl)-3-(4-pyridyl)-acrylate (357 mg, 1.38 mmol), the amidine hydrochloride (2.61 mmol) and sodium methoxide (250 mg, 4.62 mmol) in ethanol (5 ml) was 10 heated in a sealed tube at 120°C for 3 h. It was neutralized with 2N hydrochloric acid prior to evaporation. The residue was taken up in acetic acid (25 ml) and treated with sodium nitrite (670 mg, 9.71 mmol) at 44°C for 20 min. After evaporation, the 15 resultant product was taken up in dichloromethane and the solution was washed with aqueous sodium hydrogencarbonate and water before drying and evaporation. The product was purified by recrystallization from methanol. If the crude product 20 of nitrite oxidation was water soluble, as was found for 5-(4-fluorophenyl)-2-methyl-6-(4-pyridyl)-4(3H)pyrimidinone, then no aqueous work up was done, but the material obtained on evaporation was applied to a column of silica gel (5% methanol/dichloromethane) prior to 25 recrystallization.

The following compounds were prepared accordingly using the appropriate amidine hydrochloride:

- 4-1 5-(4-Fluorophenyl)-2-methyl-6-(4-pyridyl)-4(3H) pyrimidinone: MS (m/z): 282.2 (M+H)*; C_nH_nFN₀ requir.
 281.3 ¹H-NMR (DMSO-d_s): d 8.46 (m 2H, Pyrid.), 7.2-7.03 (m, 6H, PhF, Pyrid.). 2.38 (s, 3H, CH_s).
 R1 = CH₋
- 4-2 5-(4-Fluorophenyl)-2-isopropyl-6-(4-pyridyl)-4(3H)pyrimidinone: MS (m/z): 310.0 (M+H)*; C₁₈H₁₆FN₃O requir.
 35 309.4 H-NMR (DMSO-d₂): 8.45 (m, 2H, Pyrid.), 7.21-7.03

(m, 6H, PhF, Pyrid.), 2.90 (m, 1H, $CH(CH_1)_2$,) 1.26, 1.24 (2s, each 3H, 2CH₃). R1 = (CH.).CH-

4-3 2-(2,6-Dichlorobenzyl)-5-(4-fluorophenyl)-6-(4-5 pyridyl)-4(3H)-pyrimidinone: MS (m/z): 426.0 (M)*; C₂H₁,Cl₂FN₃O requir. 426.3 H-NMR (DMSO-d₄): d 8.37 (m, 2H, Pyrid.), 7.50 (d, 2H, PhCl₂), 7.35 (t, 1H, PhCl₂), 7.18-7.08 (m, 4H, PhF), 6.96 (m, 2H, Pyrid.), 4.36 (s, 2H, CH.).

10

15

4-4 5-(4-Fluorophenyl)-2-phenyl-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 344.2 (M+H)*; C_nH_nFN₀ requir.
343.4 'H-NMR (DMSO-d_q): d 8.49 (d, 2H, Pyrid.), 8,20 (d, 2H, Ph), 7.66-7.50 (m, 3H, Pyrid., Ph), 7.32-7.11 (m, 6H, PhF, Ph).

4-5 5-(4-Fluorophenyl)-2-(4-phenylbutyl)-6-(4-pyridyl)-4(3H)-pyrimidinone: Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-pyridyl)-propionate (293 mg, 1.02 mmol), 4
20 phenylbutanecarboxamidine (315 mg, 1.79 mmol) and pyridinium p-toluenesulfonate (10 mg) were suspended in p-xylene (10 ml). With efficient stirring, the mixture was heated to reflux using a Dean-Stark apparatus with continuous removal of water. After 16 h, the solvent

25 was evaporated and the product purified by column chromatography on silica gel (3% methanol/dichloromethane) followed by recrystallization from acetone. MS (m/z): 400.3 (M+H)+; C25H22FN3O requir. 399.5

R1 = Ph(CH₂)4-

WO 98/24782 PCT/US97/22390

132

Example 5

General procedure for the preparation of 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thioalkyl-4(3H)-pyrimidinones

5 Step A. Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-pyridyl)propionate:

(According to: Legrand and Lozac'h, Bull. Soc. Chim. Fr., 79-81 (1955)).

10 A mixture of ethyl 4-fluorophenylacetate (13 g, 71.35 mmol), ethyl isonicotinate (10.7 ml, 71.4 mmol) and sodium spheres (1.64 g, 71.34 mmol) was heated at 90-95 C under argon. The mixture started to reflux and gradually turned into a solid. After 2.5 h, the mixture 15 was neutralized with dil. acetic acid with cooling followed by extraction with dichloromethane. The organic solution was washed with water, dried and evaporated. Flash chromatography on a column of silica gel (hexane-acetone = 4:1, 3:1, 2:1) provided the title 20 compound as an oil. MS (m/z): 287.8 $(M+H)^+$; $C_{16}H_{14}FNO_{15}$ requir, 287.3 H-NMR (CDC1.), (ketone : enole = 1 : 0.33): d 13.50 (s, 0.3H, OH-E), 8.81 (m, 2H, Pyrid, -K), 8.48 (m, 0.66 H, Pyrid.-E), 7.72 (m, 2H, Pyrid.-K), 7.38 (m. 2H, PhF-K), 7.14-7.04 (m. 2H, PhF-K; ~0.65H, Pyrid.-25 E; ~0.65H, PhF-E), 6.96 (t, 0.64H, PhF-E), 5.51 (s, 1H, CH-K), 4.23-4.2- (m, CH,-K,E), 1.26 (t, CH,-K,E). Step B. 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thiouracil:

A stirred mixture of ethyl 2-(4-fluorophenyl)-3oxo-3-(4-pyridyl)-propionate (22.3 g, 77.6 mmol) and
thiourea (5.9 g, 77.6 mmol) was reacted at 190_ C under
argon for 40 min. The reaction mixture was allowed to
5 reach room temperature, taken up in acetone and the
precipitate was filtered to provide the title compound.
MS (m/z): 300.2 (M+H); C₁₅H₁₀FN₁OS requir. 299.3 ¹H-NMR
(DMSO-d₁): d 12.74, 12.65 (2s, 2H), 8.51 (m, 2H,
Pyrid.), 7.26 (m, 2H, Pyrid.), 7.09 and 7.03 (2m, each
10 2H, PhF).

Alternatively, ethyl 2-(4-fluorophenyl)-3-oxo-3-(4pyridyl)-propionate (2.87 g, 10 mmol) and thiourea (2.28 g, 30 mmol) were suspended in anhydrous p-xylene (50 ml)
with very efficient stirring. To the mixture pyridinium
15 p-toluenesulfonate (100 mg) was added and refluxed for
12-16 h using a Dean-Stark apparatus with continuous
removal of water (0.2 ml). Reaction mixture was cooled
and a dark brown solid was filtered using a Buchner
funnel. The collected solid was suspended in acetone
20 (25 ml) and filtered. The acetone washed product
contained a trace of thiourea, which was removed by
trituration with hot water (20-30 ml). The product was
filtered and airdried.

Step C. General procedure:

25 The arylalkyl bromide (0.36 mmol) was added dropwise to a stirring mixture of 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thiouracil (100 mg, 0.33 mmol) and potassium carbonate (46 mg, 0.33 mmol) in N,N-dimethylformamide (4.6 ml). Stirring was continued for 30 3h followed by evaporation. Flash chromatography on a column of silica gel (hexane-acetone = 3:1, 2:1, 1:1) and recrystallization from hot methanol provided the target compound.

The following compounds were obtained using the 35 appropriate arylalkyl bromide according to the above procedure: 5-1 5-(4-Fluorophenyl)-2-(2-phenylethyl)thio-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 404.2 (M+H)'; C_{3;H₁₆FN,OS requir. 403.4. 'H-NMR (DMSO-d₄): d 13.08 (bs, 0.7H), 8.49 (m, 2H, Pyrid.), 7.30-7.06 (m, 1H, Pyrid., Ph. PhF), 3.41 (dd, 2H, CH,S), 3.00 (t, 2H, CH,L).}

5-2 5-(4-Fluorophenyl)-2-(3-phenylpropyl)thio-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 418.0 (M+H);

C₂₄H₁₂FN₂OS requir. 417.5. ¹H-NMM (DMSO-d₄): d 13.10 (bs, 10 0.7H), 8.47 (m, 2H, Pyrid.), 7.29-7.06 (m, 11H, Pyrid., Ph, PhF), 3.18 (t, 2H, CH₂S), 2.71 (t, 2H, CH₂Ph), 2.03 (m, 2H, CH,).

5-3 5-(4-Fluorophenvl)-2-(2-phenoxyethyl)thio-6-(4pyridyl)-4(3H)-pyrimidinone: MS (m/z): 420.0 (M+H); C:,H:,FN,O,S requir. 419.5. 'H-NMR (DMSO-d): d 13.20 (bs, 0.7H), 8.46 (m, 2H, Pyrid.), 7.24-7.07 (m, 8H, Pyrid., PhF, Ph), 6.95 (d, 2H, Ph), 6.92 (t, overlapped, 1H, Ph), 4.30 (t, 2H, CH,O), 3.58 (t, 2H, CH,S).

$$R^{1} =$$

20

5-4 5-(4-Fluorophenyl)-2-(2-phenylaminoethyl)thio-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 419.0 (M+H)*;

C₃H₁₅FN₂OS requir. 418.5. ¹H-NMR (DMSO-d₄): d 13.20 (bs,
0.8H), 8.48, 7.22 (2m, each 2H, Pyrid), 7.16, 7.10 (2m,
25 each 2H, PhF), 6.89 (t, 2H, Ph), 6.54 (d, 2H, Ph), 6.48 (t,
1H, Ph), 5.90 (bs, 0.6H, NH), 3.43-3.25 (m, 2CH).

$$R^1 = N S$$

Example 6

General procedure for the preparation of 2-N substituted 2-amino-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)pyrimidinones:

5 Step A. 5-(4-Fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone:

Methyl iodide (90 ml, 1.44 mmol) was added dropwise to a stirred mixture of 5-(4-fluorophenyl)-6-(4
10 pyridyl)-2-thiouracil (430 mg, 1.44 mmol) and potassium carbonate (198 mg, 1.43 mmol) in N,N-dimethylformamide (13 ml) at ice-bath temperature. After 40 min, it was evaporated and the crude product purified by flash chromatography on a column of silica gel (hexane-acetone 15 = 2:1, 1:1, 1:2) to provide the title compound as a solid. MS (m/z): 314.2 (M+H), C, H,FN,OS requir. 313.3.

H-NMR (DMSO-d,): d 13.10 (bs), 8.47, 7.22 (2m, each 2H, Pyrid.), 7.16, 7.10 (2m, each 2H, PhF), 2.56 (s, 3H, CH,).

20 Step B. General procedure:

25

A mixture of 5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (100 mg, 0.32 mmol) and an amine HNR'R^a (1 mmol) was heated at 180°C for 2 h. The resulting product was purified by flash chromatography on a column of silica gel (hexane-acetone or methanol-

dichloromethane or dichloromethane-methanol-conc. ammonium hydroxide) to provide the target compound.

The following compounds were prepared using the general procedure outlined above and an appropriate amine:

6-1 2-(2-(2-Chlorophenyl)ethyl-amino)-5-(4-

fluorophenvl)-6-(4-pvridvl)-4(3H)-pvrimidinone: MS
(m/z): 421.2 (M+H)*; C₃H₁ClFN₂O requir. 420.9. ¹H-NMR
(DMSO-d₄): d 11.24 (bs), 8.44, 7.16 (2m, each 2H,
10 Pyrid.), 7.43, 7.38 (2dd, each 1H, PhCl), 7.30, 7.26
(2dt, each 1H, PhCl), 7.10-7.00 (m, 2H, PhF), 6.74 (bs, 1H, NH), 3.60 (q, 2H, CH,N), 3.03 (t, 2H, CH,)

$$R^1 = \begin{bmatrix} H \\ N \end{bmatrix}$$

6-2 5-(4-Fluorophenvl)-2-((3-phenylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 401.2 (M+H)*; C_xH_xFN_xO requir. 400.5. 'H-NMR (DMSO-d_x): d 11.16 (bs), 8.44, 7.14 (2m, each 2H, Pyrid.), 7.32-7.01 (m, 9H, Ph, PhF), 6.78 (bs, NH), 3.36 (q, 2H, CH,N), 2.67 (t, 2H, CH,Ph), 1.89 (m, 2H, CH,I).

$$R^1 = M$$

20

6-3 5-(4-Fluorophenyl)-2-((1-methyl-3-phenylpropyl)amino)-6-(4-pyridyl)-4(3H)-pyrimidinone: A reaction
time of 15 h at 180_ C was required. MS (m/z): 415.0
(M+H)*; C₂,H₂,FN₁O requir. 414.5. 'H-NNR (CDCl₃): d 8.48
25 (m, 2H, Pyrid.), 7.28-7.08 (m, 9H, Pyrid., Ph, PhF),
6.94 (m, 2H, PhF), 5.67 (bs, 1H, NH), 4.08 (m, 1H,
CHCH₃), 2.61 (t, 2H, CH₂Ph), 1.67 (m, 2H, CH₂), 1.08 (d,
3H, CH₃).

$$\mathbb{R}^{1} = \mathbb{N}$$

6-4 5-(4-Fluorophenyl)-2-((3-imidazolylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 391.0 (M-H); C₁₁H₁FN₂O requir. 390.4. 'H-NMR (DMSO-d₄): d 11.24 (5b), 8.42, 7.12 (2m, each 2H, Pyrid.), 7.62, 7.18 (2s, each 1H, Imid.), 7.08-6.99 (m, 4H, PhF), 6.88 (s, 1H, Imid.), 4.02 (t, 2H, CH₂N), 3.28 (overlapped by water signal, CH₂NH), 2.00 (m, 2H, CH₂).

10 6-5 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone
hydrochloride: The reaction was done at 170°C for 7 h.

MS (m/z): 416.1 (M+H)+; C₂₆H₂₂FN₅O requir. 415.5.

$$R1 = NH_2$$

15 Example 7

5-(4-Fluoropheny1)-2-hydrazino-6-(4-pyridy1)-4(3H)pyrimidinone

A mixture of 5-(4-fluorophenyl)-6-(4-pyridyl)-2thiouraci1 (500 mg, 1.66 mmol) and hydrazine hydrate

20 (800 ml, ~14 mmol) was heated at 120°C for 60 min. It
was evaporated and the reaction product was
recrystallized from hot methanol to provide the title
compound. MS (m/z): 298.0 (M+H)'; C₁₃H₁₁FN₃O requir.
297.3. 'H-NMR (DMSO-d₄): d 8.41, 7.12 (2m, each 2H,
Pyrid.), 7.05, 7.00 (2m, each 2H, PhF).
R'= NH-NH.

10

8-1

Example 8

General procedure for the preparation of 5-aryl-2,6-dipyridyl-(3H)-pyrimidinones

These compounds were prepared according to the literature (Kabbe, *supra*; German Patent 1271116 (1968)) as follows:

A stirred mixture of the ethyl phenylacetate (3.13 mmol), cyanopyridine (6.24 mmol) and sodium methoxide (3.5 mmol) in n-butanol (1.2 ml) was heated at $110^{\circ}\mathrm{C}$ for 2h. The reaction mixture was concentrated and dissolved in water (4 ml), followed by the addition of aqueous sat. ammonium chloride (2 ml). The precipitate was filtered and recrystallized from hot methanol.

2.5

The following compounds were prepared according to this procedure using the appropriate starting materials:

- 8-1 5-Phenvl-2,6-bis-(4-pyridyl)-4-(3H)pyrimidinone: MS (m/z): 327.2 (M+H)'; C_{sr}H₁N,0 requir. 326.4. ¹H-NMR (DMSO-5 d_s): d 8.78, 8.47, 8.13 (3m, each 2H, Pyrid.), 7.40-7.14 (m, 7H, Ph, Pyrid.).
 - 8-2 5-(4-Fluorophenv1)-2,6-bis-(4-pvridv1)-4(3H)pvrimidinone: MS (m/z): 345.2 (M+H); C₃₀H₁₀FN,0 requir.
 344.4 ³H-NMR (DMSO-d₆): d 8.80, 8.49, 8.13 (3m, each 2H,
 Pvrid.), 7.40-7.08 (m, 6H, PhF, Pvrid.).
- 8-3 2.5,6-Tris-(4-pyridyl)-4(3H)-pyrimidinone was prepared according to the general procedure by reacting ethyl 4-pyridylacetate and 4-cyanopyridine in the presence of sodium methoxide. MS (m/z): 328.2 (M+H);
 15 C,H,N,O requir. 327.4 H-NMR (DMSO-d₄): 8.65, 8.45, 8.35, 8.18, 7.25, 7.13 (6m, each 2H, Pyrid.).
- 8-4 5-(4-Fluorophenv1)-2,6-bis-(3-pvridv1)-4(3H)pvrimidinone: MS (m/z): 345.2 (M+H)*; C₂,H₁,FN₁O requir.

 344.4 'H-NMR (DMSO-d₄): d 9.34, 8.77, 8.54, 8.48, 7.78,

 20 7.60, 7.34 (7m, 3x1H, 2H, 3x1H, Pyrid.), 7.26, 7.15 (2m, each 2H, PhF).

Example 9

4-Amino-5-(4-fluorophenyl)-2,6-bis-(4-pyridyl)pyrimidine

4-Amino-5-(4-fluorophenyl)-2,6-bis-(4-pyridyl)pyrimidine was prepared according to the literature
(Kabbe, supra):

Sodium methoxide (180 mg, 3.33 mmol) was added to a 30 stirred solution of 4-cyanopyridine (650 mg, 6.24 mmol)

WO 98/24782 PCT/US97/22390

140

and 4-fluorophenylacetonitrile (375 mml, 3.12 mmol) in n-butanol (1.5 ml). The mixture was stirred for 20 min at room temperature before heating it at 110°C for 1.5 h. It was allowed to reach room temperature and ethanol (2.5 ml) was added. The precipitate was filtered and recrystallized from acetic acid/water (3.5/10 ml) to provide the title compound. MS (m/z): 344.2 (M+H)'; C₂M₁FN₂ requir. 343.4 'H-NMR (DMSO-d₆): 8.76, 8.47, 8.22 (3m, each 2H, Pyrid.), 7.4-7.16 (m, 6H, PhF, Pyrid.).

Example 10

10

4-Methoxy-5-phenyl-2,6-bis-(4-pyridyl)-pyrimidine

$$\bigcap_{N \to N} \bigcap_{N \to N} \bigcap_{N$$

A mixture of 5-pheny1-2,6-bis-(4-pyridy1)-4(3H)pyrimidinone (360 mg, 1.10 mmol) and phosphorus 15 oxychloride (2 ml) was heated at reflux for 1.5 h. Work-up was done as described for the preparation of 2chloro-5-(4-fluorophenvl)-4-(4-pyridyl)-pyrimidine. To a solution of the crude 4-chloro-5-phenv1-2.6-bis-(4pyridyl)-pyrimidine (250 mg, 0.73 mmol) in methanol (5 ml) was added methanolic 0.5 N sodium methoxide (1.45 20 ml, 0.73 mmol) and it was heated at reflux for 1 h. After evaporation, the resultant material was partitioned between ethyl acetate and water. The organic solution was washed with water, dried and evaporated. Chromatography of the crude product on a column of silica gel (ethyl acetate) provided the title compound. MS (m/z): 341.2 (M+H)*; C,H,SN,O requir. 340.4 ¹H-NMR (CDC1,): 8.82, 8.54, 8.40 (3m, each 2H, Pyrid.), 7.40-7.18 (m, 7H, Ph, Pyrid.), 4.15 (s, 3H, CH,O).

Example 11

Procedure for the preparation of 5-(4-Fluoropheny1)-2,4-bis-(4-pyridy1)-pyrimidine

Step A. 4-Chloro-5-(4-fluorophenyl)-2,6-bis-(45 pyridyl)-pyrimidine:

A mixture of 5-(4-fluorophenyl)-2,6-bis-(4-pyridyl)-4(3H)-pyrimidinone (760 mg, 2.21 mmol) in phosphorus oxychloride (3 ml) was heated at reflux for 1 lo h. Work-up was done as described for the preparation of 2-chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine. A portion (290 mg) of the resulting product (495 mg) was purified by flash chromatography (ethyl acetate, trace triethylamine) on silica gel. MS (m/z): 363.2 (M+H)*; C_{2,H1}CIPN, requir. 362.8 H-NMR (CDCl,): d 8.84, 8.60, 8.38, 7.30 (4m, each 2H, Pyrid.), 7.22, 7.13 (2m, each 2H, PhF).

Step B. 5-(4-Fluorophenyl)-2,4-bis-(4-pyridyl)pyrimidine:

20

A stirred mixture of 4-chloro-5-(4-fluorophenyl)-2,6-bis-(4-pyridyl)-pyrimidine (99 mg, 0.27 mmol) and 10% palladium-on-carbon (70 mg) in ethanol (10 ml) was hydrogenated under an atmosphere of hydrogen for 28 h. 25 Filtration and evaporation of the solvent was followed by flash chromatography (ethyl acetate) on a column of WO 98/24782

142

PCT/US97/22390

silica gel to provide the title compound. MS (m/z): 329.2 (M+H)'; $C_{20}H_{13}FN_4$ requir. 328.4. 1H -NMR (CDCl₃): d 8.91 (s, 1H, H-6, Pyrim.), 8.83, 8.65, 8.40, 7.45 (4m, each 2H, Pyrid.), 7.30-7.06 (m, 4H, PhF).

Example 12

5

Procedure for the preparation of 2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride

10 12-1 2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride: Ethyl chloroformate (86 µl, 0.901 mmol) was added at ice-bath temperature to a stirring mixture of N-(tert.-butoxycarbonyl)glycine (160 mg, 0.911 mmol) 15 and 4-methylmorpholine (110 μ l, 1.00 mmol) in tetrahydrofuran (10 ml). After 40 min, a solution 2-(((S)-2-amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3trifluoromethylphenyl)-pyrimidine (409 mg, 0.911 mmol) in tetrahydrofuran (15 ml) was added at ice-bath 20 temperature. Within 1 h, the mixture was allowed to reach room temperature. It was diluted with dichloromethane, washed with aqueous sodium hydrogencarbonate, followed by drying of the organic solution and evaporation. The resulting material was purified on a 25 column of silica gel (5% methanol/dichloromethane), then dissolved in methanol (2 ml) and 4N hydrogen chloride/dioxane (2 ml) was added. After 1 h at room temperature, it was evaporated and the remainder taken up in dichloromethane followed by washing with aqueous 30 sodium hydrogencarbonate, drying of the organic solution and evaporation. Column chromatography on silica gel

(dichloromethane - methanol - conc. ammonium hydroxide =

WO 98/24782 PCT/US97/22390

143

95 : 5 : 0; 90 : 10 : 0.6) provided the title compound as the free base which was converted into the hydrochloride by the addition of 4N hydrogen chloride/dioxane (85 μ1) to its methanolic solution (3 5 ml) followed by evaporation. MS (m/z): 507.4 (M+H); C₂,H₂,F,N₆O requir. 506.5 (free base).

The following compound was prepared using the above procedure and the appropriate starting materials:

Example 13

Procedure for the preparation of (S)-1,2-Benzylethylendiamine

15

20

25

(S)-1.2-Benzylethylendiamine: The diamine was prepared according to the literature (H. Brunner, P. Hankofer, U. Holzinger, B. Treittinger and H. Schoenenberger, Eur. J. Med. Chem. 25, 35-44, (1990)) by reduction of L-phenylalanine amide with lithium aluminium hydride. The (R)-enantiomer was prepared in the same manner from D-phenylalanine amide.

Example 14

Procedure for the preparation of 2-(((S)-2-Acetamido-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone

WO 98/24782 PCT/US97/22390

2-(((S)-2-Acetamido-3-phenylpropyl)-amino)-5-(4fluoropheny1)-3-methy1-6-(4-pyridy1)-4(3H)-pyrimidinone: A solution of 2-(((S)-2-amino-3-phenylpropyl)-amino)-5-5 (4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)pyrimidinone (25 mg, 0.058 mmol) and acetic anhydride (200 ml) in methanol (2 ml) was kept at room temperature for 1 h. Evaporation followed by chromatography of the resultant product on a column of silica gel (10% methanol/dichloromethane) provided the title compound.

MS (m/z): 472.3 (M+H)+; C27H26FN5O2 requir, 471.5.

15

Example 15

Procedure for the preparation of 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride

15-1 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride: Sodium triacetoxyborohydride (184 mg. 20 0.868 mmol) was added to a strirring mixture of 2-(((S)-2-amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3trifluoromethylphenyl)-pyrimidine (300 mg, 0.668 mmol) and acetone (50 ul. 0.675 mmol) in 1.2-dichloroethane (4 ml). After 16 h, the reaction was guenched by the addition of sat. agu. sodium hydrogencarbonate, followed 25 by extraction with dichloromethane, drying of the organic solution and evaporation. Chromatography on a

column of silica gel (5% methanol/chloroform) provided the title compound as a free base which was converted into the monohydrochloride by the addition of 6N hydrochloric acid (73 μ l) to its methanolic solution (3 ml) and subsequent evaporation. MS (m/z): 491.7 $(M)^+$; C_{*,H_*,F_*,N_*} requir. 491.6 (free base).

The following compounds were prepared using the above procedure and the appropriate starting materials:

15 15-3 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
hydrochloride: MS (m/z): 439.1 (M+H)+; C₁₄H₁₁N₅ requir.
437.6 (free base).

20 15-4 2-(((S)-2-N-Butylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 452.1 (M+H)+; C₂,H₃,N₃ requir. 451.6 (free base).

15-5 2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)25 5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
 hydrochloride: MS (m/z): 478.3 (M+H)*; C₁₁H₁₅N₅ requir.
477.7 (free base).

WO 98/24782

146

15-6 5-(4-Fluorophenyl)-2-(((S)-2-N-isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 442.1 (M+H)*; C₂₇H₁₈FN, requir.

5 441.6 (free base).

15-7 5-(4-Fluorophenyl)-2-((3-N-isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine

hydrochloride: MS (m/z): 442.2 (M+H)*; C,H,FN, requir.

10 441.6 (free base).

Example 16

Procedure for the preparation of 2-(((S)-2-Amino-3phenylpropyl)-amino)-5-(3-chloro-4-fluorophenyl)-4-(4pyridyl)- pyrimidine hydrochloride

Step A: 4-(4-Pyridyl)-2(1H)-pyrimidinone: A mixture of 4-acetylpyridine (25 ml, 226.0 mmol) and bis(dimethylamino)methoxymethane (44 ml, 293.8 mmol) was heated at 85°C for 30 min followed by evaporation to drvness to recover a solid of 3-(dimethylamino)-1-(4-10 pyridyl)-3-propen-1-one. Its ethanolic solution (200 ml) was transferred into ethanolic 1.13 N sodium ethoxide (200 ml) containing urea (16.3 g, 271 mmol). The mixture was heated to reflux overnight, then cooled down to ice-bath temperature. The precipitate was filtered, dissolved in a minimal amount of water and the aqueous solution was washed with dichloromethane. The title compound was precipitated from the aqueous solution by neutralization with 6N hydrochloric acid and filtered. More material was obtained from the original 20 reaction filtrate which was concentrated, diluted with a minimal amount of water and washed with dichloromethane. The aqueous solution was neutralized with 6N hydrochloric acid and the precipitate filtered. MS 25 (m/z): 174.1 (M+H)+; C.H.N.O requir. 173.2.

Step B: 2-Chloro-4-(4-pyridyl)-pyrimidine: With icebath cooling under argon, 4-(4-pyridyl)-2(1H)pyrimidinone (13.45 g, 77.7 mmol) and thionyl chloride (92 ml) were combined. N, N-Dimethylformamide (13.2 ml, 5 170.5 mmol) was added slowly and the mixture was heated to reflux for 1 h. It was evaporated and co-distilled with toluene. At 0°C, water was added to the remainder, then 10% ammonium hydroxide until neutral followed by extraction with dichloromethane. Drying of the organic solution was followed by evaporation and the 10 resultant solid was recrystallized from acetone. MS (m/z): 192.1,194.0 (M+H)+; C,H,ClN, requir. 191.6. Step C: 2-(((S)-2-Amino-3-phenylpropyl)-amino)-4-(4pyridyl) -pyrimidine: A mixture of 2-chloro-4-(4pyridyl)-pyrimidine (4.5 g, 23.7 mmol) and (S)-1,2-15 benzylethylendiamine (8.0 g, 53.3 mmol) was heated at 100°C for 25 min. Column chromatography on silica gel (dichloromethane - methanol - conc. ammonium hydroxide = 95 : 5 : 0.4) provided the title compound. MS (m/z): 20 306.5 (M+H)+; $C_{1s}H_{19}N_s$ requir. 305.4. Step D: 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-bromo-4-(4-pyridy1)-pyrimidine: Bromine (787 μ 1, 15.28 mmol) was added to a stirring solution of 2-(((S)-2-amino-3phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine (2.33 g, 7.64 mmol) in chloroform (25 ml). Stirring was 2.5 continued for 2 d. The mixture was partitioned between dichloromethane and aqueous sodium hydrogencarbonate. The organic solution was washed with brine, dried and evaporated. The resultant product was purified on a column of silica gel (dichloromethane - methanol - conc. 30 ammonium hydroxide = 92 : 8 : 0.6). MS (m/z) : 384.0, 386.0 (M+H)+; C,H,BrN, requir. 384.3. Step E: 2-(((S)-2-Amino-3-phenylpropyl)amino)-5-(3chloro-4-fluorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: A mixture of 2-((2(S)-amino-3-phenyl 35 propyl)amino)-5-bromo-4-(4-pyridyl)-pyrimidine (204 mg,

0.53 mmol), aqueous 2M sodium carbonate (1.66 ml, 3.32 mmol) and 3-chloro-4-fluorobenzene boronic acid (103 mg, 0.637 mmol) in toluene (5 ml) was stirred for 10 min under argon. The mixture was thoroughly degassed (10 5 times), before the addition of tetrakis (triphenylphosphine) palladium(0) (18 mg, 0.016 mmol). After heating at reflux for 16 h, the reaction mixture was diluted with toluene and washed with brine. The organic solution was dried and evaporated. Subsequent 10 column chromatography on silica gel (dichloromethane methanol - conc. ammonium hydroxide = 95 : 5 : 04) provided the title compound which was converted into the hydrochloride by the addition of 6N hydrochloric acid (64 µl) to its methanolic solution (2 ml) followed by 15 evaporation. MS (m/z): 434.1 (M)+; C₂₄H₂₁ClFN, requir. 433.9 (free base).

The following compounds were prepared according to Step E of this procedure by using the appropriate boronic acid and 5-bromopyrimidine:

16-2 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-fluorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 400.1 (M+H)*; C₂₄H₂₂FN, requir. 399.5 (free base).

25 16-3 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3isopropylphenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 424.2 (M+H)+; C₂H_mN₃ requir. 423.6 (free base).

16-4 5-(3-Acetamidophenyl)-2-(((S)-2-amino-3-0 phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 439.1 (M+H)*; C₂₄H₁₂N₄O requir. 438.5 (free base).

16-5 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-5 chlorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 416.3 (M+H)+; C_{2t}H₂ClN, requir. 415.9 (free base).

16-6 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(benzothienyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 438.3 (M+H)⁺; C₂₄H₁₃N₃S requir. 437.6 (free base).

16-7 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(2-naphthyl)-4-(4-pyridyl)-pyrimidine hydrochloride; MS (m/z): 432.5 (M+H)*; C,H,N, requir. 431.5 (free base).

Example 17

Procedure for the preparation of (S)-2-Benzylpiperazine

(S)-2-Benzylpiperazine: At ice-bath temperature, lithium aluminium hydride (1.6 g, 42.16 mmol) was added 15 in portions to a stirring mixture of (S)-2-benzyl piperazine-3,6-dione (3.0 g, 14.70 mmol) and tetrahydrofuran (80 ml). After 30 min at ice-bath temperature, the mixture was refluxed for 4 h with stirring. The reaction was quenched by the portionwise addition of sodium sulfate decahydrate and some methanol until hydrogen evolution ceased. It was filtered and the solids were washed several times with dichloromethane. The combined filtrates were evaporated to leave a white solid. MS (m/z): 177.1 (M+H)'; C₁₁H₁₄N, requir. 176.3.

Example 18

Procedure for the preparation of (S)-2-N,N-Dimethylamino-3-phenylpropylamine

$$H_2N$$
 $\stackrel{\circ}{\underset{\overline{N}}{\stackrel{\circ}{\longrightarrow}}}$
 H_2N
 $\stackrel{\circ}{\underset{\overline{N}}{\stackrel{\circ}{\longrightarrow}}}$
 $\stackrel{\circ}{\underset{\overline{N}}{\longrightarrow}}$

(6) (S)-2-N,N-Dimethylamino-3-phenylpropylamine: Sodium triacetoxyhydride (13.0 g, 61.3 mmol) was added to a

stirring mixture of phenylalanine amide (3.6 g, 21.9 mmol) and 37% formaldehyde solution (4.4 ml, 58.7 mmol) in 1,2-dichloroethane (77 ml). After stirring for 2 h, the reaction was quenched by the addition of sat. aqu. sodium hydrogencarbonate. Then potassium hydroxide pellets were added followed by extraction with dichloromethane, drying of the organic solution and evaporation. The resulting (S)-2-N,N-dimethylamino-3-phenylpropylamide was reduced with lithium aluminium hydride according to the literature (H. Brunner, P. Hankofer, U. Holzinger, B. Treittinger and H. Schoenenberger, Eur. J. Med. Chem. 25, 35-44, (1990)) to provide the title compound.

Example 19

Procedure for the preparation of 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride

$$\begin{array}{c} F \\ \downarrow \\ N \\ N \\ N \\ \end{array} \begin{array}{c} CH_3 \\ \downarrow \\ N \\ \end{array} \begin{array}{c} F \\ \downarrow \\ N \\ \downarrow \\ N \\ \end{array} \begin{array}{c} O \\ N \\ O \\ CH_3 \\ \end{array}$$

Step A. 5-(4-Fluorophenyl)-3-methyl-2-methylsulfonyl-6
(4-pyridyl)-4(3H)-pyrimidinone: A mixture of 5-(4fluorophenyl)-3-methyl-2-methylthio-6-(4-pyridyl)-4(3H)pyrimidinone (400 mg, 1.22 mmol) and Oxone" (potassium
peroxymonosulfate, 2.3 g, 3.74 mmol) in methanol (100
ml) and water (45 ml) was stirred for 13 h. The solvent

was concentrated to about 50 ml, followed by extraction
with dichloromethane, drying of the organic solution and
evaporation. The resulting white solid was used without
purification in the next step.

WO 98/24782 PCT/US97/22390

152

Step B. 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride: A mixture of crude 5-(4-fluorophenyl)-3-methyl-2-methylsulfonyl-6-(4-pyridyl)-5 4(3H)-pyrimidinone (430 mg g, 1.19 mmol) and (S)-2-N,N-dimethylamino-3-phenylpropylamine (600 mml, -3.4 mmol) was stirred at room temperature for 1h and then briefly warmed at 50°C. Column chromatography on silica gel (3-5% methanol/chloroform) provided the title compound as a 10 free base which was converted into the monohydrochloride by the addition of 4N hydrochloric acid/dioxane (160 mml, 0.64 mmol) to its methanolic solution (4 ml) and subsequent evaporation. MS (m/z): 458.0 (M+H)+; C27H28FN50 requir. 457.5 (free base).

15

20

25

30

Example 20

5-(4-fluorophenyl)-6-(4-(2-acetamido)-pyridyl)-2thioalkyl-4(3H)-pyrimidinones

Step A. Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-(2-acetamido)-pyridyl))-propionate:

A solution of 2-chloroisonicotinic acid (25.0g, 0.16 mol) in 65 mL of concentrated ammonium hydroxide was warmed to 205 Celsius in a steel bomb for 72 h. After cooling to 23 C, the solution was acidified to a pH of 1 using 6N HCl and subsequently filtered to remove unreacted starting material. The solution was concentrated to one fourth the original volume (approx 200 mL) in vacuo, and carefully adjusted to a pH of 6 using 1 N NaOH. After storing the cloudy solution at 0 C for 20 h, the desired 2-aminoisonicotinic acid was filtered off. To a suspension of 2-aminoisonicotinic acid in ethanol (600 mL) was added 47.1 mL of 4 N anhdrous HCl in dioxane. After warming to achieve reflux for 20 h, an additional 47.1 mL of 4 N anhdrous HCl in dioxane was added and the reaction was warmed to

reflux for an additional 20 h. Concentration with a

stream of nitrogen in the hood was followed by further concentration in vacuo, the remaining solid was diluted with saturated bicarbonate (200 mL), extracted with ethyl acetate (2 x 200mL), dried (Na2SO4). After 5 concentration in vacuo, the desired ethyl 2aminoisonicotinate was obtained. To a solution of ethyl 2-aminoisonicotinic acid in pyridine (45 mL) at 0 C undr an argon atmosphere was added acetyl chloride dropwise over 5 min. After 2 h at 0 C, the reaction was 10 pored into over ice 300 g, extracted with ethyl acetate (2 x300 mL), washed with water (2 x100 ml) followed by brine (2 x 100 mL), and dried (Na2SO4). After concentration in vacuo, the residue was purified by application of flash chromatography (step gradient ethyl acetate: hexane 1:4 then ethyl acetate: hexane 1:1) to afford ethyl 2-acetamidoisonicotinate. To a solution of diisopropylamine (14.15 mL, 101 mmol) and THF (40 mL) at -78 C was added n-butyl lithium (38.1 mL, 95 mmol) dropwise over 5 min. After 10 min, ethyl 4-fluorophenylacetate (17.3 g, 95 mmol) was added in 40 mL of dry THF. After 10 min, ethyl 2acetamidoisonicotinate (6.0 g. 29 mmol) was added in 20 ml of dry THF. The reaction was allowed to warm to 23 C overnight, and then acetic acid (95 mmol) was added in 2.5 one portion. The reaction was concentrated in vacuo, then partitioned repeatedly between saturated bicarbonate (200 ml) and ether (300 mL), the combined bicarbonate layers were neutralized with 10% citric acid, and extracted with ethyl acetate (2 x 300 mL). 30 The organic layers were dried (Na2SO4), concentrated in vacuo to afford the Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-(2-acetamido)-pyridyl)-propionate.

Step B. 5-(4-fluorophenyl)-6-(4-(2-acetamido)pyridyl))2-thiouracil:

Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-(2-acetamido)pyridyl)-propionate (1.3 g, 3.78 mmol) and

WO 98/24782 PCT/US97/22390

154

thiourea (863 mg, 11.3 mmol) were suspended in anhydrous p-xylene (15 ml) with very efficient stirring. To the mixture pyridinium p-toluenesulfonate (38 mg) was added and refluxed for 12-16 h using a Dean-Stark

5 apparatus with continuous removal of water (0.1 ml).
Reaction mixture was cooled and a dark brown solid was
filtered using a Buchner funnel. The collected solid
was suspended in acetone (25 ml) and filtered. The
acetone washed product contained a trace of thiourea,
10 which was removed by trituration with hot water (20-30
ml). The product was filtered and air dried followed by

azeotroping with toluene.

Example 21

Procedure for the preparation of (S)-2-N-Ethylamino-3phenylpropylamine

(S)-2-N-Ethylamino-3-phenylpropylamine: Acetic anhydride (1.2 ml, 12.7 mmol) was added to a stirring solution of L-phenylalanine amide (1.0 g, 6.10 mmol) in methanol (25 ml). After 1.5 h at room temperature, it was evaporated followed by drying in an oil pump vacuum. The resultant L-N-ethylphenylalanine amide (6.1 mmol) 10 was reduced with lithium aluminium hydride (570 mg, 15.0 mmol) in tetrahydrofuran (65 mml) at 55°C for 4 h. reaction mixture was poured into sat. agu. sodium hydrogencarbonate followed by extraction with dichloromethane, drying and evaporation. Column chromatography on silica gel (chloroform : methanol : triethylamine = 90:7:3) provided the amine as a yellowish oil. MS (m/z): 179.1 (M+H)+; C11H18N2 requir. 178.3.

Example 22

Procedure for the preparation of 2-Amino-2-methyl-3phenylpropylamine

2-Amino-2-methyl-3-phenylpropylamine: A solution of commercially available D,L-α-methyl phenylalanine methyl ester (5.0 g, 25.7 mmol) in aqu. 28% ammonium hydroxide (50 ml) was kept at room temperature for 3 d. The resulting white precipitate of D,L-α-methyl phenylalanine amide was filtered and dried (2.5 g). This material (2.0 g, 11.22 mmol) was reduced with lithium aluminium hydride (1.3 g, 34.26 mmol) in boiling tetrahydrofuran for 24 h. The reaction was quenched by the addition of sodium sulfate decahydrate at ice-bath temperature. The salts were filtered off, followed by evaporation to leave the title compound as an oil. MS (m/z): 165.1 $(M+H)^+$; $C_1OH_16N_2$ requir. 164.2. An alternative preparation was reported by M. Freiberger and R. B. Hasbrouck, J. Am. Chem. Soc. 82, 696-698 (1960).

Example 23

Procedure for the preparation of 2-Methyl-3phenylpropylamine

15

10

2-Methyl-3-phenylpropylamine: A mixture of commercially available 2-methyl-3-phenylpropylamide (4.32 g, 26.5 mmol) and lithium aluminium hydride (1.3 g, 34.3 mmol) in tetrahydrofuran (184 ml) was stirred at room temperature for 5 h. It was poured into aqu. sat. sodium sulfate and extracted with dichloromethane followed by drying of the organic solution and evaporation to provide the amine as an oil. Other syntheses have been reported, e.g. Dornow and Fust,
25 Chem. Ber. 87, 984 (1954).

Example 24

Procedure for the preparation of 5-(4-Fluorophenyl)-3methyl-2-((2-methy-3-phenylpropyl) amino)-6-(4-pyridyl)4(3H)-pyrimidinone hydrochloride

5-(4-Fluorophenyl)-3-methyl-2-((2-methy-3-phenylpropyl)
amino)-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride:
A mixture of crude 5-(4-fluorophenyl)-3-methyl-2methylsulfonyl-6-(4-pyridyl)-4(3H)-pyrimidinone (520 mg
10 g, 1.45 mmol) and 2-methyl-3-phenylpropylamine (1.5 g,
10.1 mmol) was heated at 50°c for 30 min. Column
chromatography on silica gel (2-5% methanol/
dichloromethane; hexane-acetone= 2 : 1) provided the
title compound. MS (m/z): 429.4 (M+H)+; C26H25FN4O
15 requir. 428.5 (free base).

Example 25

Procedure for the preparation of 1-Phenyl-1,3propanediamine

20 1-Phenyl-1.3-propanediamine: 3-Phenyl-3-aminopropionic acid (S. G. Cohen and S. Y. Weinstein, J. Am. Chem. Soc. 86, 725-728, 1964) was converted into 1-phenyl-1.3-propanediamine as reported in the literature (M. Kojima and J. Fujita, Bull. Chem. Soc. Jpn. 55, 1454-1459
25 (1982)).

Analogously, 1-(2-fluorophenyl)-1,3-propanediamine, 1-(2-methylphenyl)-1,3-propanediamine and 1-(2-methylphenyl)-1,3-propanediaminechlorophenyl)-1,3-propanediamine have been prepared by using the above procedure and the appropriate starting material.

Example 26

Procedure for the preparation of 3-Ethyl-5-(4fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)pyrimidinone

$$\bigcap_{N \to N} \bigcap_{N \to N} \bigcap_{N \to N} \bigcap_{N \to N} \bigcap_{N \to N} \bigcap_{CH_3} \bigcap_{N \to N} \bigcap_{N$$

10

3-Ethyl-5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone: Ethyl bromide (600 ml, 8.03 mmol) was added to a stirred mixture of 5-(4-fluorophenyl)-2methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (1.8 g, 5.97 mmol) and sodium hydride (60% oily suspension, 320 mg, 8 $\,$ 15 mmol) in N, N-dimethylformamide (60 ml) at room temperature. More ethyl bromide (2x 600 ml, 2x8.03 mmol) was added after 2 and 3.5 h. After 8 h, the reaction mixture was neutralized with acetic acid and 20 evaporated. The remainder was taken up in dichloromethane, the organic solution was washed with water, dried and evaporated. Flash chromatography on a column of silica gel (hexane-acetone = 3:1, 2:1). provided in the second main fraction the title compound as a solid

10

15

Example 27

Procedure for the preparation of 3-Ethyl-5-(4-fluorophenyl)-2-methylsulfonyl-6-(4-pyridyl)-4(3H)-pyrimidinone

3-Ethyl-5-(4-fluorophenyl)-2-methylsulfonyl-6-(4-pyridyl)-4(3H)-pyrimidinone: A mixture of 3-ethyl-5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (300 mg, 0.88 mmol) and Oxone' (potassium peroxymonosulfate, 2.54 g, 4.14 mmol) in methanol (71 ml) and water (33 ml) was stirred for 14 h. The solvent was concentrated to about 35 ml, followed by extraction with dichloromethane, drying and evaporation. The resulting white solid was used without purification in the next step.

Example 28

Procedure for the preparation of 2-(((S)-2-Amino-3-phenylpropyl)-amino)-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride

20

25

2-(((S)-2-Amino-3-phenylpropyl)-amino)-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone
hydrochloride: A mixture of 3-ethyl-5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (150 mg, 0.44 mmol) and (S)-1,2-benzylethylendiamine (200 ml, ~1.3 mmol) was heated at 190°C for 4.5 h. Column chromatography on Iatrobeads' (chloroform: methanol:

triethylamine = 90 : 7 : 3) provided the title compound as a free base which was converted into the crystallizing monohydrochloride by the addition of 2N hydrochloric acid (165 ml, 0.33 mmol) and methanol (1.5 ml). Filtration provided the title compound. MS (m/z): 444.0 (M+H)+; C265H27FN50 requir. 443.5 (free base).

Example 29

Procedure for the preparation of 3-Ethyl-5-(4fluorophenyl)-2-((2-methy-3-phenylpropyl) amino)-6-(4pyridyl)-4(3H)-pyrimidinone hydrochloride

10

25

3-Ethyl-5-(4-fluorophenyl)-2-((2-methy-3-phenylpropyl) amino)-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride: A mixture of crude 3-ethyl-5-(4-fluorophenyl)-2-15 methylsulfonyl-6-(4-pyridyl)-4(3H)-pyrimidinone (320 mg g, 0.89 mmol) and 2-methyl-3-phenylpropylamine (600 ml, ~4 mmol) was heated at 60°C for 2 h. Column chromatography on silica gel (hexane-acetone= 2 : 1; 2-5% methanol/dichloromethane) provided the title 20 compound. MS (m/z): 443.2 (M+H)+; C27H27FN40 requir. 442.5.

Example 30

Procedure for the preparation of 3-(2-Methylphenyl)propylamine

3-(2-Methylphenyl)propylamine: Diethyl cyanomethylphosphonate (5.0 ml, 30.9 mmol) was added to a stirring suspension of sodium hydride (60% oily suspension, 1.24 g, 31 mmol) in tetrahydrofuran (50 ml)

under argon. After 30 min, 2-methylbenzaldehyde (3.6 ml. 31.1 mmol) was added and stirring continued for 1 h. The reaction was quenched by the addition of water and extracted with dichloromethane followed by drying and evaporation of the organic solution. Column chromatography (hexane; hexane : ethylacetate = 3 : 1) provided 2-(2-methylphenyl)acrylonitrile as an oil. This material (3.8 g), 10% palladium on carbon (3.8 g) and 12 N hydrochloric acid (11.8 ml, 142 mmol) in methanol (125 ml) were hydrogenated with hydrogen at 10 atmospheric pressure for 2 d. The catalyst was removed by filtration and the solvent was evaporated. The resultant material was partitioned between dichloromethane and water. The aqueous layer was made basic with 10 N sodium hydroxide and extracted with dichloromethane, followed by drying and evaporation. The resultant material was purified on a silica gel column (chloroform : methaol : triethylamine = 85 : 10 : 5) to provide the title compound as an oil.

2.0

Example 31

Procedure for the preparation of 2-amino-3-(2-fluorophenyl)-propylamine

- Step A. Methyl 2-amino-3-(2-fluorophenyl)propionate:
 5g (27.3 mmol) of (D,L)-(2-fluoro-phenyl)alanine was suspended in 50 ml methanolic HCl and stirred at room temperature for 3 days. The reaction mixture was concentrated in vacuo and dried to give a yellow oil.
 MS (m/z): 198 (M+H); C_MH₁FNO, requir. 197.2.
- 30 <u>Step B. 2-Amino-3-(2-fluorophenyl)propionamide</u>: Methyl 2-amino-3-(2-fluorophenyl) propionate was suspended in 50 ml 30% ammonium hydroxide and stirred at room temperature for 18 hrs. The mixture was filtered,

washed with cold water and 2-amino-3-(2-fluoropheny1) propionamide was collected as a white solid. MS (m/z): 183.1 (M·H); C.H.FN,O requir. 182.2.

Step C. 2-Amino-3-(2-fluorophenyl)-propylamine: 2-Amino-3-(2-fluorophenyl)propionamide was added carefully to a chilled (5°) mixture of LAH (1.0g, 26.3 mmol) and 20 ml THF under argon. The reaction was then heated at reflux for 10 hrs. The reaction was cooled to 5°C and carefully treated with Na,SO,*10 H,O. The resulting mixture was stirred for 18 hrs, then filtered to remove the solids. The filtrate was concentrated in vacuo to give an amber oil. MS (m/z): 169 (M+H)'; C,H,FN, require. 168.19

Example 32

15 Procedure for the preparation of (1R,2R)-2-Methyl-1-phenyl-1,3-propanediamine

Step A: Methyl $(2S,3R,\alpha S)-3-(N-benzyl-N-\alpha-methylbenzylamino)-2-methyl-3-phenylpropionate was prepared as reported for the <math>2R,3S,\alpha R$ -enantiomer (S).G. Davies and I.A.S. Walters, J. Chem. Soc. Perkin Trans.I, 1129-1139 (1994).

Step B: Methyl (2S,3R)-3-amino-2-methyl-3phenylpropionate: A mixture of methyl (2S,3R,αS)-3-(Nbenzyl-N-α-methylbenzylamino)-2-methyl-3phenylpropionate (13.0 g, 33.55 mmol) and 10% palladium-

25

30

WO 98/24782 PCT/US97/22390

163

on-carbon (13.0 g) in glacial acetic acid (260 ml) was hydrogenated under a balloon of hydrogen for 24 h. The catalyst was removed by filtration followed by evaporation and co-distillation with toluene to provide the title compound as a white solid. MS (m/z): 194.2 (M+H); C.,H.,NO, requir. 193.3.

Step C: (2S,3R)-3-Amino-2-methyl-3-phenylpropionamide: A solution of methyl (2S, 3R) -3-amino-2-methyl-3phenylpropionate (6.3 g, 33 mmol) in 2N methanolic ammonia (20 ml) and ammonium hydroxide (28-30%, 40 ml) 10 was stirred at room temperature. After 4d, it was evaporated followed by chromatography on a short column of silica gel (dichloromethane - methanol - conc. ammonium hydroxide = 93 : 7 : 0.7; 90 : 10 : 0.8) to 15 provide the amide as a white solid. MS (m/z): 179.2 (M+H)*; C,H,N,O requir, 178.2.

Step D: (1R,2R)-2-methyl-1-phenyl-1,3-propanediamine: Lithium aluminium hydride (2.3 g, 60.60 mmol) was added in portions to a stirring solution of (2S,3R)-3-amino-2methyl-3-phenylpropionamide (2.6 g, 14.59 mmol) in tetrahydrofuran (54 ml) at ice-bath temperature. After 45 min, the mixture was heated at reflux for 16 h. With ice-bath cooling, the reaction was quenched by the portionwise addition of sodium sulfate decahydrate and some methanol until hydrogen evolution ceased. The solids were removed by filtration and washed with dichloromethane. The combined filtrates were evaporated to provide the title compound. MS (m/z): 165.2 $(M+H)^*$; C.,H.,N, requir. 164.3.

Analogously, the enantiomer (1S,2S)-2-methyl-1phenyl-1,3-propanediamine was prepared from methyl $(2R, 3S, \alpha R) - 3 - (N-benzyl-N-\alpha-methylbenzylamino) - 2-methyl-$ 3-phenylpropionate. MS (m/z): 165.3 (M+H); C.H.N. requir. 164.3.

Analogously, the enantiomers (1S.2R)-2-methyl-1phenyl-1,3-propanediamine and (1R.2S)-2-methyl-1-phenyl1,3-propanediamine may be prepared from tert.butyl
(2S,3S,\alphaR)- and -(2R,3R,\alphaS)-3-(N-benzyl-N-\alphamethylbenzylamino)-2-methyl-3-phenylpropionate (Davies
et al., J. Chem. Soc. Chem. Commun. 1153-1155, 1993).

Example 33

Procedure for the preparation of 5-(4-fluorophenyl)-2-(4-phenylbutyl)-6-(4-pyridyl)-4(3H)-pyrimidinone

10

399.5.

5-(4-Fluorophenyl)-2-(4-phenylbutyl)-6-(4-pyridyl)4(3H)-pyrimidinone: Ethyl 2-(4-fluorophenyl)-3-oxo-3(4-pyridyl)-propionate (293 mg, 1.02 mmol), 4phenylbutanecarboxamidine (315 mg, 1.79 mmol) and

15 pyridinium p-toluenesulfonate (10 mg) were suspended in
p-xylene (10 ml). With efficient stirring, the mixture
was heated to reflux using a Dean-Stark apparatus with
continuous removal of water. After 16 h, the solvent
was evaporated and the product purified by column

20 chromatography on silica gel (3%
methanol/dichloromethane) followed by recrystallization
from acetone. MS (m/z): 400.3 (M+H)+; C25H22FN3O requir.

WO 98/24782 PCT/US97/22390

165

Example 34

Procedure for the preparation of 5-(4-fluoropheny1)-2-(N-methy1-N-(2-phenylethy1)amino)-6-(4-pyridy1)-4(3H)-pyrimidinone

 $\begin{array}{lll} & \underline{5-(4-Fluorophenyl)-2-(N-methyl-N-(2-phenylethyl)\,amino)-6-(4-pyridyl)-4(3H)-pyrimidinone} \ was \ prepared using the methods described above. MS <math>(m/z): 401.2\ (M+H)^+; C_{24H21FN40}\ requir. 400.5. \end{array}$

Example 35


The compounds shown in Tables I-II can be prepared using the procedures of Examples 1-33.

TABLE I

15

5

TABLE II



Example 36

Biological Assavs

The following assays were used to characterize the ability of compounds of the invention to inhibit the production of TNF- α and IL-1- β . The second assay measured the inhibition of TNF- α and/or IL-1- β in mice after oral administration of the test compounds. The third assay, a glucagon binding inhibition in vitro assay, can be used to characterize the ability of compounds of the invention to inhibit glucagon binding. The fourth assay, a Cyclooxygenase enzyme (COX-1 and COX-2) inhibition activity in vitro assay, can be used

to characterize the ability of compounds of the invention to inhibit COX-1 and/or COX-2.

Lipopolysaccharide-activated monocyte TNF production assay

5 Isolation of monocytes

Test compounds were evaluated in vitro for the ability to inhibit the production of TNF by monocytes activated with bacterial lipopolysaccharide (LPS). Fresh residual source leukocytes (a byproduct of plateletpheresis) were obtained from a local blood bank, 10 and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation on Ficol-Paque Plus (Pharmacia). PBMCs were suspended at 2 x 105/ml in DMEM supplemented to contain 2% FCS, 10 mM, 0.3 mg/ml glutamate, 100 U/ml penicillin G and 100 mg/ml 15 streptomycin sulfate (complete media). Cells were plated into Falcon flat bottom, 96 well culture plates (200 ul/well) and cultured overnight at 37°C and 6% CO,. Non-adherent cells were removed by washing with 200 ul/well of fresh medium. Wells containing adherent 20 cells (~70% monocytes) were replenished with 100 ul of fresh medium.

Preparation of test compound stock solutions

Test compounds were dissolved in DMZ. Compound

25 stock solutions were prepared to an initial
 concentration of 10 - 50 µM. Stocks were diluted
 initially to 20 - 200 µM in complete media. Nine twofold serial dilutions of each compound were then
 prepared in complete medium.

30 Treatment of cells with test compounds and activation of TNF production with lipopolysaccharide

One hundred microliters of each test compound dilution were added to microtiter wells containing adherent monocytes and 100 µl complete medium. Monocytes were cultured with test compounds for 60 min at which time 25 µl of complete medium containing 30

ng/ml lipopolysaccharide from *E. coli* K532 were added to each well. Cells were cultured an additional 4 hrs. Culture supernatants were then removed and TNF presence in the supernatants was quantified using an ELISA.

TNF ELISA

Flat bottom, 96 well Corning High Binding ELISA plates were coated overnight (4°C) with 150 µL/well of 3 ug/ml murine anti-human TNF-α MAb (R&D Systems #MAB210). Wells were then blocked for 1 hr at room temperature with 200 µL/well of CaCl,-free ELISA buffer supplemented 10 to contain 20 mg/ml BSA (standard ELISA buffer: 20 mM, 150 mM NaCl, 2 mM CaCl, 0.15 mM thimerosal, pH 7.4). Plates were washed and replenished with 100 ul of test supernatants (diluted 1:3) or standards. Standards consisted of eleven 1.5-fold serial dilutions from a 15 stock of 1 ng/ml recombinant human TNF (R&D Systems). Plates were incubated at room temperature for 1 hr on orbital shaker (300 rpm), washed and replenished with 100 ul/well of 0.5 ug/ml goat anti-human TNF-α (R&D 20 systems #AB-210-NA) biotinylated at a 4:1 ratio. Plates were incubated for 40 min, washed and replenished with 100 ul/well of alkaline phosphatase-conjugated streptavidin (Jackson ImmunoResearch #016-050-084) at 0.02 ug/ml. Plates were incubated 30 min, washed and 25 replenished with 200 µ1/well of 1 mg/ml of p-nitrophenyl phosphate. After 30 min, plates were read at 405 nm on a V ... plate reader.

Data analysis

Standard curve data were fit to a second order

polynomial and unknown TNF-α concentrations determined from their OD by solving this equation for concentration. TNF concentrations were then plotted vs. test compound concentration using a second order polynomial. This equation was then used to calculate the concentration of test compounds causing a 50% reduction in TNF production.

15

25

Compounds of the invention can also be shown to inhibit LPS-induced release of IL-18, IL-6 and/or IL-8 from monocytes by measuring concentrations of IL-1B, IL-6 and/or IL-8 by methods well known to those skilled in the art. In a similar manner to the above described assay involving the LPS induced release of TNF-0 from monocytes, compounds of this invention can also be shown to inhibit LPS induced release of IL-18, IL-6 and/or IL-8 from monocytes by measuring concentrations of IL-1β, IL-6 and/or IL-8 by methods well known to those skilled in the art. Thus, the compounds of the invention may lower elevated levels of TNF-α, IL-1, IL-6, and IL-8 levels. Reducing elevated levels of these inflammatory cytokines to basal levels or below is favorable in controlling, slowing progression, and alleviating many disease states. All of the compounds are useful in the methods of treating disease states in which $TNF-\alpha$, IL- 1β , IL-6, and IL-8 play a role to the full extent of the definition of TNF-α-mediated diseases described herein.

20 Inhibition of LPS-Induced TNF-α production in mice

Male DBA/1LACJ mice were dosed with vehicle or test compounds in a vehicle (the vehicle consisting of 0.5% tragacanth in 0.03 N HCl) 30 minutes prior to lipopolysaccharide (2 mg/kg, I.V.) injection. Ninety minutes after LPS injection, blood was collected and the serum was analyzed by ELISA for TNF levels.

The following compounds exhibit activities in the monocyte assay (LPS induced TNF release) with IC $_{so}$ values of 20 μM or less:

- 30 5-(4-Fluorophenyl)-2-(4-pyridyl)-4-(4-pyridyl)pyrimidine
 5-(4-Fluorophenyl)-2-(2-methylthiazol-4-yl)-4-(4pyridyl)-pyrimidine
 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(2-thienyl)-
- 35 pyrimidine

10

15

20

25

3.0

35

40

```
2-(2-Diethylaminoethylamino)-5-(4-fluorophenyl)-4-(4-
pyridyl) -pyrimidine
2-(2-Aminoethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-
pyrimidine
2-(3-Aminopropylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-
pyrimidine
2-(4-Aminobutylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-
pyrimidine
2-(2,6-Dichlorobenzyl)-5-(4-fluorophenyl)-4-(4-pyridyl)-
pyrimidine
2-(2,6-Dichlorophenylamino)-5-(4-fluorophenyl)-4-(4-
pyridyl)-pyrimidine
2-(2,6-Dimethylphenylamino)-5-(4-fluorophenyl)-4-(4-
pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(2-methoxyphenylamino)-4-(4-
pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(4-fluorophenylamino)-4-(4-
pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-phenylthiomethyl-4-(4-pyridinyl)-
pyrimidine
2-(Benzylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-
pyrimidine
5-(4-Fluorophenyl)-2-(2-phenylethylamino)-4-(4-pyridyl)-
pyrimidine
5-(4-Fluorophenyl)-2-(methyl-(2-phenylethyl)-amino)-4-
(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-((2-hydroxy-2-phenyl-ethyl)amino)-
4-(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(2-(4-hydroxyphenyl)ethyl-amino)-4-
(4-pyridyl)-pyrimidine
2-(2-(4-Aminophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-
(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(2-(4-fluorophenyl)ethyl-amino)-4-
(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(2-(2-fluorophenyl)ethyl-amino)-4-
(4-pyridyl)-pyrimidine
2-(2-(2-Chlorophenyl)ethyl-amino))-5-(4-fluorophenyl)-4-
(4-pyridyl)-pyrimidine
2-(2-(4-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-
(4-pyridyl)-pyrimidine
2-(2-(3-Chlorophenyl)ethyl-amino))-5-(4-fluorophenyl)-4-
(4-pyridyl)-pyrimidine
```

2-(2-(2,4-Dichloropheny1)ethyl-amino)-5-(4-fluoropheny1)-4-(4-pyridyl)-pyrimidine

1.0

15

20

2.5

30

35

40

45

pyridyl) -4(3H) -pyrimidinone

```
2-(2-(4-Bromophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-
(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(2-(2-methoxyphenyl)ethyl-amino)-4-
(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(2-(3-methoxyphenyl)ethyl-amino)-4-
(4-pyridyl)-pyrimidine
5-(4-Fluorophenvl)-2-((3-phenvlpropvl)amino)-4-(4-
pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-((1-methyl-3-phenylpropyl)-amino)-
4-(4-pyridyl)-pyrimidine
2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-
fluorophenyl) -4-(4-pyridyl) -pyrimidine
5-(4-Fluorophenyl)-2-(2-phenylaminoethylamino)-4-(4-
pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-((3-imidazolylpropyl)-amino)-4-(4-
pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-((4-phenylbutyl)-amino)-4-(4-
pyridyl)-pyrimidine
5-(4-Fluorophenyl)-4-(4-pyridyl)-2-pyrrolidino-
pyrimidine
5-(4-Fluorophenyl)-2-morpholino-4-(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(1-piperazinyl)-4-(4-pyridyl)-
pyrimidine
5-(4-Fluorophenvl)-4-(4-pvridvl)-2-(2-
pyrrolidinoethylamino)-pyrimidine
5-(4-Fluorophenyl)-2-(2-morpholinoethylamino)-4-(4-
pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(2-piperidinoethylamino)-4-(4-
pyridyl) -pyrimidine
 5-(4-Fluorophenyl)-2-(3-(2-pyrrolidinon-1-yl)propyl-
amino) -4-(4-pyridyl) -pyrimidine
 2-(2.6-Dichlorobenzyl)-5-(4-fluorophenyl)-6-(4-pyridyl)-
 4(3H)-pyrimidinone
 5-(4-Fluorophenyl)-2-(2-phenylethyl)thio-6-(4-pyridyl)-
4(3H)-pyrimidinone
 5-(4-Fluorophenyl)-2-(3-phenylpropyl)thio-6-(4-pyridyl)-
 4(3H)-pyrimidinone
 5-(4-Fluorophenyl)-2-(2-phenoxyethyl)thio-6-(4-pyridyl)-
 4(3H)-pyrimidinone
 5-(4-Fluorophenyl)-2-(2-phenylaminoethyl)thio-6-(4-
 pyridyl) -4(3H)-pyrimidinone
 2-(2-(2-Chlorophenvl)ethyl-amino)-5-(4-fluorophenvl)-6-
 (4-pyridyl) -4 (3H) -pyrimidinone
 5-(4-Fluorophenyl)-2-((3-phenylpropyl)amino)-6-(4-
```

10

```
5-(4-Fluorophenyl)-2-((1-methyl-3-phenylpropyl)-amino)-
   6-(4-pyridy1)-4(3H)-pyrimidinone
   5-(4-Fluorophenyl)-2-((3-imidazolylpropyl)amino)-6-(4-
   pyridyl) -4 (3H) -pyrimidinone
   2-(((S)-2-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-
   (3-trifluoromethylphenyl)-pyrimidine
    2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-
    methylphenyl) -4-(4-pyridyl)-pyrimidine
    2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(4-
   fluorophenyl)-4-(4-pyridyl)-pyrimidine
    2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(3-
    methylphenyl)-4-(4-pyridyl)-pyrimidine
    2-((3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-
    (4-pyridyl)-pyrimidine
   2-((3-Amino-3-phenylpropv1)-amino)-4-(4-pyridy1)-5-(3-
15
    trifluoromethylphenyl)-pyrimidine
    2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-4-(4-
    pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
    2-((3-Amino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-
    (4-pyridyl)-pyrimidine
2.0
    2-((2-Amino-2-methyl-3-phenylpropyl)-amino)-5-(3-
    methylphenyl) -4-(4-pyridyl)-pyrimidine
     2-((3-Hydroxy-3-phenylpropyl)-amino)-5-(3-methylphenyl)-
     4-(4-pyridyl)-pyrimidine
     2-(((2S,3S)-3-Amino-2-methyl-3-phenylpropyl)-amino)-4-
25
     (4-pyridyl) -5-(3-trifluoromethylphenyl)-pyrimidine
     2-(((2R,3R)-3-Amino-2-methyl-3-phenylpropyl)-amino)-4-
     (4-pyridv1)-5-(3-trifluoromethylphenyl)-pyrimidine
     2-((S)-3-Benzylpiperazinyl)-4-(4-pyridyl)-5-(3-
     trifluoromethylphenyl)-pyrimidine
 3.0
      4-(4-Pyridyl)-2-(((S)-tetrahydroisoquinol-3-
     ylmethylen)amino)-5-(3-trifluoromethylphenyl)-pyrimidine
      5-(3-Methylphenyl)-4-(4-pyridyl)-2-(((S)-
      tetrahydroisoquinol-3-ylmethyl)amino)-pyrimidine
      2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-4-(4-
 35
      pyridyl) - 5-(3-trifluoromethylphenyl)-pyrimidine
      2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)-4-(4-
      pyridy1)-5-(3-trifluoromethylpheny1)-pyrimidine
      2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-5-(3-
  40 methylphenyl) -4-(4-pyridyl)-pyrimidine
      2-(((S)-2-N-Butylamino-3-phenylpropyl)-amino)-5-(3-
      methylphenyl) -4-(4-pyridyl) -pyrimidine
      2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)-5-(3-
```

methylphenyl)-4-(4-pyridyl)-pyrimidine

1.0

15

20

25

```
5-(4-Fluorophenvl)-2-(((S)-2-N-isopropylamino-3-
   phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine
   5-(4-Fluorophenyl)-2-((3-N-isopropylamino-3-
   phenylpropyl) -amino) -4-(4-pyridyl) -pyrimidine
   2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-4-(4-
   pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
   2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-5-(3-
   methylphenyl)-4-(4-pyridyl)-pyrimidine
    2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-chloro-4-
   fluorophenyl)-4-(4-pyridyl)-pyrimidine
    2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-
    fluorophenyl) -4-(4-pyridyl)-pyrimidine
    2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-
    isopropylphenyl) -4-(4-pyridyl)-pyrimidine
    5-(3-Acetamidophenyl)-2-(((S)-2-amino-3-phenylpropyl)-
    amino)-4-(4-pyridyl)-pyrimidine
    2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-
    chlorophenvl)-4-(4-pvridvl)-
    2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(benzothienyl)-
    4-(4-pyridyl)-pyrimidine
    2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(2-naphthyl)-4-
    (4-pyridyl)-pyrimidine
    2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-
    fluorophenvl)-6-(4-pyridyl)-4(3H)-pyrimidinone.
         The following compounds exhibit activities in the
    monocyte assay (LPS induced TNF release) with IC., values
    of 5 uM or less:
    2-(2-Aminoethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-
    pyrimidine
30
    2-(3-Aminopropylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-
    pyrimidine
    2-(Benzylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-
    pyrimidine
    5-(4-Fluorophenyl)-2-(2-phenylethylamino)-4-(4-pyridyl)-
35
    pyrimidine
    5-(4-Fluorophenyl)-2-(N-methyl-N-(2-phenylethyl)amino)-
```

(4-pyridyl)-pyrimidine 40 5-(4-Fluorophenyl)-2-(2-(4-hydroxyphenyl)ethylamino)-4-(4-pyridyl)-pyrimidine

4-(4-pyridyl)-pyrimidine

5-(4-Fluorophenyl)-2-(2-(4-fluorophenyl)ethylamino)-4-(4-pyridyl)-pyrimidine

5-(4-Fluorophenyl)-2-(2-hydroxy-2-phenyl-ethyl)amino-4-

10

15

20

2.5

30

35

40

```
5-(4-Fluorophenyl)-2-(2-(2-fluorophenyl)ethylamino)-4-
(4-pyridyl)-pyrimidine
2-(2-(2-Chlorophenyl)ethylamino))-5-(4-fluorophenyl)-4-
(4-pyridyl)-pyrimidine
2-(2-(4-Chlorophenv1)ethvlamino)-5-(4-fluorophenv1)-4-
(4-pyridyl)-pyrimidine
2-(2-(2,4-Dichlorophenyl)ethylamino)-5-(4-fluorophenyl)-
4-(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(3-phenylpropyl)amino-4-(4-
pyridyl)-pyrimidine
2-((S)-2-Amino-3-phenylpropyl)amino-5-(4-fluorophenyl)-
4-(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(2-phenylaminoethylamino)-4-(4-
pyridyl) -pyrimidine
5-(4-Fluorophenyl)-2-(3-imidazolylpropyl)amino-4-(4-
pyridyl) -pyrimidine
5-(4-Fluorophenyl)-4-(4-pyridyl)-2-pyrrolidino-
pyrimidine
5-(4-Fluorophenyl)-2-(1-piperazinyl)-4-(4-pyridyl)-
pyrimidine
5-(4-Fluorophenyl)-2-(2-phenylethyl)thio-6-(4-pyridyl)-
4(3H)-pvrimidinone
5-(4-Fluorophenyl)-2-(3-phenylpropyl)thio-6-(4-pyridyl)-
4(3H)-pyrimidinone
2-(2-(2-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-6-
(4-pyridyl) -4(3H) -pyrimidinone
5-(4-Fluorophenyl)-2-(3-phenylpropyl)amino-6-(4-
pyridyl) -4 (3H) -pyrimidinone
5-(4-Fluorophenyl)-2-(1-methyl-3-phenylpropyl)amino-6-
(4-pyridyl)-4(3H)-pyrimidinone
2-(((S)-2-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-
(3-trifluoromethylphenyl)-pyrimidine
2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-
methylphenyl)-4-(4-pyridyl)-pyrimidine
2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(4-
fluorophenyl) -4-(4-pyridyl) -pyrimidine
2-(((S)-2-N, N-Dimethylamino-3-phenylpropyl)-amino)-5-(3-
methylphenyl)-4-(4-pyridyl)-pyrimidine
2-((3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-
 (4-pyridyl)-pyrimidine
2-((3-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-
trifluoromethylphenyl)-pyrimidine
```

2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine

15

20

25

30

35

```
2-((3-Amino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-
(4-pyridyl)-pyrimidine
2-((2-Amino-2-methyl-3-phenylpropyl)-amino)-5-(3-
methylphenyl) -4-(4-pyridyl) -pyrimidine
2-((3-Hydroxy-3-phenylpropyl)-amino)-5-(3-methylphenyl)-
4-(4-pyridyl)-pyrimidine
2-(((2S,3S)-3-Amino-2-methyl-3-phenylpropyl)-amino)-4-
(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
2-(((2R,3R)-3-Amino-2-methyl-3-phenylpropyl)-amino)-4-
(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
2-((S)-3-Benzylpiperazinyl)-4-(4-pyridyl)-5-(3-
trifluoromethylphenyl)-pyrimidine
4-(4-Pyridy1)-2-(((S)-tetrahydroisoguino1-3-
vlmethyl)amino)-5-(3-trifluoromethylphenyl)-pyrimidine
5-(3-Methylphenyl)-4-(4-pyridyl)-2-(((S)-
tetrahydroisoguinol-3-vlmethylen)amino)-pyrimidine
2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-4-(4-
pyridyl) - 5-(3-trifluoromethylphenyl)-pyrimidine
2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)-4-(4-
pyridyl) -5-(3-trifluoromethylphenyl)-pyrimidine
2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-5-(3-
methylphenyl)-4-(4-pyridyl)-pyrimidine
2-(((S)-2-N-Butylamino-3-phenylpropyl)-amino)-5-(3-
methylphenyl)-4-(4-pyridyl)-pyrimidine
2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)-5-(3-
methylphenyl) -4-(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(((S)-2-N-isopropylamino-3-
phenylpropyl) -amino) -4- (4-pyridyl) -pyrimidine
5-(4-Fluorophenyl)-2-((3-N-isopropylamino-3-
phenylpropyl) -amino) -4-(4-pyridyl) -pyrimidine
2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-4-(4-
pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-5-(3-
methylphenyl)-4-(4-pyridyl)-pyrimidine
2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-chloro-4-
fluorophenvl)-4-(4-pyridyl)-pyrimidine
 2-(((S)-2-Amino-3-phenylpropy1)-amino)-5-(3-
 fluorophenvl)-4-(4-pyridyl)-pyrimidine
 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-
isopropylphenyl)-4-(4-pyridyl)-pyrimidine
 5-(3-Acetamidophenyl)-2-(((S)-2-amino-3-phenylpropyl)-
 amino) -4-(4-pyridyl) -pyrimidine
 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-
 chlorophenvl)-4-(4-pvridvl)-
```

179

2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(benzothienyl)-4-(4-pyridyl)-pyrimidine

2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(2-naphthyl)-4-(4-pyridyl)-pyrimidine

2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4-(3H)pyrimidinone.

Compounds of the invention may be shown to have anti-inflammatory properties in animal models of inflammation, including carageenan paw edema, collagen induced arthritis and adjuvant arthritis, such as the carageenan paw edema model (C. A. Winter et al Proc. Soc. Exp. Biol. Med. (1962) vol 111, p 544; K. F. Swingle, in R. A. Scherrer and M. W. Whitehouse, Eds., Antiinflammatory Agents, Chemistry and Pharmacology, Vol. 13-II, Academic, New York, 1974, p. 33) and collagen induced arthritis (D. E. Trentham et al J. Exp. Med. (1977) vol. 146, p 857; J. S. Courtenay, Nature (New Biol.) (1980), Vol. 283, p 666).

20

25

30

35

1.5

10

125 I-Glucagon Binding Screen with CHO/hGLUR Cells

The assay is described in WO 97/16442, which is incorporated herein by reference in its entirety. $\underline{\text{Reacents}}$

The reagents can be prepared as follows: (a) prepare fresh 1M o-Phenanthroline (Aldrich) (198.2 mg/ml ethanol); (b) prepare fresh 0.5M DTT (Sigma); (c) Protease Inhibitor Mix (1000X): 5 mg leupeptin, 10 mg benzamidine, 40 mg bacitracin and 5 mg soybean trypsin inhibitor per ml DMSO and store aliquots at -20°C; (d) 250 µM human glucagon (Peninsula): solubilize 0.5 mg vial in 575 µl 0.1N acetic acid (1 µl yields 1 µM final concentration in assay for non-specific binding) and store in aliquots at -20°C; (e) Assay Buffer: 20mM Tris (pH 7.8), 1 mM DTT and 3 mM o-phenanthroline; (f) Assay Buffer with 0.1% BSA (for dilution of label only; 0.01% final in assay): 10 µl 10% BSA (heat-inactivated) and

180

grade, 2200 Ci/mmol): dilute to 50,000 cpm/25 μ l in assay buffer with BSA (about 50pM final concentration in assay).

Harvesting of CHO/hGLUR Cells for Assay

- Remove media from confluent flask then rinse once each with PBS (Ca, Mg-free) and Enzyme-free Dissociation Fluid (Specialty Media, Inc.).
 - 2. Add 10 ml Enzyme-free Dissoc. Fluid and hold for about 4 min. at 37°C.
- 3. Gently tap cells free, triturate, take aliquot for counting and centrifuge remainder for 5 min. at 1000 rpm.
 - 4. Resuspend pellet in Assay Buffer at 75000 cells per 100 $\mu l\,.$

Membrane preparations of CHO/hGLUR cells can be used in place of whole cells at the same assay volume. Final protein concentration of a membrane preparation is determined on a per batch basis.

Assav

5

15

20

The determination of inhibition of glucagon binding can be carried out by measuring the reduction of ${\tt I}^{\tt us}$ -glucagon binding in the presence of compounds of Formula I. The reagents are combined as follows:

	Compound/ Vehicle	250 μM Glucagon	125I- Glucagon	CHO/hGLUR Cells
Total Binding	/5 μl		25 μ1	100 μ1
+ Compound	5 μ1/		25 μ1	100 μ1
Nonspecif ic Binding	/5 μl	1 μ1	25 μ1	100 μl

25

The mixture is incubated for 60 min. at 22°C on a shaker at 275 rpm. The mixture is filtered over pre-soaked (0.5% polyethylimine (PEI)) GF/C filtermat using an

181

Innotech Harvester or Tomtec Harvester with four washes of ice-cold 20mM Tris buffer (pH 7.8). The radioactivity in the filters is determined by a gammascintillation counter.

Thus, compounds of the invention may also be shown to inhibit the binding of glucagon to glucagon receptors.

Cyclooxygenase Enzyme Activity Assay

The human monocytic leukemia cell line, THP-1, differentiated by exposure to phorbol esters expresses only COX-1; the human osteosarcoma cell line 143B expresses predominantly COX-2. THP-1 cells are routinely cultured in RPMI complete media supplemented with 10% FBS and human osteosarcoma cells (HOSC) are cultured in minimal essential media supplemented with 10% fetal bovine serum (MEM-10%FBS); all cell incubations are at 37°C in a humidified environment containing 5% CO.

COX-1 Assay

In preparation for the COX-1 assay, THP-1 cells are grown to confluency, split 1:3 into RPMI containing 2% FBS and 10 mM phorbol 12-myristate 13-acetate (TPA), and incubated for 48 hours on a shaker to prevent attachment. Cells are pelleted and resuspended in Hank's Buffered Saline (HBS) at a concentration of 2.5 × 10⁴ cells/mL and plated in 96-well culture plates at a density of 5 × 10³ cells/mL. Test compounds are diluted in HBS and added to the desired final concentration and the cells are incubated for an additional 4 hours. Arachidonic acid is added to a final concentration of 30 mM, the cells incubated for 20 minutes at 37°C, and enzyme activity determined as described below.

35

10

15

182

For the COX-2 assay, subconfluent HOSC are trypsinized and resuspended at 3 × 10° cells/mL in MEM-FBS containing 1 ng human IL-1b/mL, plated in 96-well tissue culture plates at a density of 3 x 104 cells per well, incubated on a shaker for 1 hour to evenly distribute cells, followed by an additional 2 hour static incubation to allow attachment. The media is then replaced with MEM containing 2% FBS (MEM-2%FBS) and 1 ng human IL-1b/mL, and the cells incubated for 18-22 hours. Following replacement of media with 190 mJ MEM. 10 mL of test compound diluted in HBS is added to achieve the desired concentration and the cells incubated for 4 hours. The supernatants are removed and replaced with MEM containing 30 mM arachidonic acid, the cells incubated for 20 minutes at 37°C, and enzyme 15 activity determined as described below.

COX Activity Determined

30

After incubation with arachidonic acid, the 2.0 reactions are stopped by the addition of 1 N HCl. followed by neutralization with 1 N NaOH and centrifugation to pellet cell debris. Cyclooxygenase enzyme activity in both HOSC and THP-1 cell supernatants is determined by measuring the concentration of PGE, using a commercially available ELISA (Neogen #404110). 25 A standard curve of PGE, is used for calibration, and commercially available COX-1 and COX-2 inhibitors are included as standard controls.

Accordingly, the compounds of the invention or a pharmaceutical composition thereof are useful for prophylaxis and treatment of rheumatoid arthritis; Pagets disease; osteophorosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; pancreatic & cell destruction: osteoarthritis: rheumatoid spondylitis; gouty arthritis; inflammatory 35 bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; 10

15

20

25

ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; Alzheimer's disease; stroke; myocardial infarction; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster, all of which are sensitive to TNF-a and/or IL-1 inhibition or glucagon antagonism, will also be positively effected by the compounds and methods of the invention.

The compounds of the present invention also may possess analgesic properties and may be useful for the treatment of pain disorders, such as hyperalgesia due to excessive IL-1. The compounds of the present invention may also prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway, including cyclooxygenase (WO 96/03387, incorporated herein by reference in its entirety).

Because of their ability to lower TNF- α and IL-1 concentrations or inhibit glucagon binding to its receptor, the compounds of the invention are also useful research tools for studying the physiology associated with blocking these effects.

The methods of the invention comprise administering
an effective dose of a compound of the invention, a
pharmaceutical salt thereof, or a pharmaceutical
composition of either, to a subject (i.e., an animal,
preferably a mammal, most preferably a human) in need of
a reduction in the level of TNF-α, IL-1, IL-6, and/or
IL-8 levels and/or reduction in plasma glucose levels
and/or which subject may be suffering from rheumatoid

arthritis; Pagets disease; osteophorosis; multiple

184

myeloma; uveititis; acute and chronic myelogenous leukemia; pancreatic & cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylavie; contact domethicies

(ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; Alzheimer's disease; stroke; myocardial infarction; ischemia reperfusion

5

10

30

35

stroke; myocardial infarction; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection, or which subject is infected by HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes

15 cytomegalovirus (CMV), influenza, adenovirus, the herpe viruses (including HSV-1, HSV-2), or herpes zoster.

In another aspect, this invention comprises the use of a compound of the invention, or pharmaceutically acceptable salts thereof, in the manufacture of a 20 medicament for the treatment either acutely or chronically of a TNF-α, IL-1β, IL-6, and/or IL-8 mediated disease state, including those described previously. Also, the compounds of this invention are useful in the manufacture of a analgesic medicament and a medicament for treating pain disorders, such as hyperalgesia. The compounds of the present invention also are useful in the manufacture of a medicament to prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway.

In still another aspect, this invention provides a pharmaceutical composition comprising an effective TNF- α , IL-1 β , IL-6, and/or IL-8 lowering amount and/or effective plasma glucose level lowering amount of a compound of the invention and a pharmaceutically acceptable carrier or diluent, and if desired other active ingredients. The compounds of the invention are administered by any suitable route, preferably in the

10

15

35

form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds of the present invention required to arrest the progress or prevent tissue damage associated with the disease are readily ascertained by one of ordinary skill in the art using standard methods.

For the treatment of $TNF-\alpha$, $IL-1\beta$, IL-6, and IL-8 mediated diseases and/or hyperglycemia, the compounds of the present invention may be administered orally, parentally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally.

The dosage regimen for treating a TNF- α , IL-1, IL-6, and IL-8 mediated diseases and/or hyperglycemia with the compounds of this invention and/or compositions of this invention is based on a variety of factors, 20 including the type of disease, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen 25 may vary widely, but can be determined routinely using standard methods. Dosage levels of the order from about 0.01 mg to 30 mg per kilogram of body weight per day, preferably from about 0.1 mg to 10 mg/kg, more preferably from about 0.25 mg to 1 mg/kg are useful for 3.0 all methods of use disclosed herein.

The pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals.

For oral administration, the pharmaceutical composition may be in the form of, for example, a

1.0

15

35

capsule, a tablet, a suspension, or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a given amount of the active ingredient. For example, these may contain an amount of active ingredient from about 1 to 2000 mg, preferably from about 1 to 500 mg, more preferably from about 5 to 150 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods.

The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water. The daily parenteral dosage regimen will be from about 0.1 to about 30 mg/kg of total body weight, preferably from about 0.1 to about 10 mg/kg, and more preferably from about 0.25 mg to 1 mg/kg.

Injectable preparations, such as sterile injectable aqueous or oleaginous suspensions, may be formulated 20 according to the known are using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution 25 in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including 3.0 synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols that are solid at ordinary

187

temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

A suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg

5 administered one to four, preferably one or two times daily. For topical administration, the active ingredient may comprise from 0.001% to 10% w/w, e.g., from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more 10 than 5% w/w, and more preferably from 0.1% to 1% of the formulation.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin (e.g., liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eve. ear. or nose.

15

For administration, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration. 2.0 The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinyl-25 pyrrolidine, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or 30 various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in 35 the art.

20

25

30

The pharmaceutical compositions may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions). The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc.

Solid dosage forms for oral administration may

include capsules, tablets, pills, powders, and granules.

In such solid dosage forms, the active compound may be
admixed with at least one inert diluent such as sucrose,
lactose, or starch. Such dosage forms may also
comprise, as in normal practice, additional substances

other than inert diluents, e.g., lubricating agents such
as magnesium stearate. In the case of capsules,
tablets, and pills, the dosage forms may also comprise
buffering agents. Tablets and pills can additionally be
prepared with enteric coatings.

Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.

Compounds of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by treatment with an optically active acid or base. Examples of appropriate acids are tartaric,

diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed

by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves 5 synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, 10 distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of the invention can likewise be obtained by using active starting materials.

15 These isomers may be in the form of a free acid, a free base, an ester or a salt.

The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. The salts include, but are not limited to, the 20 following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, 25 heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hyroxy-ethanesulfonate, lactate, maleate, methansulfonate, nicotinate, 2naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 2-phenylpropionate, picrate, pivalate, 30 propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate. Also, the basic nitrogencontaining groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates 35 like dimethyl, diethyl, dibutyl, and diamyl sulfates. long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides

190

like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.

Examples of acids that may be employed to from pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.

10

15

20

25

30

While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions that are given at the same time or different times, or the therapeutic agents can be given as a single composition.

The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

WHAT IS CLAIMED IS:

1. A compound of formula

5 or a pharmacutically acceptable salt thereof, wherein

wherein R_1 and R_2 are each independently -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R_1 and R_2 is 0-4;

wherein each Z is independently a

15 (1) bond:

10

- (2) alkyl, alkenyl or alkynyl radical optionally substituted by (a) 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio or halo,
- and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, halo, alkyl or haloalkyl;
 - (3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or
 - (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino.
 - alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl:

each Y is independently a

- hydrogen radical;
- (2) halo or nitro radical;
- (3) -C(O)-R₂₀ or -C(NR₅)-NR₅R₂₁ radical;
 - (4) $-OR_{21}$, $-O-C(0)-R_{21}$, $-O-C(0)-NR_5R_{21}$ or $-O-C(0)-NR_{22}-S(0)_2-R_{20}$ radical;
 - $\begin{array}{lll} (5) & -SR_{21}, & -S(0)-R_{20}, & -S(0)_2-R_{20}, & -S(0)_2-NR_5R_{21}, & -S(0)_2-NR_{22}-C(0)-R_{21}, & -S(0)_2-NR_{22}-C(0)-R_{20} & or & -S(0)_2-NR_{22}-C(0)-R_{20} & or & -S(0)_2-NR_{22}-C(0)-R_{20} & or & -S(0)_2-NR_{20}-C(0)-R_{20} & or & -S(0)_2-NR_{20}-R_{20} & or & -S(0)_2-NR_{20} & or & -S(0)_2-NR_{20} & or & -S(0)_2-NR_{20}-R_{20} & or & -S(0)_2-NR_{20}-R_{20} & or & -S(0)_2-NR_{20}-R_{20} & or & -S(0)_2-NR_{20} & or & -S(0)_2-NR_{20}-R_{20} & or & -S(0)_2-NR_{20}-R_{20} & or & -S(0)_2-NR_{20}-R_{20} & or & -S(0)_2-NR_{20}-R_{20} & or & -S(0)_2-NR_{20} & or & -S(0)_2-NR_{20} & or & -S(0)_2-NR_{20} & or$
- 10 NR₅R₂₁ radical; or
 - (6) $-NR_5R_{21}$, $-NR_{22}-C(O)-R_{21}$, $-NR_{22}-C(O)-OR_{20}$, $-NR_{22}-C(O)-NR_5R_{21}$, $-NR_{22}-C(O)-NR_5R_{21}$, $-NR_{22}-S(O)_2-R_{20}$ or $-NR_{22}-S(O)_2-NR_5R_{21}$ radical;
- 15 wherein each R5 is independently
 - (1) hydrogen radicals;
 - (2) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, -SO,H or halo;
- 20 or
 - (3) aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl or cycloalkylalkyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy,
- 25 alkoxy, alkylthio, alkyl or haloalkyl; and

wherein each R20 is independently

- alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino,
- 30 dialkylamino, alkanoylamino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, aminocarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halo or aralkoxy, aralkylthio, aralkylsulfonyl, cycloalkyl, heterocyclyl,
- 35 aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino,

alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkanoyl, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halo, alkyl or haloalkyl;

- (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or
 - (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino,
- 10 alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, cyano, halo, azido, alkyl or haloalkyl;

each $\ensuremath{\text{R}}_{21}$ is independently hydrogen radical or $\ensuremath{\text{R}}_{20};$

15

each R22 is independently

- (1) hydrogen radical;
- (2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted
- 20 by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl,
 - alkylsulfonyl, cyano, halo, alkyl or haloalkyl; or
 - (3) heterocyclyl, aryl or heteroaryl radicals optionally
- 25 substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl; provided when Z is a bond and Y is -NR22-
- 30 C(O)-NH₂, then R₂₂ is other then an optionally substituted aryl radical; and

 R_{11} and R_{12} are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radicals of

- 35 (1) Ran;
 - (2) halo or cyano radicals;

- (3) $-C(0)-R_{30}$, $-C(0)-OR_{29}$, $-C(0)-NR_{31}R_{32}$ or $-C(NR_{31})-NR_{31}R_{32}$ rádicals;
- (4) $-OR_{29}$, $-O-C(0)-R_{29}$, $-O-C(0)-NR_{31}R_{32}$ or $-O-C(0)-NR_{33}-S(0)_2-R_{30}$ radicals;
- 5 (5) $-SR_{29}$, $-S(0)-R_{30}$, $-S(0)_2-R_{30}$, $-S(0)_2-NR_{31}R_{32}$, $-S(0)_2-NR_{33}-C(0)-R_{30}$, $-S(0)_2-NR_{33}-C(0)-OR_{30}$ or $-S(0)_2-NR_{33}-C(0)-NR_{31}R_{32}$ radicals; or
 - (6) -NR₃₁R₃₂, -NR₃₃-C(0)-R₂₉, -NR₃₃-C(0)-OR₃₀, -NR₃₃-C(0)-NR₃₁R₃₂, -NR₃₃-C(NR₃₁)-NR₃₁R₃₂, -NR₃₃-S(0)₂-R₃₀ or -NR₃₃-
- 10 S(0)₂-NR₃₁R₃₂ radicals; provided that (1) R₁₁ is other than a 4-pyridyl, 4-pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and
- total number of aryl, necessaryl, cycloarkyl and 15 heterocyclyl radicals substituted on each of R₁₁ and R₁₂ is 0-1;

wherein each R30 is independently

- (1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of -NR₃₁R₃₁, -CO₂R₂₃, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo or aralkoxy, aralkylthio, aralkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl;
- (2) heterocyclyl radical optionally substituted by 1-3 30 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
- (3) aryl or heteroaryl radicals optionally substituted 35 by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino,

195

hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl;

each R29 is independently hydrogen radical or R30;

- each R_{31} and R_{32} are each independently
- (1) hydrogen radicals;

- (2) alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical
- optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or (3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical optionally substituted by 1-3 radicals of amino.
 - 5 optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; and
- 20 wherein each R33 is independently
- hydrogen radical; or
 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino,
 alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; and
- provided that (1) when R¹ and R¹² are the same and are a

 30 5- or 6-member ring having from 1-3 heteroatoms
 independently selected from N, S, and O, to which ring a
 benzene ring is optionally fused, R¹¹ is phenyl or
 naphthyl optionally substituted with halo, C₁-C₄ alkyl,
 C₁-C₄ alkoxy, C₁-C₄ alkylthiol, hydroxy, amino, C₁-C₄
 35 alkylamino, or dialkylamino, or R¹¹ is a 5- or 6-membered
 ring having from 1-3 heteroatoms independently selected
 from N, S, and O, to which ring a benzene ring is

optionally fused and optionally substituted with C_i - C_6 alkyl, then R^i is other than OH or NH_2 ; (2) when R^i is H, R^{11} is phenyl and R^{12} is phenyl or 4-pyridyl, then R^i is other than H, methyl, or amino; (3) when R^i is H, R^{11} is 2-methylphenyl and R^{12} is 2-pyridyl, then R^i is other than n-propyl; and (4) when R^{11} and R^{12} are each an optionally substituted phenyl radical, then R^i is other than an optionally substituted 2-pyridyl radical.

10

2. The compound of Claim 1 or a pharmaceutically acceptable salt thereof, wherein

wherein R₁ and R₂ are each independently -Z-Y, provided 15 that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R₁ and R₂ is 0-4;

2.0

each Z is independently a

- (1) bond:
- (2) C_1-C_8 alky1, C_2-C_8 alkenyl or C_2-C_8 alkynyl radical optionally substituted by (a) 1-3 radicals of amino, C_1-C_4 alkylamino, $di-(C_1-C_4$ alkylamino, C_1-C_5
- 25 C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3
- 30 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl) amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy) carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
- 35 (3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄

- alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4 alkoxy)carbonylamino, C_1 - C_4 alkylsulfonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, C_1 - C_4 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals; or
- (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl
- 10 or C1-C4 haloalkyl of 1-3 halo radicals;

each Y is independently a

- (1) hydrogen radical;
- (2) halo or nitro radical;
- 15 (3) $-C(0)-R_{20}$ or $-C(NR_5)-NR_5R_{21}$ radical;
 - (4) $-OR_{21}$, $-O-C(O)-R_{21}$, $-O-C(O)-NR_5R_{21}$ or $-O-C(O)-NR_{22}-S(O)_2-R_{20}$ radical;
- $(5) -SR_{21}, -S(0)-R_{20}, -S(0)_2-R_{20}, -S(0)_2-NR_5R_{21}, -S(0)_2-NR_{22}-C(0)-R_{21}, -S(0)_2-NR_{22}-C(0)-0R_{20} \text{ or } -S(0)_2-NR_{22}-C(0)-20$ NR₅R₂₁ radical; or
 - (6) $-NR_5R_{21}$, $-NR_{22}-C(0)-R_{21}$, $-NR_{22}-C(0)-OR_{20}$, $-NR_{22}-C(0)-NR_5R_{21}$, $-NR_{22}-C(NR_5)-NR_5R_{21}$, $-NR_{22}-S(0)_2-R_{20}$ or $-NR_{22}-S(0)_2-NR_5R_{21}$ radical:
- 25 each R₅ is independently
 - (1) hydrogen radicals;
 - (2) C_1-C_8 alkyl, C_2-C_8 alkenyl or C_2-C_8 alkynyl radicals optionally substituted by 1-3 radicals of amino, C_1-C_4 alkylamino, $di-(C_1-C_4-alkyl)$ amino, hydroxy, C_1-C_4
- 30 alkoxy, C₁-C₄ alkylthio, -SO,H or halo; or (3) aryl, heteroaryl, aryl-C₁-C₄-alkyl, heteroaryl-C₁-C₄-alkyl, heterocyclyl, heterocyclyl-C₁-C₄-alkyl, C₃-C₈ cycloalkyl or C₃-C₈-cycloalkyl-C₁-C₄-alkyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄
- 35 alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄

alkoxy, C_1 - C_4 alkylthio, C_1 - C_4 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals:

each R20 is independently

- 5 (1) C₁-C₈ alkyl, C₂-C₈ alkenyl or C₂-C₈ alkynyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-N-(C₁-C₄ alkyl)amino, aminocarbonylamino, C₁-C₄
 10 alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄
- alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄
 alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl,
 halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-alkylthio, aryl-C₁C₄-alkylsulfonyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl
 or heteroaryl radicals optionally substituted by 1-3
- 15 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄
 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
 alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, C₁-C₅
 alkanoyl, hydroxy, C₁-C₄ alkylsulfonylamino, C₁-C₄
 alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo, C₁-C₄ alkyl or
 20 C₁-C₄ haloalkyl of 1-3 halo radicals;
 - (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy,
 - 5 C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or
 - (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4
- 30 alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
- 35 each R21 is independently hydrogen radical or R20;

each Roo is independently

- (1) hydrogen radical:
- (2) C1-C4 alkyl radical optionally substituted by a
- radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 1.0 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4
- haloalkyl of 1-3 halo radicals; or
 - (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4
- 15 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; provided when Z is a bond and Y is -NR22-C(O)-NH2, then R22 is other then an 2.0
 - optionally substituted aryl radical;

R11 and R12 are each independently an arvl or heteroaryl radical optionally substituted by 1-3 radicals of

- (1) Ran:
- (2) halo or cvano radicals: 25
 - (3) -C(0)-R₃₀, -C(0)-OR₂₉, -C(0)-NR₃₁R₃₂ or -C(NR₃₁)-NR31R32 radicals;
 - (4) -OR29, -O-C(O)-R29, -O-C(O)-NR31R32 or -O-C(O)-NR33-S(0)2-R30 radicals;
- 30 $(5) -SR_{29}, -S(0)-R_{30}, -S(0)_2-R_{30}, -S(0)_2-NR_{31}R_{32}, -S(0)_2 NR_{33}-C(0)-R_{30}$, $-S(0)_2-NR_{33}-C(0)-OR_{30}$ or $-S(0)_2-NR_{33}-C(0)-OR_{30}$ NR31R32 radicals; or
 - (6) -NR₃₁R₃₂, -NR₃₃-C(O)-R₂₉, -NR₃₃-C(O)-OR₃₀, -NR₃₃-C(O)-NR31R32, -NR33-C(NR31)-NR31R32, -NR33-S(O)2-R30 or -NR33-
- S(O)2-NR31R32 radicals;

200

provided that (1) R_{11} is other than a 4-pyridyl, 4-pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R_{11} and R_{12}

each Ran is independently

is 0-1;

(1) C₁-C₄ alkyl, C₂-C₄ alkenyl or C₂-C₄ alkynyl radicals optionally substituted by 1-3 radicals of -NR₃₁R₃₁, -C₂R₂₃, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, cyano, halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-alkylthio, aryl-C₁-C₄-alkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylsulfonyl, cyano, halo, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, cyano, halo, C₁-C₄ alkyl of 1-3 halo radicals;

(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, d_1 - $(C_1$ - C_4 alkyl) amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4 alkoxy) carbonylamino, C_1 - C_4 alkylsulfonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, cyano, C_1 - C_4 alkyl or C_1 -

(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄

C4 haloalkyl of 1-3 halo radicals; or

30 alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

each R29 is independently hydrogen radical or R30;

201

each R31 and R32 are each independently

- (1) hydrogen radicals;
- (2) $\rm C_1{-}C_4$ alkyl radical optionally substituted by an $\rm C_3{-}C_8$ cycloalkyl, aryl, heterocyclyl or heteroaryl radical

optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C4 alkylamino, C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or

10 (3) aryl, heteroaryl, heterocyclyl or C3-C8 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 balo radicals; and

each R_{33} is independently

- (1) hydrogen radical; or
- 20 (2) C₁-C₄ alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkylamino, C₁-C₅ alkanoylamino, (C₁-C₄ alkylsulfonylamino, hydroxy, alkoyy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ alkylsulfonylamino,
- 25 C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, cyano, C_1 - C_4 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals; and

wherein heterocyclyl is a radical of a monocyclic or bicyclic saturated heterocyclic ring system having 5-8 30 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is stradical of a monocyclic or bicyclic aromatic heterocyclic ring system having 5-6 ring members per

202

ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused or saturated C₃-C₄-carbocyclic-fused.

5

3. The compound of Claim 2 or a pharmaceutically acceptable salt thereof, wherein

each Z is independently a

10 (1) bond;

(2) C₁-C₈ alky₁, C₂-C₈ alkeny₁ or C₂-C₈ alky₁y₁ radical optionally substituted by (a) 1-3 radicals of amino, C₁-C₄ alky₁amino, di-(C₁-C₄ alky₁) amino, C₁-C₅ alkanoy₁amino, (C₁-C₄ alkoxy₁) carbony₁amino, C₁-C₄

- alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl) amino, C₁-C₅ alkanoylamino, (C₁-C₄
- 20 alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
 - (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, $C_1\!-\!C_4$ alkylamino, di-($C_1\!-\!C_4$
 - alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
 alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy,
 C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄
 haloalkyl of 1-3 halo radicals; or
 - (4) aryl or heteroaryl radical optionally substituted by
- 30 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl) amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy) carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

each R5 is independently

- (1) hydrogen radicals:
- (2) C_1-C_4 alkyl, C_2-C_5 alkenyl or C_2-C_5 alkynyl radicals optionally substituted by 1-3 radicals of amino, C_1-C_4
- 5 alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, -SO,H or halo; or
 - (3) aryl, heteroaryl, aryl- C_1 - C_4 -alkyl, heteroaryl- C_1 - C_4 -alkyl, heterocyclyl, heterocyclyl- C_1 - C_4 -alkyl, C_3 - C_8 -cycloalkyl- C_1 - C_4 -alkyl radicals
- optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals:

15 each R20 is independently

- (1) C₁-C₈ alkyl, C₂-C₅ alkenyl or C₂-C₅ alkynyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-
- 20 N-(C₁-C₄ alkyl)amino, aminocarbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-alkylthio, aryl-C₁-C₄-alkylsulfonyl, C₁-C₈ cycloalkyl, heterocyclyl, aryl
- or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl) amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy) carbonylamino, C₁-C₄ alkylsulfonylamino, C₁-C₅ alkanoyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₅
- 30 alkylsulfinyl, C_1 - C_4 alkylsulfonyl, halo, C_1 - C_4 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals;
 - (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4 alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4
- 35 alkoxy)carbonylamino, C1-C4 alkylsulfonylamino, hydroxy,

 C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, C_1 - C_4 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals; or

- (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4
- 5 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

10

each R21 is independently hydrogen radical or R20;

each R30 is independently

- (1) C₁-C₄ alkyl radical optionally substituted by 1-3 15 radicals of
 - (a) -NR31R31;
 - (b) C_1-C_4 alkoxy-carbonyl or phenoxycarbonyl or phenylmethoxycarbonyl optionally substituted by 1-3 radicals of amino, alkylamino, $di-(C_1-C_4-alkyl)$ amino,
- 20 C_1 - C_5 alkanoylamino, $(C_1$ - C_4 alkoxy)carbonylamino, C_1 - C_4 alkylsulfonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, cyano, halo, C_1 - C_4 alkyl or trifluoromethyl; or
- (c) hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, or phenyl-C₁-25 C₄-alkoxy, phenyl-C₁-C₄-alkylthio, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy) carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄
- 30 alkylthio, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
 - (2) C1-C4 haloalkyl of 1-3 halo radical; or
 - (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4
- 35 alkyl)amino, C1-C5 alkanoylamino, (C1-C4

alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;

each R29 is independently hydrogen radical or R30; 5

each R31 is independently

- (1) hydrogen radicals; or
- (2) C_1 - C_4 alkyl radical optionally substituted by an phenyl or heteroaryl radical optionally substituted by 10 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C_1 - C_4 alkyl or trifluoromethyl
- radicals; and 15

each R32 is independently

- (1) hydrogen radicals;
- (2) C_1 - C_4 alkyl radical optionally substituted by an C_3 -
- C_{θ} cycloalkyl, aryl, heterocyclyl or heteroaryl radical 20 optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di-(C_1 - C_4 alkyl)amino, C_1 - C_5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, cyano, C_1 - C_4
- alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or 25 (3) aryl, heteroaryl, heterocyclyl or C_3 - C_6 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, $(C_1-C_4$ alkoxy)carbonylamino, C_1-C_4
- 30 alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C_1 - C_4 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals; and

each R33 is independently hydrogen or C1-C4 alkyl 35 radical.

- 4. The compound of Claim 3 or a pharmaceutically acceptable salt thereof, wherein
- wherein R_1 is -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R_1 is 0-3:
- 10 Zisa

- (1) bond;
- (2) C_1-C_8 alkyl or C_2-C_8 alkenyl radical optionally substituted by (a) 1-3 radicals of amino, C_1-C_4 alkylamino, G_1-G_4 alkylamino, G_1-G_5 alkanovlamino,
- 15 (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
- 20 alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals:
 - (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, $di-(C_1-C_4 \text{ alkyl})$ amino, $(C_1-C_4 \text{ alkyl})$ amino, $(C_1-C_4 \text{ alkyl})$
- 25 alkoxy)carbonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio or C_1 - C_4 alkyl radicals; or
 - (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanovlamino, (C₁-C₄
- 30 alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals;
 - Y is a
- 35 (1) hydrogen radical;
 - (2) halo radical;

207

- (3) -C(O)-R₂₀ or -C(NR₅)-NR₅R₂₁ radical;
- (4) -OR₂₁, -O-C(O)-R₂₁ or -O-C(O)-NR₅R₂₁ radical;
- (5) $-SR_{21}$, $-S(0)-R_{20}$, $-S(0)_2-R_{20}$ or $-S(0)_2-NR_5R_{21}$ radical; or
- 5 (6) -NR₅R₂₁, -NR₂₂-C(0)-R₂₁, -NR₂₂-C(0)-OR₂₀, -NR₂₂-C(0)-NR₅R₂₁, -NR₂₂-C(NR₅)-NR₅R₂₁, -NR₂₂-S(0)₂-R₂₀ or -NR₂₂-S(0)₂-NR₅R₂₁ radical;

each R5 is independently

- 10 (1) hydrogen radicals;
 - (2) C_1-C_4 alkyl or C_2-C_5 alkenyl radicals optionally substituted by 1-3 radicals of amino, $di-(C_1-C_4-alkyl)$ amino, hydroxy, C_1-C_4 alkoxy, C_1-C_4 alkylthio, -SO.H or halo; or
- 15 (3) phenyl-C₁-C₂-alkyl, heteroaryl-C₁-C₂-alkyl, heterocyclyl-C₁-C₂-alkyl or C₃-C₆-cycloalkyl-C₁-C₂-alkyl radicals optionally substituted by 1-3 radicals of amino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo 20 radicals;

each R20 is independently

(1) C1-C8 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, 25 di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, N-((C1-C4 alkoxy)carbonyl)-N-(C1-C4 alkoxy)carbonylamino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylsulfonyl, halo or ary1-C1-C4-alkoxy, ary1-C1-C4-alkylsulfonyl, halo or ary1-C1-C4-alkoxy, ary1-C1-C4-alkylthio, ary1-C1-C4-alkylsulfonyl, C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C1-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, C1-C5 alkoxylsulfonylamino, C1-C5

208

alkanoyl, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, halo, C_1 - C_4 alkyl or C_1 - C_2 haloalkyl of 1-3 halo radicals;

- (2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, $C_1\text{-}C_4$ alkylamino, $\text{di-}(C_1\text{-}C_4$
- 5 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or C₁-C₄ alkyl; or
 - (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, $C_1\text{-}C_4$ alkylamino, di- $(C_1\text{-}C_4$
- alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals;
- each R21 is independently hydrogen radical or R20;

each R22 is independently

- (1) hydrogen radical; or
- 20 (2) C₁-C₄ alkyl radical optionally substituted by a radical of phenyl or heteroaryl optionally substituted by 1-3 radicals of amino, d₁-(C₁-C₂ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or
 25 C₁-C₂ haloalkyl of 1-3 halo radicals;
 - R_2 is a radical of hydrogen, C_1 - C_4 alkyl, halo, hydroxy, C_1 - C_4 alkoxy, C_1 - C_2 haloalkoxy of 1-3 halo radicals, thiol, C_1 - C_4 alkylthio, aminosulfonyl, C_1 - C_4
- 30 alkylaminosulfonyl, di- $(C_1-C_4$ alkyl)aminosulfonyl, amino, C_1-C_4 alkylamino, di- $(C_1-C_4$ alkyl)amino, C_1-C_5 alkanoylamino, $(C_1-C_4$ alkoxy)carbonylamino, C_1-C_4 alkylsulfonylamino or C_1-C_2 haloalkyl of 1-3 halo radicals:

1.5

 $\ensuremath{R_{11}}$ and $\ensuremath{R_{12}}$ are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of

- (1) R₃₀;
- (2) halo or cyano radicals;
- 5 (3) -C(0)-R₃₀, -C(0)-OR₂₉, -C(0)-NR₃₁R₃₂ or -C(NR₃₁)-NR₃₁R₃₂ radicals; or
- pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R₁₁ and R₁₂ is 0-1;

15

each R₃₀ is independently

- (1) C_1-C_4 alkyl radical optionally substituted by
- (a) amino, C_1 - C_4 alkylamino or di-(C_1 - C_4 -alkyl)amino radicals; or
- 20 (b) hydroxy, C₁-C₄ alkoxy, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl radicals:
 - (2) C1-C2 haloalkyl of 1-3 halo radical; or
 - (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4
- 30 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl radicals;
- 35 each R₂₉ is independently hydrogen radical or R₃₀;

each R_{31} is independently hydrogen or C_1 - C_4 alkyl radicals; and

- 5 each R32 is independently
 - (1) hydrogen radicals;
 - (2) C_1 - C_4 alkyl radical optionally substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4
- alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4 alkoxy)carbonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkyl or trifluoromethyl radicals; or
 - (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, $C_1\!-\!C_4$ alkylamino, $\text{di-}(C_1\!-\!C_4$
- alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkyl or trifluoromethyl radicals; and

each R_{33} is independently hydrogen or methyl radical; 20 and

wherein heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-6 ring members, wherein 1-3 ring members are oxygen, sulfur or 25 nitrogen heteroatoms, which is optionally benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic aromatic heterocyclic ring system having 5-6 ring members,

- 0 wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused or saturated C₃-C₄-carbocyclic-fused.
- 35 5. The compound of Claim 4 or a pharmaceutically acceptable salt thereof, wherein

- Z is a
- (1) bond;
- (2) C1-C4 alkyl or C2-C5 alkenyl radical optionally
- 5 substituted by (a) 1-3 radicals of amino, di-(C1-C2 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy)carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3
- 10 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₂ alkyl) amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy) carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl radicals;
- 15 (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, $di-(C_1-C_2 \text{ alkyl}) \text{ amino}$, $(C_1-C_4 \text{ alkoxy}) \text{ carbonylamino}$, hydroxy, $C_1-C_2 \text{ alkoxy}$, $C_1-C_2 \text{ alkylthio}$ or $C_1-C_4 \text{ alkyl radicals}$; or
- (4) aryl or heteroaryl radical optionally substituted by 20 $\,$ 1-3 radicals of amino, di-(C1-C2 alkyl)amino, C1-C5
 - alkanoylamino, (C_1 - C_4 alkoxy)carbonylamino, hydroxy, C_1 - C_2 alkoxy, C_1 - C_2 alkylthio, cyano, halo, C_1 - C_4 alkyl or trifluoromethyl radicals;
- 25 each R5 is independently
 - (1) hydrogen radical:
 - (2) C_1-C_4 alkyl radical optionally substituted by 1-3 radicals of amino, di- $(C_1-C_2-alkyl)$ amino, hydroxy, C_1-C_2 alkoxy, C_1-C_2 alkylthio or halo; or
- 30 (3) phenyl-C₁-C₂-alkyl, heteroaryl-C₁-C₂-alkyl, heterocyclyl-C₁-C₂-alkyl or C₃-C₆-cycloalkyl-C₁-C₂-alkyl radicals optionally substituted by 1-3 radicals of amino, di-(C₁-C₂-alkyl)amino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, methoxy, methylthio, C₁-C₄ alkyl or
- 35 trifluoromethyl radicals:

each R_{22} is independently hydrogen or C_1 - C_4 alkyl radical;

- R_{11} is an aryl radical and R_{12} is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of
 - (1) Ran:
 - (2) halo or cyano radicals;
- .0 (3) -C(0)-R₃₀, -C(0)-OR₂₉, -C(0)-NR₃₁R₃₂ or -C(NR₃₁)-NR₃₁R₃₂ radicals; or
 - (4) $-0R_{29}$, $-SR_{29}$, $-S(0)-R_{30}$, $-S(0)_2-R_{30}$, $-S(0)_2-NR_{31}R_{32}$, $-NR_{31}R_{32}$ or $-NR_{32}-C(0)-R_{29}$ radicals; provided that the total number of arvl. heteroarvl.
- 15 cycloalkyl and heterocyclyl radicals substituted on each of $\ensuremath{\text{R}_{11}}$ and $\ensuremath{\text{R}_{12}}$ is 0-1;

each R30 is independently

- (1) C1-C4 alkyl radical optionally substituted by a
- 20 phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C1-C2 alkyl)amino, acetamido, hydroxy, C1-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;
 - (2) trifluoromethyl radical; or
- 25 (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, acetamido, hydroxy, C₁-C₂ alkoxy, halo, C₁-C₄ alkyl or trifluoromethyl radicals;
- 30 each R29 is independently hydrogen radical or R30; and
 - each R32 is independently
 - (1) hydrogen radicals;
 - (2) C1-C4 alkyl radical or C1-C2 alkyl radical
- 35 substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, $di-(C_1-C_2)$

alkyl)amino, acetamido, hydroxy, C_1-C_2 alkoxy, C_1-C_4 alkyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted

(3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, $di-(C_1-C_2 \text{ alkyl})$ amino,

5 acetamido, hydroxy, C₁-C₂ alkoxy, C₁-C₄ alkyl or trifluoromethyl radicals; and

wherein heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-6 ring 10 members, wherein 1-2 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic aromatic 15 heterocyclic ring system having 5-6 ring members, wherein 1-2 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused.

20 6. The compound of Claim 5 or a pharmaceutically acceptable salt thereof, wherein

wherein R_1 is -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R_1 is 0-2:

Z is a

- (1) bond;
- (2) C₁-C₄ alkyl or C₂-C₅ alkenyl radical optionally 30 substituted by (a) 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio or halo, and (b) 1-2 radicals of aryl or heteroaryl optionally substituted by 1-2 radicals of amino, di-(C₁-C₂ alkyl)amino, acetamido,
- 35 (C_1 - C_4 alkoxy)carbonylamino, hydroxy, C_1 - C_2 alkoxy, C_1 - C_2

- alkylthio, halo, C_1 - C_4 alkyl or trifluoromethyl radicals: or
- (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, $di-(C_1-C_2 \text{ alkyl})$ amino, acetamido,
- (C₁-C₄ alkoxy) carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl radicals:

Y is a

- 10 (1) hydrogen radical;
 - (2) -C(0)-R20 radical;
 - (3) $-OR_{21}$, $-SR_{21}$, $-S(O)-R_{20}$, $-S(O)_2-R_{20}$ or $-S(O)_2-NR_5R_{21}$ radical; or
 - (4) $-NR_5R_{21}$, $-NR_{22}-C(O)-R_{21}$, $-NR_{22}-C(O)-OR_{20}$, $-NR_{22}-C(O)-OR_{20}$
- 15 NR₅R₂₁, -NR₂₂-S(O)₂-R₂₀ or -NR₂₂-S(O)₂-NR₅R₂₁ radical;

each R₅ is independently

- (1) hydrogen radical;
- (2) C_1 - C_4 alkyl radical optionally substituted by 1-3
- 20 halo radicals; or

- (3) phenyl- C_1 - C_2 -alkyl or heteroaryl- C_1 - C_2 -alkyl, radicals optionally substituted by 1-3 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, methyl or trifluoromethyl radicals;
- each R20 is independently
- 30 alkoxy) carbonylamino, N-((C₁-C₄ alkoxy) carbonyl)-N-(C₁-C₄ alkyl) amino, aminocarbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-alkylthio, aryl-C₁-C₄-alkylsulfonyl, C₃-C₆ cycloalkyl,
- 35 heterocycly1, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino,

$$\begin{split} & \text{di-(C}_1\text{-C}_4 \text{ alkyl)amino, } C_1\text{-C}_5 \text{ alkanoylamino, } (C_1\text{-C}_4 \\ & \text{alkoxy)carbonylamino, } C_1\text{-C}_4 \text{ alkylsulfonylamino, } C_1\text{-C}_5 \\ & \text{alkanoyl, hydroxy, } C_1\text{-C}_4 \text{ alkoxy, } C_1\text{-C}_4 \text{ alkylthio, halo, } \\ & C_1\text{-C}_4 \text{ alkyl or } C_1\text{-C}_2 \text{ haloalkyl of 1-3 halo radicals;} \end{split}$$

- 5 (2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C₁-C₄ alkyl)amino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or C₁-C₄ alkyl; or
 - (3) aryl or heteroaryl radicals optionally substituted
- by 1-2 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl) amino, acetamido, (C₁-C₄ alkoxy) carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy) carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or trifluoromethyl radicals;

each R21 is independently hydrogen radical or R20;

 R_2 is a radical of hydrogen, C_1 - C_4 alkyl, halo, hydroxy, C_1 - C_4 alkoxy, trifluoromethoxy, thiol, C_1 - C_4 alkylthio,

- 20 amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino or trifluoromethyl;
- R₁₁ is an aryl radical and R₁₂ is a heteroaryl radical, 25 wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of
 - (1) R₃₀;
 - (2) halo or cyano radicals; or
 - (3) $-C(0)-NR_{31}R_{32}$, $-OR_{29}$, $-SR_{29}$, $-S(0)-R_{30}$, $-S(0)_2-R_{30}$, $-S(0)_2-R_{30}$, $-S(0)_3-R_{30}$
- 30 S(O)₂-NR₃₁R₃₂, -NR₃₁R₃₂ or -NR₃₃-C(O)-R₂₉ radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R₁₁ and R₁₂ is 0-1;
- 35 each R₃₀ is independently

- (1) C₁-C₄ alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl 5 radicals:
 - (2) trifluoromethyl radical; or
 - (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl

10 radicals;

each R29 is independently hydrogen radical or R30;

each R_{31} is independently hydrogen, methyl or ethyl 15 radicals; and

each R32 is independently

- hydrogen radicals;
- (2) C₁-C₄ alkyl radical or C₁-C₂ alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; or
- (3) phenyl or heteroaryl radical optionally substituted 25 by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
- 7. The compound of Claim 6 or a pharmaceutically 30 acceptable salt thereof, wherein

 $\ensuremath{R_{11}}$ is an aryl radical optionally substituted by 1-2 radicals of

- (1) R₃₀;
- 35 (2) halo or cyano radicals: or
 - (3) $-C(0)-NR_{31}R_{32}$, $-OR_{29}$, $-SR_{29}$, $-S(0)-R_{30}$, $-S(0)_2-R_{30}$, $-S(0)_2-NR_{31}R_{32}$, $-NR_{31}R_{32}$ or $-NR_{33}-C(0)-R_{29}$ radicals; and

- $\ensuremath{R_{12}}$ is a heteroaryl radical optionally substituted by 1- 2 radicals of
- (1) R₃₀;
- (2) halo or cyano radicals; or
 - (3) $-C(0)-NR_{31}R_{32}$, $-OR_{29}$, $-SR_{29}$, $-NR_{31}R_{32}$ or $-NR_{33}-C(0)-R_{29}$ radicals;

provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each 10 of R_{11} and R_{12} is 0-1;

R₃₀ is independently

- (1) C₁-C₄ alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 15 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
 - (2) trifluoromethyl radical; or
- (3) aryl or heteroaryl radicals optionally substituted 20 by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

R29 is an aryl or heteroaryl radicals optionally 25 substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; and

R₃₂ is independently

35

- 30 (1) hydrogen or C1-C4 alkyl radical; or
 - (2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.

The compound of Claim 7 or a pharmaceutically acceptable salt thereof, wherein wherein R_1 is -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R_1 is 0-1;

7 is a

5

(1) bond: or

(2) C_1 - C_4 alkyl radical optionally substituted by 1-2 radicals of amino, di- $(C_1$ - C_2 alkyl)amino, $(C_1$ - C_4

alkoxy) carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl radicals;

15

each R_5 is independently hydrogen or $C_1\text{-}C_4$ alkyl radical;

each R20 is independently

20 (1) C₁-C₈ alkyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl) amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy) carbonylamino, N-((C₁-C₄ alkoxy) carbonylamino, not constant alkoxy) carbonylamino, aminocarbonylamino, hydroxy, C₁-C₄

25 alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo or C₃-C₆ cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄

30 alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl radicals:

- (2) heterocyclyl radical optionally substituted by 1-2 radicals of hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio or C_1 -
- 35 C4 alkyl; or

(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (C₁-C₄ alkoxy)carbonyl, amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or trifluoromethyl radicals:

each R21 is independently hydrogen radical or R20;

R2 is a radical of hydrogen, methyl, ethyl, fluoro, 10 chloro, hydroxy, methoxy, trifluoromethoxy, amino, methylamino, dimethylamino, acetylamino or trifluoromethyl;

R₁₁ is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; and

20 R₁₂ is a heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.

25

The compound of Claim 8 or a pharmaceutically acceptable salt thereof, wherein

Z is a

- 30 (1) bond; or
 - (2) C₁-C₄ alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;
- 35 Yisa
 - (1) hydrogen radical:

220

```
(2) -C(0)-Ron radical:
```

- (3) $-OR_{21}$, $-SR_{21}$, $-S(O)-R_{20}$, $-S(O)_2-R_{20}$ or $-S(O)_2-NR_5R_{21}$ radical: or
- (4) $-NR_5R_{21}$, $-NR_{22}-C(O)-R_{21}$ or $-NR_{22}-S(O)_2-R_{20}$ radical;

R₅ is a hydrogen radical;

each R20 is independently

- (1) C₁-C₆ alkyl radicals optionally substituted by 1-3
 radicals of amino, methylamino, dimethylamino, t-butoxycarbonylamino, N-((t-butoxy)carbonyl)-N-(methyl)amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C₅-C₆ cycloalkyl, heterocyclyl,
 phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
- (2) heterocyclyl radical optionally substituted by 1-2 20 radicals of hydroxy or C₁-C₄ alkyl; or
 - (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

25

5

each R21 is independently hydrogen radical or R20;

each $\ensuremath{\text{R}}_{22}$ is independently hydrogen or methyl radical;

30 R₁₁ is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; and

221

 R_{12} is a 4-pyridyl, 4-quinolinyl, 4-imidazolyl or 4-pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.

5

- 10. The compound of Claim 9 or a pharmaceutically acceptable salt thereof, wherein
- 10 Yisa
 - (1) -C(0)-R20 radical;
 - (2) $-OR_{21}$, $-SR_{21}$, $-S(O)-R_{20}$, $-S(O)_2-R_{20}$ or $-S(O)_2-NR_5R_{21}$ radical: or
 - (3) $-NR_5R_{21}$, $-NR_{22}-C(O)-R_{21}$ or $-NR_{22}-S(O)_2-R_{20}$ radical;

15

each R20 is independently

- (1) C₁-C₆ alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, t-butoxycarbonylamino, N-((t-butoxy)carbonyl)-N-
- 20 (methyl)amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino,
- 25 hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
 - (2) heterocyclyl radical; or
 - (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy,
- 30 methoxy, methylthio, halo, methyl or trifluoromethyl radicals: and
 - each $\ensuremath{\text{R}}_{21}$ is independently hydrogen radical or $\ensuremath{\text{R}}_{20}.$

35

11. The compound of Claim 10 or a pharmaceutically acceptable salt thereof, wherein

Y is a -OR21, -SR21 or -NR5R21 radical;

each R20 is independently

- 5 (1) C₁-C₆ alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, hydroxy or phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl
- 10 radicals;
 - (2) heterocyclyl radical; or
 - (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl methoxy.
- 15 radicals;

each R21 is independently hydrogen radical or R20;

R₁₁ is an unsubstituted phenyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfonyl, methyl or trifluoromethyl radicals: and

25 R₁₂ is a 4-pyridyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.

3.0

- 12. The compound of Claim 1 which is:
- 5-(4-Fluorophenyl)-2-(4-pyridyl)-4-(4-pyridyl)-pyrimidine,
- 35 5-(4-Fluorophenyl)-2-(2-methylthiazol-4-yl)-4-(4-pyridyl)-pyrimidine,

```
5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(2-thienyl)-
pyrimidine,
```

- 2 (2 Diethylaminoethylamino) 5 (4 fluorophenyl) 4 (4 pyridyl) pyrimidine,
- 5 2-(4-Aminobutylamino)-5-(4-fluoropheny1)-4-(4-pyridy1)pyrimidine,
 - 2-(2,6-Dichlorobenzyl) 5-(4-fluorophenyl) 4-(4-pyridyl) pyrimidine,
 - 2-(2,6-Dichlorophenylamino)-5-(4-fluorophenyl)-4-(4-
- 10 pyridyl)-pyrimidine,

20

- 2-(2,6-Dimethylphenylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine,
- 5-(4-Fluorophenyl)-2-(2-methoxyphenylamino)-4-(4-pyridyl)-pyrimidine,
- 15 5-(4-Fluorophenyl)-2-(4-fluorophenylamino)-4-(4pvridvl)-pvrimidine,
 - 5-(4-Fluorophenyl)-2-phenylthiomethyl-4-(4-pyridinyl)-pyrimidine,
 - 2-(2-(4-Aminophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine,
 - 2-(2-(Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine,
 - 2-(2-(4-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine,
- 25 2-(2-(3-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine,
 - 2-(2-(2,4-Dichlorophenyl)ethyl-amino)-5-(4-
 - fluorophenyl)-4-(4-pyridyl)-pyrimidine,
 - $2-(2-(4-\texttt{Bromophenyl})\,\texttt{ethyl-amino})\,-5-(4-\texttt{fluorophenyl})\,-4-$
- 30 (4-pyridyl)-pyrimidine,
 - 5-(4-Fluorophenyl)-2-(2-(2-methoxyphenyl)ethyl-amino)-4-
 - (4-pyridy1)-pyrimidine,
 5-(4-Fluoropheny1)-2-(2-(3-methoxypheny1)ethy1-amino)-4(4-pyridy1)-pyrimidine,
- 35 5-(4-Fluorophenyl)-2-((1-methyl-3-phenylpropyl)-amino)4-(4-pyridyl)-pyrimidine,

224

```
5-(4-Fluorophenyl)-2-((4-phenyl-butyl)-amino)-4-(4-
    pyridyl)-pyrimidine.
    5-(4-Fluorophenyl)-2-morpholino-4-(4-pyridyl)-
    pyrimidine.
  5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(2-
    pyrrolidinoethylamino) -pyrimidine,
    5-(4-Fluorophenyl)-2-(2-morpholinoethylamino)-4-(4-
    pyridyl)-pyrimidine.
    5-(4-Fluorophenyl)-2-(2-piperidinoethylamino)-4-(4-
10 pyridyl)-pyrimidine,
    5-(4-Fluorophenyl)-2-(3-(2-pyrrolidinon-1-yl)propyl-
    amino)-4-(4-pyridyl)-pyrimidine,
    5-(4-Fluorophenyl)-2-(2-phenoxyethyl)thio-6-(4-pyridyl)-
    4-hvdroxy-pyrimidine.
    5-(4-Fluorophenyl)-2-(2-phenylaminoethyl)thio-6-(4-
    pyridyl)-4-hydroxy-pyrimidine.
    2-(2-Aminoethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-
    pyrimidine.
    2-(3-Aminopropylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-
    pyrimidine.
    2-(Benzylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-
    pyrimidine,
    5-(4-Fluorophenyl)-2-(2-phenylethylamino)-4-(4-pyridyl)-
    pyrimidine,
    5-(4-Fluorophenyl)-2-(N-methyl-N-(2-phenylethyl)-amino)-
    4-(4-pyridyl)-pyrimidine,
     5-(4-Fluorophenyl)-2-(2-hydroxy-2-phenyl-ethyl)amino-4-
     (4-pyridyl)-pyrimidine,
     5-(4-Fluorophenyl)-2-(2-(4-hydroxyphenyl)ethyl-amino)-4-
     (4-pyridyl)-pyrimidine,
     5-(4-Fluorophenyl)-2-(2-(4-fluorophenyl)ethyl-amino)-4-
     (4-pyridyl)-pyrimidine.
     5-(4-Fluorophenyl)-2-(2-(2-fluorophenyl)ethyl-amino)-4-
     (4-pyridyl)-pyrimidine,
```

15

20

25

3.0

35 5-(4-Fluorophenyl)-2-((3-phenylpropyl)-amino)-4-(4pyridyl)-pyrimidine,

225

```
2-((2(S)-Amino-3-phenylpropyl)-amino)-5-(4-
 fluorophenyl)-4-(4-pyridyl)-pyrimidine.
 5-(4-Fluorophenyl)-2-(2-phenylaminoethylamino)-4-(4-
 pyridyl) -pyrimidine,
5-(4-Fluorophenyl)-2-((3-imidazolylpropyl)-amino)-4-(4-
 pvridvl) -pvrimidine.
 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-pyrrolidino-
 pyrimidine,
 5-(4-Fluorophenyl)-2-(1-piperazinyl)-4-(4-pyridyl)-
 pyrimidine,
 2-(2,6-Dichlorobenzyl)-5-(4-fluorophenyl)-6-(4-pyridyl)-
 4-hydroxy-pyrimidine,
 5-(4-Fluorophenyl)-2-(2-phenylethyl)thio-6-(4-pyridyl)-
 4-hvdroxy-pyrimidine.
 5-(4-Fluorophenyl)-2-(3-phenylpropyl)thio-6-(4-pyridyl)-
 4-hydroxy-pyrimidine,
 2-(2-(2-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-6-
 (4-pyridyl)-4-hydroxy-pyrimidine,
 5-(4-Fluorophenyl)-2-((3-phenylpropyl)-amino)-6-(4-
 pyridyl)-4-hydroxy-pyrimidine,
 5-(4-Fluorophenyl)-2-((1-methyl-3-phenylpropyl)-amino)-
 6-(4-pyridyl)-4-hydroxy-pyrimidine,
 2-(2-(2-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-6-
 (4-pyridyl)-4-hydroxy-pyrimidine.
 2-((S)-2-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-
 (3-trifluoromethylphenyl)-pyrimidine.
 2-((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-
 methylphenyl) -4-(4-pyridyl)-pyrimidine.
 2-((S)-2-N, N-Dimethylamino-3-phenylpropyl)-amino)-5-(4-
fluorophenyl) -4-(4-pyridyl)-pyrimidine,
 2-((S)-2-N, N-Dimethylamino-3-phenylpropyl)-amino)-5-(3-
 methylphenyl) -4-(4-pyridyl)-pyrimidine,
 2-((3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-
 (4-pyridyl)-pyrimidine.
```

1.0

15

20

25

30

35 2-((3-Amino-3-phenylpropyl) -amino)-4-(4-pyridyl)-5-(3trifluoromethylphenyl)-pyrimidine, 10

15

20

25

```
2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-4-(4-
   pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine.
   2-((3-Amino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-
   (4-pyridyl)-pyrimidine,
5 2-((2-Amino-2-methyl-3-phenylpropyl)-amino)-5-(3-
   methylphenyl)-4-(4-pyridyl)-pyrimidine,
    2-((3-Hydroxy-3-phenylpropyl)-amino)-5-(3-methylphenyl)-
    4-(4-pyridyl)-pyrimidine.
    2-(((2S,3S)-3-Amino-2-methyl-3-phenylpropyl)-amino)-4-
   (4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine,
    2-(((2R,3R)-3-Amino-2-methyl-3-phenylpropyl)-amino)-4-
    (4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine.
    2-((S)-3-Benzylpiperazinyl)-4-(4-pyridyl)-5-(3-
    trifluoromethylphenyl)-pyrimidine.
    4-(4-Pyridy1)-2-(((S)-tetrahydroisoguino1-3-
    ylmethylen)amino)-5-(3-trifluoromethylphenyl)-
    pyrimidine,
    5-(3-Methylphenyl)-4-(4-pyridyl)-2-(((S)-
    tetrahydroisoguinol-3-vlmethylen)amino)-pyrimidine,
    2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-4-(4-
    pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine,
    2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)-4-(4-
    pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine,
    2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-5-(3-
    methylphenyl) -4-(4-pyridyl) -pyrimidine,
    2-(((S)-2-N-Butylamino-3-phenylpropyl)-amino)-5-(3-
    methylphenyl) -4-(4-pyridyl)-pvrimidine,
    2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)-5-(3-
    methylphenyl)-4-(4-pyridyl)-pyrimidine,
    5-(4-Fluorophenyl)-2-(((S)-2-N-isopropylamino-3-
30
    phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine,
    5-(4-Fluorophenyl)-2-((3-N-isopropylamino-3-
    phenylpropyl) -amino) -4 - (4-pyridyl) -pyrimidine,
    2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-4-(4-
    pyridyl) -5-(3-trifluoromethylphenyl)-pyrimidine,
35
    2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-5-(3-
    methylphenyl) -4-(4-pyridyl)-pyrimidine,
```

3.0

- 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-chloro-4fluorophenyl)-4-(4-pyridyl)-pyrimidine, 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3fluorophenyl)-4-(4-pyridyl)-pyrimidine, 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3isopropylphenyl) -4-(4-pyridyl) -pyrimidine. 5-(3-Acetamidophenyl)-2-(((S)-2-amino-3-phenylpropyl)amino) -4-(4-pyridyl)-pyrimidine, 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4chlorophenyl) -4-(4-pyridyl)-pyrimidine, 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(benzothienyl)-4-(4-pyridyl)-pyrimidine. 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(2-naphthyl)-4-(4-pyridyl)-pyrimidine, or 15 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4fluorophenyl)-6-(4-pyridy)-4(3H)pyrimidinone or a pharmaceutically acceptable salt thereof.
- 20 13. A pharmaceutical composition comprising a compound of Claims 1 to 12 and a pharmaceutically acceptable carrier.
- 14. A method of prophylaxis or treatment of 25 inflammation comprising administering an effective amount of a compound of Claims 1 to 12.
 - 15. A method of prophylaxis or treatment of inflammation comprising administering an effective amount of a composition of Claim 13.
 - 16. A method of prophylaxis or treatment of rheumatoid arthritis, Pagets disease, osteophorosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic & cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress

syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due 10 to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount of a compound of Claims 1-12.

- 17. A method of prophylaxis or treatment of 15 rheumatoid arthritis, Pagets disease, osteophorosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic & cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress 20 syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, 25 Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount of a composition of Claim 13.
- 35 18. A method of lowering plasma concentrations of either or both TNF-a and IL-1 comprising administering an effective amount of a compound of Claims 1-12.

5

- 19. A method of lowering plasma concentrations of either or both TNF-a and IL-1 comprising administering an effective amount of a composition of Claim 13.
- 20. A method of lowering plasma concentrations of either or both IL-6 and IL-8 comprising administering an effective amount of a compound of Claims 1-12.
- 21. A method of lowering plasma concentrations of either or both IL-6 and IL-8 comprising administering an effective amount of a composition of Claim 13.
- 22. A method of prophylaxis or treatment of diabetes disease in a mammal comprising administering an effective amount of a compound according to claims 1 to 12 to produce a glucagon antagonist effect.
- 23. A method of prophylaxis or treatment of diabetes disease in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 13 to produce a glucagon antagonist effect.
- 25 24. A method of prophylaxis or treatment of a pain disorder in a mammal comprising administering an effective amount of a compound according to claims 1 to 12.
- 30 25. A method of prophylaxis or treatment of a pain disorder in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 13.
- 35 26. A method of decreasing prostaglandins production in a mammal comprising administering an

230

effective amount of a compound according to claims 1 to 12.

- 27. A method of decreasing prostaglandins production in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 13.
- 28. A method of decreasing cyclooxygenase enzyme

 10 activity in a mammal comprising administering an
 effective amount of a compound according to claims 1 to
 12.
- 29. The method of claim 28 wherein the 15 cyclooxygenase enzyme is COX-2.
 - 30. A method of decreasing cyclooxygenase enzyme activity in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 13.
 - 31. The method of claim 30 wherein the cyclooxygenase enzyme is COX-2.

2.0